<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3065466/results/search/drugs/results.xml">
   <result pre="stockpile of antiviral drugs, [1], [2], [3], [4], such as" exact="oseltamivir" post="and zananivir. The size of the antiviral stockpile and"/>
   <result pre="experimental human influenza.JAMA2752952998544269 6HaydenFGTreanorJJFritzaRSLoboMBettsRFet al.1999Use of the oral neuraminidase inhibitor" exact="oseltamivir" post="in experimental human influenza: randomized controlled trials for prevention"/>
   <result pre="8MosconaA2005Neuraminidase inhibitors for influenza.N Engl J Med3531363137316192481 9WelliverRMontoASCarewiczOSchattemanEHassmanMet al.2001Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts.JAMA28574875411176912 10Hayden FG etal1997Efficacy"/>
   <result pre="contacts.JAMA28574875411176912 10Hayden FG etal1997Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzavirus infections.N Engl J Med3378748809302301"/>
   <result pre="influenzavirus infections.N Engl J Med3378748809302301 11NicholsonKGAokiFYOsterhausATrottierSCarewiczOet al.2000Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial.Lancet3551845185010866439"/>
   <result pre="trial.Lancet3551845185010866439 12TreanorJJet al.2000Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza.J Am Med Assoc28310161024 13JeffersonTDemicheliVRivettiDJonesMPietrantonjCDet al.2006Antivirals"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3136400/results/search/drugs/results.xml">
   <result pre="treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus" exact="ribavirin" post="(RBV) which has significant side effects depending upon the"/>
   <result pre="standard treatment pegylated interferon-α (PEG IFN- α) in combination with" exact="ribavirin" post="(RBV) have been employed with certain side effects and"/>
   <result pre="in different phases of clinical trials. Debio 025, a non-immunosuppressive" exact="cyclosporine" post="(Cs) analogue, is found to exhibit novel inhibition of"/>
   <result pre="Combined effect of HCV-796 (an NNI of HCV NS5B) and" exact="boceprevir" post="SCH 503034 (an inhibitor of NS3 serine protease) was"/>
   <result pre="for the clinical estimation of three-part combination of PEG IFN-α," exact="boceprevir" post="and HCV-796 [26]. Since RdRp is deficient in proof"/>
   <result pre="or β-D-2'-deoxy-2'-fluoro-2'- C-methylcytidine (2'-F-C-MeC; PSI-6130) with interferon-α 2b (IFN-α2b) plus" exact="ribavirin" post="(RBV) were assessed in subgenomic HCV relicon. β-D-2'-C-methylcytidine (2'-C-MeC;"/>
   <result pre="and different concentrations of compound [32]. High SVR rate of" exact="nitazoxanide" post="along with interferon suggested that nitazoxanide can be exercised"/>
   <result pre="High SVR rate of nitazoxanide along with interferon suggested that" exact="nitazoxanide" post="can be exercised instead of ribavirin to avoid side"/>
   <result pre="with interferon suggested that nitazoxanide can be exercised instead of" exact="ribavirin" post="to avoid side effect of this drug. Another newly"/>
   <result pre="process entailed for the HCVpp entry [71]. Fluphenazine, PCperazine, and" exact="trifluoperazine" post="were currently recognized as inhibitors of HCV entry [64]."/>
   <result pre="HCV entry [64]. These compounds alienated the D2 and D1" exact="dopamine" post="[65,66] and 5-HT2 serotonin receptors [67] in neural signaling"/>
   <result pre="1S385312591185 PoynardTRatziuVMcHutchisonJMannsMGoodmanZZeuzemSYounossiZAlbrechtJEffect of treatment with peginterferon or interferon alfa-2b and" exact="ribavirin" post="on steatosis in patients infected with hepatitis CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis"/>
   <result pre="via clathrin-coated vesiclesJ Virol200680115711157810.1128/JVI.01717-0617005647 FeldJJHoofnagleJHMechanism of action of interferon and" exact="ribavirin" post="in treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients"/>
   <result pre="dually resistant to the polymerase and protease inhibitors HCV-796 and" exact="boceprevir" post="(SCH 503034)Antimicrob Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug"/>
   <result pre="BassitLGrierJBennettMSchinaziRFCombinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with" exact="ribavirin" post="in the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555"/>
   <result pre="systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for hepatitis C virus resistance to" exact="nitazoxanide" post="or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV)"/>
   <result pre="Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV) NS4B RNA binding inhibitor" exact="clemizole" post="is highly synergistic with HCV protease inhibitorsJ Infect Dis2026574"/>
   <result pre="virus polymerase that increase RNA binding can confer resistance to" exact="cyclosporine" post="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a"/>
   <result pre="protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
   <result pre="preclinical speciesBioorg Med Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir," exact="peginterferon alfa-2a," post="and ribavirin for 28 days in hepatitis C patientsJ"/>
   <result pre="Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir, peginterferon alfa-2a, and" exact="ribavirin" post="for 28 days in hepatitis C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA"/>
   <result pre="USA107291296 CaiGGurdalHSmithCWangHYFriedmanEInverse agonist properties of dopaminergic antagonists at the D(1A)" exact="dopamine" post="receptor: uncoupling of the D(1A) dopamine receptor from G(s)"/>
   <result pre="antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A)" exact="dopamine" post="receptor from G(s) proteinMol Pharmacol19995698999610531405 LummisSCBakerJRadioligand binding and photoaffinity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3184032/results/search/drugs/results.xml">
   <result pre="protein or the enzyme neuraminidase. Combination therapy with Interferon-α and" exact="ribavirin" post="remains the backbone treatment for chronic hepatitis C; the"/>
   <result pre="Some antiviral drugs possess multiple potential clinical applications, such as" exact="ribavirin" post="for the treatment of chronic hepatitis C and respiratory"/>
   <result pre="treatment of chronic hepatitis C and respiratory syncytial virus and" exact="cidofovir" post="for the treatment of cytomegalovirus and other DNA viruses."/>
   <result pre="discussed in these sections possess other potential applications, such as" exact="ribavirin" post="for the treatment of respiratory syncytial virus (RSV) and"/>
   <result pre="ribavirin for the treatment of respiratory syncytial virus (RSV) and" exact="cidofovir" post="for the treatment of cytomegalovirus (CMV) and other DNA"/>
   <result pre="CMV disease, gastrointestinal disease, pneumonia, and encephalitis Transition to oral" exact="valganciclovir" post="on clinical and virologic improvement Duration of therapy is"/>
   <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use Duration of therapy is guided by CMV surveillance"/>
   <result pre="no longer a preferred drug because of its poor bioavailability;" exact="valganciclovir" post="is preferred Valacyclovir (oral) 2 g orally 4 times"/>
   <result pre="(IV) 5 mg/kg IV every 12 h Less preferred than" exact="valganciclovir" post="because of the logistics of IV administration Oral ganciclovir"/>
   <result pre="than valganciclovir because of the logistics of IV administration Oral" exact="ganciclovir" post="should not be used for treating active CMV infection"/>
   <result pre="until immune reconstitution For sight-threatening retinitis, use in combination with" exact="ganciclovir" post="intraocular implant (see below) Ganciclovir (IV) Induction: 5 mg/kg"/>
   <result pre="until immune reconstitution For sight-threatening retinitis, use in combination with" exact="ganciclovir" post="intraocular implant (see below) Ganciclovir (intraocular implant) One sustained-release"/>
   <result pre="6–8 mo until immune reconstitution Use in combination with systemic" exact="ganciclovir" post="(or valganciclovir) because of the systemic nature of CMV"/>
   <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use CMV disease other than retinitis in HIV-infected patients"/>
   <result pre="CMV disease High risk of nephrotoxicity; requires concomitant hydration and" exact="probenecid" post="use aCMV = cytomegalovirus; HIV = human immunodeficiency virus;"/>
   <result pre="of acyclovir may still be beneficial in immunocompromised patients. Short-course" exact="prednisone" post="may be added as an adjunct to acyclovir treatment"/>
   <result pre="during the early period after transplant in patients not receiving" exact="ganciclovir" post="or valganciclovir prophylaxis.14 Acyclovir is generally well tolerated. However,"/>
   <result pre="early period after transplant in patients not receiving ganciclovir or" exact="valganciclovir" post="prophylaxis.14 Acyclovir is generally well tolerated. However, IV acyclovir"/>
   <result pre="available as an IV formulation, and an oral prodrug of" exact="cidofovir" post="(known as CMX-001) is under clinical development.28 This investigational"/>
   <result pre="is under clinical development.28 This investigational lipid ester formulation of" exact="cidofovir" post="has enhanced bioavailability, resulting in improved 50% inhibitory concentrations.28"/>
   <result pre="resulting in improved 50% inhibitory concentrations.28 Direct intraocular injection of" exact="cidofovir" post="is contraindicated due to ocular hypotony.27 Serum cidofovir concentrations"/>
   <result pre="injection of cidofovir is contraindicated due to ocular hypotony.27 Serum" exact="cidofovir" post="concentrations decline rapidly after IV infusion, with a half-life"/>
   <result pre="hours. Cidofovir is eliminated by glomerular filtration and tubular secretion;" exact="probenecid" post="reduces its excretion by blocking tubular secretion.29, 30 Cidofovir"/>
   <result pre="thereby halting viral DNA synthesis.27 The major clinical indication for" exact="cidofovir" post="is the treatment of CMV retinitis in HIV-infected patients"/>
   <result pre="CMV disease resistant or unresponsive to ganciclovir.32 Because activation of" exact="cidofovir" post="does not rely on viral kinases, it retains activity"/>
   <result pre="UL97 mutation and HSV with the TK mutation.33 Resistance to" exact="cidofovir" post="occurs when the virus develops mutations in the DNA"/>
   <result pre="Famciclovir Famciclovir is a diacetyl 6-deoxy analogue of penciclovir. Oral" exact="famciclovir" post="is rapidly absorbed and achieves a bioavailability of 77%.51"/>
   <result pre="of 77%.51 Famciclovir is metabolized into penciclovir, reaching peak plasma" exact="penciclovir" post="concentrations within 1 hour. Because of extensive hepatic metabolism,"/>
   <result pre="within 1 hour. Because of extensive hepatic metabolism, virtually no" exact="famciclovir" post="is detectable in plasma.51 Famciclovir is excreted renally as"/>
   <result pre="famciclovir is detectable in plasma.51 Famciclovir is excreted renally as" exact="penciclovir" post="and its 6-deoxy precursor.9 Famciclovir is active against HSV-1,"/>
   <result pre="extent, against EBV. Its mechanism of action is through penciclovir;" exact="penciclovir" post="triphosphate inhibits herpes DNA synthesis by acting as a"/>
   <result pre="substrate for viral DNA polymerase. The major clinical indications for" exact="famciclovir" post="use are treatment of herpes zoster, recurrent genital herpes,52"/>
   <result pre="varicella in HIV-infected patients. The most common adverse effects of" exact="famciclovir" post="are headache and nausea.54 Rare adverse events include jaundice,"/>
   <result pre="of standard CMV therapies, or whose virus is resistant to" exact="ganciclovir" post="and foscarnet.55, 56, 57 The main adverse effect of"/>
   <result pre="CMV diseases in immunocompromised patients, especially those unable to tolerate" exact="ganciclovir" post="and those infected with ganciclovir-resistant virus.60, 61 Foscarnet is"/>
   <result pre="CMV.65 It is available in oral and parenteral formulations. Oral" exact="ganciclovir" post="is poorly absorbed, with a bioavailability of only 5%.65"/>
   <result pre="5%.65 Management of active CMV disease is therefore with IV" exact="ganciclovir" post="or its oral valyl prodrug valganciclovir. Intravitreal ganciclovir implants"/>
   <result pre="with IV ganciclovir or its oral valyl prodrug valganciclovir. Intravitreal" exact="ganciclovir" post="implants are also available, with minimal systemic absorption. Ganciclovir"/>
   <result pre="herpes simplex keratitis, and CMV prophylaxis in transplant recipients. Intravenous" exact="ganciclovir" post="may also be used to treat other forms of"/>
   <result pre="disease, such as colitis or esophagitis. Induction therapy with IV" exact="ganciclovir" post="for CMV retinitis in patients with AIDS has an"/>
   <result pre="95% in stabilizing disease.68 Because it is poorly absorbed, oral" exact="ganciclovir" post="should not be used for induction treatment of CMV"/>
   <result pre="or progresses in patients with advanced AIDS, oral or IV" exact="ganciclovir" post="(or valganciclovir) is given as maintenance therapy until immune"/>
   <result pre="given as maintenance therapy until immune reconstitution is achieved.69 Intravitreal" exact="ganciclovir" post="may also be surgically implanted for the treatment of"/>
   <result pre="treatment should be used together with systemic therapy with IV" exact="ganciclovir" post="or oral valganciclovir therapy. Oral ganciclovir may be used"/>
   <result pre="used together with systemic therapy with IV ganciclovir or oral" exact="valganciclovir" post="therapy. Oral ganciclovir may be used to prevent CMV"/>
   <result pre="systemic therapy with IV ganciclovir or oral valganciclovir therapy. Oral" exact="ganciclovir" post="may be used to prevent CMV in patients with"/>
   <result pre="era of highly active antiretroviral therapy. Although IV and oral" exact="ganciclovir" post="have also been used to prevent CMV disease in"/>
   <result pre="also been used to prevent CMV disease in transplant recipients," exact="valganciclovir" post="is currently the preferred drug for this indication.60, 61,"/>
   <result pre="currently the preferred drug for this indication.60, 61, 70 Intravenous" exact="ganciclovir" post="is also used as a first-line treatment of CMV"/>
   <result pre="creatinine and liver enzymes. Neurotoxicity may occur occasionally. Resistance to" exact="ganciclovir" post="occurs most commonly in severely immunocompromised patients with prolonged"/>
   <result pre="prolonged exposure to the drug. The most common mechanism for" exact="ganciclovir" post="resistance is UL97 gene mutation71; this mutation leads to"/>
   <result pre="viral kinase that is necessary for the initial phosphorylation of" exact="ganciclovir" post="into its active form. A less common mechanism is"/>
   <result pre="available as topical therapy for mucocutaneous herpes. For systemic use," exact="penciclovir" post="has been reformulated into the oral prodrug famciclovir. The"/>
   <result pre="reformulated into the oral prodrug famciclovir. The antiviral activity of" exact="penciclovir" post="is similar to that of acyclovir, with efficacy against"/>
   <result pre="for prevention of CMV disease in kidney transplant recipients.78 Although" exact="ganciclovir" post="is the backbone for CMV prevention in transplant recipients,"/>
   <result pre="Valganciclovir Valganciclovir is the L-valyl ester prodrug of ganciclovir. Oral" exact="valganciclovir" post="is well absorbed and converted to ganciclovir by first-pass"/>
   <result pre="of ganciclovir. Oral valganciclovir is well absorbed and converted to" exact="ganciclovir" post="by first-pass intestinal or hepatic metabolism.79 The bioavailability of"/>
   <result pre="ganciclovir by first-pass intestinal or hepatic metabolism.79 The bioavailability of" exact="ganciclovir" post="after valganciclovir administration is about 60%, and peak plasma"/>
   <result pre="first-pass intestinal or hepatic metabolism.79 The bioavailability of ganciclovir after" exact="valganciclovir" post="administration is about 60%, and peak plasma concentrations are"/>
   <result pre="CMV retinitis in patients with AIDS.83 For immediate sight-threatening lesions," exact="valganciclovir" post="is used in combination with an intravitreal ganciclovir implant."/>
   <result pre="sight-threatening lesions, valganciclovir is used in combination with an intravitreal" exact="ganciclovir" post="implant. Valganciclovir is also used for preventing CMV disease"/>
   <result pre="kidney, heart, or kidney-pancreas transplants.61, 84 In the United States," exact="valganciclovir" post="is not approved for preventing CMV disease in liver"/>
   <result pre="higher incidence of tissue-invasive CMV disease in patients who received" exact="valganciclovir" post="vs oral ganciclovir prophylaxis. In other countries, valganciclovir is"/>
   <result pre="tissue-invasive CMV disease in patients who received valganciclovir vs oral" exact="ganciclovir" post="prophylaxis. In other countries, valganciclovir is used for preventing"/>
   <result pre="who received valganciclovir vs oral ganciclovir prophylaxis. In other countries," exact="valganciclovir" post="is used for preventing CMV disease in all solid"/>
   <result pre="Valganciclovir was recently demonstrated to be as effective as IV" exact="ganciclovir" post="for treating mild to moderate CMV disease in transplant"/>
   <result pre="as diarrhea, nausea, and vomiting, may be observed. Resistance to" exact="valganciclovir" post="occurs through mechanisms identical to those underlying ganciclovir resistance,"/>
   <result pre="Resistance to valganciclovir occurs through mechanisms identical to those underlying" exact="ganciclovir" post="resistance, ie, through mutations in the UL97 gene, which"/>
   <result pre="keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its active form," exact="vidarabine" post="inhibits viral DNA polymerase. Adverse effects of ophthalmic vidarabine"/>
   <result pre="form, vidarabine inhibits viral DNA polymerase. Adverse effects of ophthalmic" exact="vidarabine" post="include irritation, pain, photophobia, lacrimation, and occlusion of the"/>
   <result pre="in elderly patients and those taking neuroaffective drugs. Emergence of" exact="amantadine" post="resistance has limited its use in the clinical setting.94,"/>
   <result pre="2 to 4 days of treatment. Because of widespread resistance," exact="amantadine" post="is no longer recommended for empiric treatment of influenza.94,"/>
   <result pre="is excreted in the urine. The mechanism of action of" exact="rimantadine" post="is similar to that of amantadine; it inhibits the"/>
   <result pre="limited by drug resistance.96, 97 A few trials that compared" exact="amantadine" post="and rimantadine suggested similar efficacy; however, neurologic adverse events"/>
   <result pre="drug resistance.96, 97 A few trials that compared amantadine and" exact="rimantadine" post="suggested similar efficacy; however, neurologic adverse events are less"/>
   <result pre="rimantadine. Neuraminidase Inhibitors Oseltamivir. Oseltamivir phosphate is a prodrug of" exact="oseltamivir" post="carboxylate, which is an inhibitor of neuraminidase that is"/>
   <result pre="in the replication of influenza A and B viruses.98 Oral" exact="oseltamivir" post="is well absorbed and reaches peak serum concentrations in"/>
   <result pre="and reaches peak serum concentrations in 1 hour. Bioavailability of" exact="oseltamivir" post="phosphate is at least 75%. The prodrug oseltamivir phosphate"/>
   <result pre="Bioavailability of oseltamivir phosphate is at least 75%. The prodrug" exact="oseltamivir" post="phosphate undergoes extensive hepatic metabolism via ester hydrolysis. More"/>
   <result pre="hepatic metabolism via ester hydrolysis. More than 99% of active" exact="oseltamivir" post="carboxylate is excreted renally. Oseltamivir carboxylate, the active drug"/>
   <result pre="influenza A and B, including pandemic strains. For this indication," exact="oseltamivir" post="should be started within 48 hours of exposure and"/>
   <result pre="outbreak. A systematic review reported no statistically significant difference between" exact="oseltamivir" post="and zanamivir prophylaxis for preventing symptomatic influenza among immunocompetent"/>
   <result pre="systematic review reported no statistically significant difference between oseltamivir and" exact="zanamivir" post="prophylaxis for preventing symptomatic influenza among immunocompetent adults.100 The"/>
   <result pre="influenza among immunocompetent adults.100 The most common adverse effects of" exact="oseltamivir" post="are nausea, vomiting, diarrhea, abdominal pain, insomnia, and vertigo."/>
   <result pre="the neuraminidase gene, such as R292K101 and H274Y,98 account for" exact="oseltamivir" post="resistance. Surveillance conducted during the 2009 H1N1 influenza pandemic"/>
   <result pre="is not available orally since it is poorly absorbed.106 Inhaled" exact="zanamivir" post="produces high concentrations in the respiratory tract where influenza"/>
   <result pre="influenza virus infection occurs. About 4% to 20% of inhaled" exact="zanamivir" post="is absorbed systemically, producing peak serum concentrations at 1"/>
   <result pre="is excreted in the feces.106 The mechanism of action of" exact="zanamivir" post="is similar to oseltamivir, by inhibiting neuraminidase, which is"/>
   <result pre="of newly formed viral particles from infected cells.106 For treatment," exact="zanamivir" post="is given by inhalation twice daily for 5 days,"/>
   <result pre="IV to treat critically ill patients with influenza.107, 108 Inhaled" exact="zanamivir" post="is well tolerated.106 Acute bronchospasm with decline in respiratory"/>
   <result pre="SC IFN-α.114 Likewise, SC peginterferon-α may be more effective than" exact="lamivudine" post="in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients"/>
   <result pre="HBeAg-negative patients with CHB,115, 116, 117 and the addition of" exact="lamivudine" post="to peginterferon-α did not significantly enhance efficacy.118 Interferon-α is"/>
   <result pre="CHC.124, 125, 126 However, combination therapy with IFN-α and oral" exact="ribavirin" post="is more effective than either drug used alone.127 Combining"/>
   <result pre="is more effective than either drug used alone.127 Combining oral" exact="ribavirin" post="with peginterferon-α may be more effective than combining it"/>
   <result pre="of Liver Diseases130 recommends once-weekly SC peginterferon-α combined with oral" exact="ribavirin" post="as the first line of treatment of CHC. The"/>
   <result pre="rate of intolerance to a combination regimen of IFN-α and" exact="ribavirin" post="is higher and the rate of sustained virologic response"/>
   <result pre="plus ribavirin.132 A lower SVR rate to combination peginterferon-α plus" exact="ribavirin" post="therapy was observed in patients coinfected with HCV genotype"/>
   <result pre="In general, the guidelines recommend combination therapy with peginterferon-α and" exact="ribavirin" post="for 48 weeks. Interferons are generally not recommended in"/>
   <result pre="guanine, is available in oral, aerosolized, and IV formulations. Oral" exact="ribavirin" post="is absorbed extensively, but its bioavailability is only 65%"/>
   <result pre="bioavailability is only 65% because of first-pass metabolism. Peak plasma" exact="ribavirin" post="concentrations occur within 1 to 2 hours after oral"/>
   <result pre="times higher after 4 weeks of treatment. Administration of aerosolized" exact="ribavirin" post="leads to high concentrations in the respiratory tract, with"/>
   <result pre="leads to high concentrations in the respiratory tract, with some" exact="ribavirin" post="absorbed systemically. Ribavirin is mainly excreted in the urine.149"/>
   <result pre="mainly excreted in the urine.149 The mechanism of action of" exact="ribavirin" post="is known to be diverse but is not completely"/>
   <result pre="its antiviral activity is reversed by guanosine. Its triphosphorylated form," exact="ribavirin" post="triphosphate, is a potent competitive inhibitor of inosine monophosphate"/>
   <result pre="triphosphorylated form, ribavirin triphosphate, is a potent competitive inhibitor of" exact="inosine" post="monophosphate dehydrogenase, influenza virus RNA polymerase, and mRNA guanylyltransferase."/>
   <result pre="in vitro activity and its activity against human infections. Oral" exact="ribavirin" post="is approved for use, in combination with IFN-α or"/>
   <result pre="transplant recipients. When used for the treatment of RSV pneumonia," exact="ribavirin" post="is usually given by the aerosol route, which delivers"/>
   <result pre="which delivers high concentrations at the site of infection.152 Oral" exact="ribavirin" post="has also been used with good outcomes.153 Ribavirin has"/>
   <result pre="fever,160, 161 Bolivian hemorrhagic fever,162 and hantavirus pulmonary syndrome.163 Aerosolized" exact="ribavirin" post="can cause sudden deterioration of respiratory function and cardiovascular"/>
   <result pre="deterioration of respiratory function and cardiovascular effects. Precipitation of inhaled" exact="ribavirin" post="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154"/>
   <result pre="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154 and" exact="ribavirin" post="should not be given to patients with preexisting medical"/>
   <result pre="suicidal ideation, and relapse of drug abuse may occur, and" exact="ribavirin" post="is contraindicated in patients with a history of, or"/>
   <result pre="Adefovir 10 mg orally once daily Acyclic nucleotide analogue of" exact="adenosine" post="monophosphate Nephrotoxicity Lactic acidosis Rebound hepatitis rtN236T is most"/>
   <result pre="orally once daily Nucleoside analogue of cytidine Very similar to" exact="lamivudine" post="Used often in combination with tenofovir Lactic acidosis Rebound"/>
   <result pre="cytidine Very similar to lamivudine Used often in combination with" exact="tenofovir" post="Lactic acidosis Rebound hepatitis rtM204V/I provides cross-resistance with lamivudine"/>
   <result pre="with tenofovir Lactic acidosis Rebound hepatitis rtM204V/I provides cross-resistance with" exact="lamivudine" post="Entecavir 0.5 mg orally once daily for treatment-naive patients"/>
   <result pre="orally once daily Acyclic nucleoside phosphonate di ester analogue of" exact="adenosine" post="monophosphate One of the most potent anti-HBV drugs Nephrotoxicity"/>
   <result pre="competitive substrate for the HBV DNA polymerase. All drugs except" exact="telbivudine" post="have anti-HBV properties, and all patients with chronic hepatitis"/>
   <result pre="hepatomegaly. Adefovir. Adefovir dipivoxil is an acyclic nucleotide analogue of" exact="adenosine" post="monophosphate.164 Oral adefovir dipivoxil is rapidly absorbed and converted"/>
   <result pre="such as lamivudine.165 However, concomitant use with the related drug" exact="tenofovir" post="disoproxil fumarate is not recommended because of the augmented"/>
   <result pre="cytidine. Although not currently approved for the treatment of CHB," exact="emtricitabine" post="has been used clinically in combination with tenofovir in"/>
   <result pre="of CHB, emtricitabine has been used clinically in combination with" exact="tenofovir" post="in HIV/HBV-coinfected patients. Emtricitabine is very similar to lamivudine,"/>
   <result pre="because of high rates of resistance development.170 The rate of" exact="emtricitabine" post="resistance among patients with HBV monoinfection is 18% at"/>
   <result pre="of patients with CHB, including those resistant to lamivudine.172 Oral" exact="entecavir" post="is extensively absorbed: peak plasma concentrations occur in 30"/>
   <result pre="and oral bioavailability is almost 100%. Despite low plasma concentrations," exact="entecavir" post="maintains its potency by the long intracellular half-life of"/>
   <result pre="potency by the long intracellular half-life of its active metabolite" exact="entecavir" post="triphosphate. Entecavir is mainly excreted by glomerular filtration and"/>
   <result pre="filtration and active tubular secretion. The mechanism of action of" exact="entecavir" post="is somewhat unique because it inhibits 3 specific functions"/>
   <result pre="liver disease.173 In randomized trials of HBeAg-positive and HBeAg-negative patients," exact="entecavir" post="demonstrated better outcomes than lamivudine, with improvement in histologic"/>
   <result pre="and normalization or improvement of ALT levels. Adverse effects of" exact="entecavir" post="are generally mild and include headache, fatigue, nausea, diarrhea,"/>
   <result pre="rtT184S/A/I/L, rtS202G/C, or rtM250L. Among nucleoside-naive patients, the rate of" exact="entecavir" post="resistance is less than 1% after 5 years, but"/>
   <result pre="but patients with preexisting rtM204V/I have a higher rate of" exact="entecavir" post="resistance (51%) after 5 years.173 Lamivudine. Lamivudine is a"/>
   <result pre="years.173 Lamivudine. Lamivudine is a nucleoside analogue of cytosine. Oral" exact="lamivudine" post="provides bioavailability of about 85%, and peak serum concentrations"/>
   <result pre="kidneys.174 Lamivudine is phosphorylated intracellularly into its active 5′-triphosphate metabolite," exact="lamivudine" post="triphosphate. When the active metabolite is incorporated into viral"/>
   <result pre="In a double-blind study involving about 350 patients with CHB," exact="lamivudine" post="was associated with substantial histologic improvement, HBeAg antibody seroconversion,"/>
   <result pre="are common once treatment is discontinued.178 The adverse effects of" exact="lamivudine" post="are mild and include abdominal pain, nausea, and headache."/>
   <result pre="include abdominal pain, nausea, and headache. The clinical utility of" exact="lamivudine" post="is limited by the rapid development of antiviral resistance."/>
   <result pre="which occurs easily and confers cross-resistance. After 4 years of" exact="lamivudine" post="monotherapy, rtM204V/I resistance develops in up to 70% and"/>
   <result pre="is a synthetic thymidine nucleoside analogue. Unlike other anti-HBV drugs," exact="telbivudine" post="has no activity against HIV. Oral telbivudine is well"/>
   <result pre="other anti-HBV drugs, telbivudine has no activity against HIV. Oral" exact="telbivudine" post="is well absorbed and achieves peak plasma concentrations after"/>
   <result pre="inhibits HBV by competitive inhibition of viral DNA polymerase. Oral" exact="telbivudine" post="is approved for the treatment of CHB in patients"/>
   <result pre="inflammation and fibrosis.180, 181 It is considered more effective than" exact="lamivudine" post="and adefovir.182, 183 Compared with lamivudine, telbivudine was associated"/>
   <result pre="more effective than lamivudine and adefovir.182, 183 Compared with lamivudine," exact="telbivudine" post="was associated with a higher degree of reduction in"/>
   <result pre="or anti-HBe seroconversion. The most common adverse effects reported for" exact="telbivudine" post="are dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse"/>
   <result pre="neuropathy or myopathy is diagnosed. The rate of resistance to" exact="telbivudine" post="is 25% after 96 weeks of treatment. Tenofovir. Tenofovir"/>
   <result pre="Tenofovir disoproxil fumarate, an acyclic nucleoside phosphonate diester analogue of" exact="adenosine" post="monophosphate, is considered one of the most potent anti-HBV"/>
   <result pre="taken with a high-fat meal. The terminal elimination half-life of" exact="tenofovir" post="is 12 to 18 hours, and it is excreted"/>
   <result pre="for conversion to tenofovir. Subsequent phosphorylation by cellular enzymes forms" exact="tenofovir" post="diphosphate, which competes with the natural substrate deoxyadenosine 5′-triphosphate"/>
   <result pre="for the treatment of CHB. In a randomized trial comparing" exact="tenofovir" post="and adefovir, a higher percentage of patients receiving tenofovir"/>
   <result pre="comparing tenofovir and adefovir, a higher percentage of patients receiving" exact="tenofovir" post="achieved HBV DNA level suppression. In HBeAg-positive patients, the"/>
   <result pre="adefovir and tenofovir.185, 186, 187, 188 The adverse effects of" exact="tenofovir" post="include gastrointestinal symptoms, dizziness, fatigue, and headache. Renal toxicities,"/>
   <result pre="have been associated with tenofovir.189, 190, 191, 192, 193 Primary" exact="tenofovir" post="resistance mutations have not been well defined. Although viruses"/>
   <result pre="than do wild-type viruses. One study reported rtA194T as a" exact="tenofovir" post="resistance mutation; however, this pattern was not confirmed in"/>
   <result pre="current standard treatment of CHC is peginterferon-α in combination with" exact="ribavirin" post="for 24 weeks (for HCV genotype 2 or 3)"/>
   <result pre="after completion of treatment. A combination regimen of peginterferon-α and" exact="ribavirin" post="results in SVR rates between 38% and 46%, and"/>
   <result pre="serine protease inhibitors to the backbone therapies of peginterferon-α and" exact="ribavirin" post="will emerge as the standard of care for the"/>
   <result pre="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition of" exact="boceprevir" post="for 22 weeks or 44 weeks to standard therapy"/>
   <result pre="HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2) trial evaluated" exact="boceprevir" post="for the treatment of patients who had experienced a"/>
   <result pre="rates were significantly higher for patients who received peginterferon-ribavirin plus" exact="boceprevir" post="treatment for 32 weeks (59%) or 44 weeks (66%)"/>
   <result pre="logistic regression analysis, the baseline factors associated with SVR were" exact="boceprevir" post="use, previous relapse (compared with previous nonresponder), low viral"/>
   <result pre="with peginterferon and ribavirin. The most common adverse effects of" exact="boceprevir" post="are flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The"/>
   <result pre="flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The addition of" exact="boceprevir" post="nearly doubled the rate of anemia compared with the"/>
   <result pre="of anemia compared with the use of standard peginterferon and" exact="ribavirin" post="therapy, with many patients requiring the use of erythropoietin.195"/>
   <result pre="binding reversibly to nonstructural 3 serine protease. After oral administration," exact="telaprevir" post="achieves peak plasma concentrations in 4 to 5 hours."/>
   <result pre="3 international randomized double-blind placebo-controlled clinical trial, the addition of" exact="telaprevir" post="to the standard treatment of peginterferon-ribavirin was associated with"/>
   <result pre="Specifically, the group of patients who received 12 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin, followed by peginterferon-ribavirin for 12 weeks"/>
   <result pre="standard therapy among patients who received only 8 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin (69% vs 44%).201 In the second"/>
   <result pre="44%).201 In the second randomized phase 3 trial that evaluated" exact="telaprevir" post="in treatment-experienced patients with HCV genotype 1 infection, the"/>
   <result pre="treatment-experienced patients with HCV genotype 1 infection, the addition of" exact="telaprevir" post="to the standard treatment regimen of peginterferon-α and ribavirin"/>
   <result pre="of telaprevir to the standard treatment regimen of peginterferon-α and" exact="ribavirin" post="was associated with significantly higher SVR rates compared with"/>
   <result pre="peginterferon-ribavirin alone.202 Collectively, these studies indicate that the addition of" exact="telaprevir" post="to standard peginterferon-ribavirin therapy can significantly improve SVR rates"/>
   <result pre="ribavirin. As a result of these findings, the FDA approved" exact="telaprevir" post="(750 mg 3 times daily) for this treatment indication."/>
   <result pre="most infections, such as acyclovir for herpes simplex virus and" exact="ganciclovir" post="for CMV. However, other of these &quot;old&quot; antiviral drugs"/>
   <result pre="for CMV. However, other of these &quot;old&quot; antiviral drugs (eg," exact="amantadine" post="and rimantadine for influenza virus infections) have lost their"/>
   <result pre="However, other of these &quot;old&quot; antiviral drugs (eg, amantadine and" exact="rimantadine" post="for influenza virus infections) have lost their clinical utility"/>
   <result pre="zosterJ Infect Dis15119853623653881542 16PerazellaMACrystal-induced acute renal failureAm J Med106199945946510225250 17HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
   <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatmentJ Antimicrob Chemother57200694594916540518 18ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicityAnn"/>
   <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatmentJ Antimicrob Chemother57200694594916540518 18ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicityAnn Pharmacother3219981111139475829 19WadeJCMeyersJDNeurologic"/>
   <result pre="follow-upJ Clin Microbiol42200424224914715760 23BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapyClin Microbiol Rev16200311412812525428 24MalvyDTreilhaudMBoueeSA"/>
   <result pre="the treatment of poxvirus infectionsViruses220102740276221499452 29WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects of" exact="cidofovir" post="with a reduced dose of probenecid in HIV-infected patients"/>
   <result pre="and renal effects of cidofovir with a reduced dose of" exact="probenecid" post="in HIV-infected patients with cytomegalovirus retinitisJ Clin Pharmacol432003435112520627 30CundyKCClinical"/>
   <result pre="retinitisJ Clin Pharmacol432003435112520627 30CundyKCClinical pharmacokinetics of the antiviral nucleotide analogues" exact="cidofovir" post="and adefovirClin Pharmacokinet36199912714310092959 31KendleJBFan-HavardPCidofovir in the treatment of cytomegaloviral"/>
   <result pre="of isolates from cytomegalovirus retinitis patients receiving first- or second-line" exact="cidofovir" post="therapy: relationship to clinical outcomeJ Infect Dis1781998182118259815243 33JabsDAEngerCFormanMDunnJPThe Cytomegalovirus"/>
   <result pre="Retinitis and Viral Resistance Study GroupIncidence of foscarnet resistance and" exact="cidofovir" post="resistance in patients treated for cytomegalovirus retinitisAntimicrob Agents Chemother421998224022449736542"/>
   <result pre="patients treated for cytomegalovirus retinitisAntimicrob Agents Chemother421998224022449736542 34SnoeckRDe ClercqERole of" exact="cidofovir" post="in the treatment of DNA virus infections, other than"/>
   <result pre="patientsCurr Opin Investig Drugs3200215611566 35ChaSJohnstonLNatkunamYBrownJTreatment of verruca vulgaris with topical" exact="cidofovir" post="in an immunocompromised patient: a case report and review"/>
   <result pre="case report and review of the literatureTranspl Infect Dis7200515816116390407 36LamothFPascualMErardVVenetzJPNseirGMeylanPLow-dose" exact="cidofovir" post="for the treatment of polyomavirus-associated nephropathy: two case reports"/>
   <result pre="two case reports and review of the literatureAntivir Ther1320081001100919195325 37ToroJRSanchezSTurianskyGBlauveltATopical" exact="cidofovir" post="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial"/>
   <result pre="Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a childPediatr Infect Dis J2020011083108611734717 40KoppTGeusauARiegerAStinglGSuccessful treatment of"/>
   <result pre="treatment of an aciclovir-resistant herpes simplex type 2 infection with" exact="cidofovir" post="in an AIDS patientBr J Dermatol147200213413812100196 41GarveyLThomsonECTaylorGPProgressive multifocal leukoencephalopathy:"/>
   <result pre="inhibitors and cidofovir: a case seriesAIDS20200679179316514320 42MarraCMRajicicNBarkerDEA pilot study of" exact="cidofovir" post="for progressive multifocal leukoencephalopathy in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of"/>
   <result pre="patient receiving highly active antiretroviral therapyMayo Clin Proc7620011171117511702907 44Segarra-NewnhamMVodoloKMUse of" exact="cidofovir" post="in progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of progressive multifocal"/>
   <result pre="progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of progressive multifocal leukoencephalopathy after" exact="cidofovir" post="therapy in a patient with a destructive polyarthritisInfection352007333617297588 46CesaroSHirschHHFaraciMCidofovir"/>
   <result pre="associated with cidofovirJ Antimicrob Chemother60200719319417496056 49AmbatiJWynneKBAngerameMCRobinsonMRAnterior uveitis associated with intravenous" exact="cidofovir" post="use in patients with cytomegalovirus retinitisBr J Ophthalmol8319991153115810502577 50TsengALMortimerCBSalitIEIritis"/>
   <result pre="Pharmacother33199916717110084411 51GillKSWoodMJThe clinical pharmacokinetics of famciclovirClin Pharmacokinet311996188827396 52FaroSA review of" exact="famciclovir" post="in the management of genital herpesInfect Dis Obstet Gynecol6199838439678146"/>
   <result pre="update and review of new single-day dosing indicationsCutis802007778117725069 54SaltzmanRJurewiczRBoonRSafety of" exact="famciclovir" post="in patients with herpes zoster and genital herpesAntimicrob Agents"/>
   <result pre="Group; Cytomegalovirus Cooperative Study GroupA randomized, controlled study of intravenous" exact="ganciclovir" post="therapy for cytomegalovirus peripheral retinitis in patients with AIDSJ"/>
   <result pre="with AIDSJ Infect Dis16819935575638394858 69DrewWLIvesDLalezariJPSyntex Cooperative Oral Ganciclovir Study GroupOral" exact="ganciclovir" post="as maintenance treatment for cytomegalovirus retinitis in patients with"/>
   <result pre="Transplantation Study GroupRandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients"/>
   <result pre="Lancet. 1998;351(9100):454]Lancet3501997172917339413463 71EidAJArthursSKDezielPJWilhelmMPRazonableRREmergence of drug-resistant cytomegalovirus in the era of" exact="valganciclovir" post="prophylaxis: therapeutic implications and outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling penciclovir susceptibility"/>
   <result pre="era of valganciclovir prophylaxis: therapeutic implications and outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
   <result pre="simplex virus isolates across eleven clinical trialsArch Virol14820031757176914505088 73BaconTHBoydMRActivity of" exact="penciclovir" post="against Epstein-Barr virusAntimicrob Agents Chemother391995159916027492112 74SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonRTopical Penciclovir Collaborative Study"/>
   <result pre="76SpruanceSLTyringSKDeGregorioBMillerCBeutnerKValaciclovir HSV Study GroupA large-scale, placebo-controlled, dose-ranging trial of peroral" exact="valaciclovir" post="for episodic treatment of recurrent herpes genitalisArch Intern Med1561996172917358694673"/>
   <result pre="disease in immunocompromised hostsExpert Rev Anti Infect Ther22004274115482169 80BrownFBankenLSaywellKArumIPharmacokinetics of" exact="valganciclovir" post="and ganciclovir following multiple oral dosages of valganciclovir in"/>
   <result pre="immunocompromised hostsExpert Rev Anti Infect Ther22004274115482169 80BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and" exact="ganciclovir" post="following multiple oral dosages of valganciclovir in HIV- and"/>
   <result pre="80BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of" exact="valganciclovir" post="in HIV- and CMV-seropositive volunteersClin Pharmacokinet37199916717610496303 81WiltshireHHirankarnSFarrellCPharmacokinetic profile of"/>
   <result pre="valganciclovir in HIV- and CMV-seropositive volunteersClin Pharmacokinet37199916717610496303 81WiltshireHHirankarnSFarrellCPharmacokinetic profile of" exact="ganciclovir" post="after its oral administration and from its prodrug, valganciclovir,"/>
   <result pre="valganciclovir, in solid organ transplant recipientsClin Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of" exact="ganciclovir" post="after intravenous ganciclovir and oral valganciclovir administration in solid"/>
   <result pre="organ transplant recipientsClin Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of ganciclovir after intravenous" exact="ganciclovir" post="and oral valganciclovir administration in solid organ transplant patients"/>
   <result pre="Pharmacokinet44200549550715871635 82CaldesAColomHArmendarizYPopulation pharmacokinetics of ganciclovir after intravenous ganciclovir and oral" exact="valganciclovir" post="administration in solid organ transplant patients infected with cytomegalovirusAntimicrob"/>
   <result pre="patients infected with cytomegalovirusAntimicrob Agents Chemother5320094816482419738014 83MartinDFSierra-MaderoJWalmsleySA controlled trial of" exact="valganciclovir" post="as induction therapy for cytomegalovirus retinitisN Engl J Med34620021119112611948271"/>
   <result pre="for cytomegalovirus retinitisN Engl J Med34620021119112611948271 84PayaCHumarADominguezEEfficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="Engl J Med34620021119112611948271 84PayaCHumarADominguezEEfficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="solid organ transplant recipientsAm J Transplant4200461162015023154 85KhouryJAStorchGABohlDLProphylactic versus preemptive oral" exact="valganciclovir" post="for the management of cytomegalovirus infection in adult renal"/>
   <result pre="infection in adult renal transplant recipientsAm J Transplant620062134214316780548 86SnydmanDRUse of" exact="valganciclovir" post="for prevention and treatment of cytomegalovirus disease [editorial]Clin Infect"/>
   <result pre="prevention and treatment of cytomegalovirus disease [editorial]Clin Infect Dis462008282918171209 87EinseleHReusserPBornhauserMOral" exact="valganciclovir" post="leads to higher exposure to ganciclovir than intravenous ganciclovir"/>
   <result pre="[editorial]Clin Infect Dis462008282918171209 87EinseleHReusserPBornhauserMOral valganciclovir leads to higher exposure to" exact="ganciclovir" post="than intravenous ganciclovir in patients following allogeneic stem cell"/>
   <result pre="87EinseleHReusserPBornhauserMOral valganciclovir leads to higher exposure to ganciclovir than intravenous" exact="ganciclovir" post="in patients following allogeneic stem cell transplantationBlood10720063002300816352807 88LenOGavaldaJAguadoJMValganciclovir as"/>
   <result pre="cytomegalovirus disease in solid organ transplant recipientsClin Infect Dis462008202718171208 89AsbergAHumarARollagHOral" exact="valganciclovir" post="is noninferior to intravenous ganciclovir for the treatment of"/>
   <result pre="transplant recipientsClin Infect Dis462008202718171208 89AsbergAHumarARollagHOral valganciclovir is noninferior to intravenous" exact="ganciclovir" post="for the treatment of cytomegalovirus disease in solid organ"/>
   <result pre="91De ClercqEAntiviral drugs in current clinical useJ Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine," exact="oseltamivir" post="and zanamivir for the prophylaxis of influenza (including a"/>
   <result pre="drugs in current clinical useJ Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine, oseltamivir and" exact="zanamivir" post="for the prophylaxis of influenza (including a review of"/>
   <result pre="systematic review and economic evaluationHealth Technol Assess131120091246iii, ix-xii 93BettsRFAmantadine and" exact="rimantadine" post="for the prevention of influenza ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh"/>
   <result pre="the prevention of influenza ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of" exact="amantadine" post="resistance among circulating European porcine influenza A virusesJ Gen"/>
   <result pre="Virol442009919319019729 96HaydenFGHayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadineCurr Top Microbiol Immunol17619921191301600749 97HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of drug-resistant influenza"/>
   <result pre="pandemicJ Antimicrob Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of" exact="oseltamivir" post="and zanamivir against influenza virus infection in childrenClin Infect"/>
   <result pre="Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of oseltamivir and" exact="zanamivir" post="against influenza virus infection in childrenClin Infect Dis47200833934518582202 100KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic"/>
   <result pre="neuraminidase inhibitorsJAMA29720071435144217405969 106FreundBGravensteinSElliottMMillerIZanamivir: a review of clinical safetyDrug Saf21199926728110514019 107GaurAHBaggaBBarmanSIntravenous" exact="zanamivir" post="for oseltamivir-resistant 2009 H1N1 influenza [letter]N Engl J Med36212010888920032317"/>
   <result pre="HBeAg-positive chronic hepatitis BN Engl J Med35220052682269515987917 117MarcellinPLauGKBoninoFPeginterferon alfa-2a alone," exact="lamivudine" post="alone, and the two in combination in patients with"/>
   <result pre="Med35120041206121715371578 118JanssenHLvan ZonneveldMSenturkHPegylated Interferon alfa-2b alone or in combination with" exact="lamivudine" post="for HBeAg-positive chronic hepatitis B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment"/>
   <result pre="for chronic hepatitis CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infectionN Engl J Med347200297598212324553"/>
   <result pre="hepatitis C virus infectionN Engl J Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
   <result pre="in HIV-infected patients: a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon Alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection in HIV-infected patientsN"/>
   <result pre="infection in HIV-infected patientsN Engl J Med351200443845015282351 133ChungRTAndersenJVolberdingPPeginterferon Alfa-2a plus" exact="ribavirin" post="versus interferon alfa-2a plus ribavirin for chronic hepatitis C"/>
   <result pre="J Med351200443845015282351 133ChungRTAndersenJVolberdingPPeginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C in HIV-coinfected personsN Engl J"/>
   <result pre="J Med310198432356689738 147AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin therapyDermatology205200230030112399683 148WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of" exact="ribavirin" post="in patients with hepatitis C virusBr J Clin Pharmacol62200671071417118126"/>
   <result pre="clearance of intravenously administered ribavirinAntimicrob Agents Chemother3419904894902334164 150GishRGTreating HCV with" exact="ribavirin" post="analogues and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus ribavirin"/>
   <result pre="with ribavirin analogues and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus" exact="ribavirin" post="for chronic hepatitis C in patients with human immunodeficiency"/>
   <result pre="infants and young childrenCochrane Database Syst Rev2007CD00018117253446 153PelaezALyonGMForceSDEfficacy of oral" exact="ribavirin" post="in lung transplant patients with respiratory syncytial virus lower"/>
   <result pre="Lung Transplant282009677119134533 154KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin Infect Dis3720031139114214523782"/>
   <result pre="156McJunkinJEKhanRde los ReyesECTreatment of severe La Crosse encephalitis with intravenous" exact="ribavirin" post="following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment of acute Nipah"/>
   <result pre="J Med314198620263940312 159HugginsJWHsiangCMCosgriffTMProspective, double-blind, concurrent, placebo-controlled clinical trial of intravenous" exact="ribavirin" post="therapy of hemorrhagic fever with renal syndromeJ Infect Dis1641991111911271683355"/>
   <result pre="Congo-haemorrhagic fever treated with oral ribavirinLancet34619954724757637481 161MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in IranClin"/>
   <result pre="with adefovir dipivoxilJ Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA double-blind placebo-controlled study of" exact="emtricitabine" post="in chronic hepatitis BArch Intern Med1662006495616401810 171SimsKAWoodlandAMEntecavir: a new"/>
   <result pre="BDrugs6920091003103319496629 174JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of" exact="lamivudine" post="for chronic hepatitis B infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine"/>
   <result pre="J Med34119991256126310528035 177LaiCLChienRNLeungNWAsia Hepatitis Lamivudine Study GroupA one-year trial of" exact="lamivudine" post="for chronic hepatitis BN Engl J Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis"/>
   <result pre="Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B reactivation after lamivudineLancet3461995115611577475613 179ZhouXJKeJSallasWMFarrellCMayersDLPentikisHSPopulation pharmacokinetics of" exact="telbivudine" post="and determination of dose adjustment for patients with renal"/>
   <result pre="agents: a focus on telbivudineInt J Clin Pract6020061295129916981973 182LaiCLGaneELiawYFTelbivudine versus" exact="lamivudine" post="in patients with chronic hepatitis BN Engl J Med35720072576258818094378"/>
   <result pre="183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e antigen positive chronic hepatitis with" exact="telbivudine" post="or adefovir: a randomized trialAnn Intern Med147200774575417909201 184KearneyBPFlahertyJFShahJTenofovir disoproxil"/>
   <result pre="187WongSNLokASTenofovir disoproxil fumarate: role in hepatitis B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of" exact="tenofovir" post="in chronic hepatitis B: mono or combination therapy?J Hepatol48200838338618191272"/>
   <result pre="Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial nephritis of HIV-positive patients under" exact="atazanavir" post="and tenofovir therapy in a retrospective analysis of kidney"/>
   <result pre="STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial nephritis of HIV-positive patients under atazanavir and" exact="tenofovir" post="therapy in a retrospective analysis of kidney biopsiesVirchows Arch450200766567017464512"/>
   <result pre="treated with the protease inhibitor telaprevirGastroenterology13220071767177717484874 199McHutchisonJGEversonGTGordonSCTelaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infectionN Engl J Med36020091827183819403902"/>
   <result pre="infectionN Engl J Med36020091827183819403902 200HézodeCForestierNDusheikoGTelaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infectionN Engl J Med36020091839185019403903 201JacobsonIMMcHutchisonJGDusheikoGTelaprevir for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3764029/results/search/drugs/results.xml">
   <result pre="used by anyone for any lawful purpose. Abstract Background While" exact="ribavirin" post="mono-therapy regimens have minimal effect on patients with chronic"/>
   <result pre="with interferon. Clinical studies show that interferon-free combination therapies containing" exact="ribavirin" post="are also efficacious, suggesting that an interferon-free therapy could"/>
   <result pre="the treatment. Therefore, understanding the mechanism of HCV resistance to" exact="ribavirin" post="and cross resistance to other antiviral drugs could be"/>
   <result pre="Methods We tested the ability of a J6/JFH1 derived HCV" exact="ribavirin" post="resistant mutant to grow in tissue cultured Huh7D cells"/>
   <result pre="mutations. Conclusions These results indicate that determinants of resistance to" exact="ribavirin" post="could also confer resistance to other anti-HCV drugs, shedding"/>
   <result pre="drugs, shedding light toward understanding the mechanism of action of" exact="ribavirin" post="and highlighting the importance of combination drug selection for"/>
   <result pre="patients consists of a combination of pegylated interferon alpha and" exact="ribavirin" post="[4]. Recently, two protease inhibitors were approved by the"/>
   <result pre="HCV infections is highly desirable. Recent studies have shown that" exact="ribavirin" post="in combination with other antiviral drugs, without interferon, can"/>
   <result pre="be efficacious [7], [8], suggesting that an interferon-free therapy containing" exact="ribavirin" post="could be adopted in the near future. However, generation"/>
   <result pre="treatment. In addition, the anti HCV mechanism of action of" exact="ribavirin" post="is not completely elucidated. Several mechanisms of action of"/>
   <result pre="ribavirin is not completely elucidated. Several mechanisms of action of" exact="ribavirin" post="against HCV were proposed including a direct effect against"/>
   <result pre="[10]. In order to study the cross-resistance of HCV to" exact="ribavirin" post="and other antiviral drugs that could have a mechanism"/>
   <result pre="we tested the ability of a J6/JFH1 [11] HCV derived" exact="ribavirin" post="resistant mutant, HCV-RR [12], to grow in the presence"/>
   <result pre="a similar lethal mutagenic effect has also been observed for" exact="ribavirin" post="on several viruses including poliovirus [17], coxsackievirus B3 [18],"/>
   <result pre="[21], and Hantaan virus [22]. It has been shown that" exact="ribavirin" post="also has a mutagenic effect on HCV, increasing its"/>
   <result pre="in vivo [25], [27]. Deep sequencing has recently revealed that" exact="ribavirin" post="exerts mutagenic activity in chronic HCV infected patients by"/>
   <result pre="cell-free biochemical assays [36]. It has also been shown that" exact="ribavirin" post="antagonizes the in vitro anti-HCV activity of 2′-C-Methylcytidine [37],"/>
   <result pre="this study we show that an HCV mutant resistant to" exact="ribavirin" post="is more resistant than parental J6/JFH1 to 5-Fluorouracil, but"/>
   <result pre="resistant than parental J6/JFH1 to 2′-C-Methylcytidine. These results indicate that" exact="ribavirin" post="resistant viruses could have elevated resistance to other inhibitors,"/>
   <result pre="light toward the understanding of the mechanism of action of" exact="ribavirin" post="and HCV resistance to this drug. In addition, the"/>
   <result pre="5-Fluorouracil In order to test the sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 5-Fluorouracil, parental J6/JFH1 [11] and J6/JFH1"/>
   <result pre="of 2′-C-Methylcytidine In order to test sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 2′-C-Methylcytidine, parental J6/JFH1 and HCV-RR2 were"/>
   <result pre="of the drug (Figure 4) and are still resistant to" exact="ribavirin" post="(not shown). Figure 4 Further passage of HCV in"/>
   <result pre="In this study we compared the growth of an HCV" exact="ribavirin" post="resistant mutant (HCV-RR2) to the growth of its parental"/>
   <result pre="the nucleoside analog 2′-C-Methylcytidine. We show that HCV resistant to" exact="ribavirin" post="is more resistant to 5-Fluorouracil but is not more"/>
   <result pre="along the genome (Table 1). The mechanism of action of" exact="ribavirin" post="against HCV in vitro and in vivo and the"/>
   <result pre="vitro and in vivo and the mechanism of resistance to" exact="ribavirin" post="by HCV ribavirin resistant mutants has not been completely"/>
   <result pre="vivo and the mechanism of resistance to ribavirin by HCV" exact="ribavirin" post="resistant mutants has not been completely elucidated. The differential"/>
   <result pre="fact that 5-Fluorouracil is a pyrimidine analog and 2′-C-Methylcytidine and" exact="ribavirin" post="are both nucleoside analogs. Given the nature of these"/>
   <result pre="nature of these drugs, it is tempting to speculate that" exact="ribavirin" post="acts on HCV at the RNA replication level, as"/>
   <result pre="shown for 2′-C-Methylcytidine [36]. We previously showed that an HCV" exact="ribavirin" post="resistant mutant has mutations in different positions of its"/>
   <result pre="that the RNA dependent RNA polymerase from HCV can use" exact="ribavirin" post="triphosphate as a nucleotide substrate. Once ribavirin monophosphate has"/>
   <result pre="HCV can use ribavirin triphosphate as a nucleotide substrate. Once" exact="ribavirin" post="monophosphate has been incorporated in the nascent chain, it"/>
   <result pre="RNA elongation [38], [39]. As noted above, mutagenic activity of" exact="ribavirin" post="on HCV has been observed in vivo and in"/>
   <result pre="its parental J6/JFH1. This indicates that determinants conferring resistance to" exact="ribavirin" post="also confer resistance to 5-Fluorouracil and could confer resistance"/>
   <result pre="drug treatments. Given the observed efficacy of the inclusion of" exact="ribavirin" post="in interferon free regimens in the treatment of chronic"/>
   <result pre="the treatment of chronic HCV, cross resistance of HCV to" exact="ribavirin" post="and to other antiviral drugs could be of major"/>
   <result pre="In FMDV, a single point mutation (M296I) confers resistance to" exact="ribavirin" post="[40]. This mutant was as sensitive as wild type"/>
   <result pre="the action of antiviral drugs. Of note, the concentrations of" exact="ribavirin" post="(5 mM) and 5-Fluorouracil (200 or 500 µg/ml) for"/>
   <result pre="[12]. Mutations in the finger domain have been identified in" exact="ribavirin" post="resistant mutants of poliovirus [44], [45]. Five other non-synonymous"/>
   <result pre="viral replication. Conclusion In this report, we show that a" exact="ribavirin" post="resistant mutant of HCV has differential sensitivity to other"/>
   <result pre="suggests that mutations that are responsible for HCV resistance to" exact="ribavirin" post="can be involved in the sensitivity to other drugs,"/>
   <result pre="clinically important for drug selection, since an interferon-free regimen containing" exact="ribavirin" post="for the treatment of HCV infections seems currently plausible."/>
   <result pre="10% bovine calf serum (Atlanta Biologicals), L-glutamine (Gibco), penicillin, and" exact="streptomycin" post="(Gibco). Viruses Virus J6/JFH1 was obtained from plasmid pFL-"/>
   <result pre="ShiffmanML, ReddyKR, SmithC, MarinosG, et al. (2002) Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
   <result pre="975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE, FlammSL, AfdhalNH, NelsonDR, SulkowskiMS, et al. (2011) Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
   <result pre="polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus" exact="ribavirin" post="in hepatitis C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP,"/>
   <result pre="the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and" exact="ribavirin" post="in patients with chronic HCV infection. Gastroenterology 1412047–2055: S0016–5085(11)01248-0doi:10.1053/j.gastro.2011.08.051"/>
   <result pre="LiangTJ, et al. (2008) Mechanisms of action of interferon and" exact="ribavirin" post="in chronic hepatitis C: Summary of a workshop. Hepatology47:"/>
   <result pre="ArnoldJJ, ZhongW, LauJY, et al. (2000) The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med6: 1375–1379.11100123 18GraciJD,"/>
   <result pre="Curing of foot-and-mouth disease virus from persistently infected cells by" exact="ribavirin" post="involves enhanced mutagenesis. Virology 311339–349: S0042682203001442. 20Day CW, Smee"/>
   <result pre="23BrochotE, DuverlieG, CastelainS, MorelV, WychowskiC, et al. (2007) Effect of" exact="ribavirin" post="on the hepatitis C virus (JFH-1) and its correlation"/>
   <result pre="(2002) Viral RNA mutations are region specific and increased by" exact="ribavirin" post="in a full-length hepatitis C virus replication system. J"/>
   <result pre="PoltaA, HerrmannE, MihmU, KronenbergerB, et al. (2007) Mutagenic effect of" exact="ribavirin" post="on hepatitis C nonstructural 5B quasispecies in vitro and"/>
   <result pre="Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells:" exact="ribavirin" post="induces mutagenesis in HCV RNA. J Viral Hepat11: 479–487.15500548"/>
   <result pre="the hepatitis C virus NS5B in patients undergoing treatment with" exact="ribavirin" post="monotherapy. Gastroenterology132: 1757–1766.17484873 28DietzJ, SchelhornSE, FittingD, MihmU, SusserS, et"/>
   <result pre="SusserS, et al. (2013) Deep sequencing reveals mutagenic effects of" exact="ribavirin" post="during monotherapy of hepatitis C virus genotype 1-infected patients."/>
   <result pre="46094–46098.11602568 39VoNV, YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3854647/results/search/drugs/results.xml">
   <result pre="severe or with complications were considered [5]. In the Netherlands," exact="oseltamivir" post="was the drug of first choice for treatment of"/>
   <result pre="risk patients suspected of influenza during the pandemic. Treatment with" exact="zanamivir" post="was reserved for patients suspected for an infection with"/>
   <result pre="this study was therefore to investigate whether the prescription of" exact="oseltamivir" post="by general practitioners (GPs) in the Netherlands was in"/>
   <result pre="national database to estimate 1) the proportion of patients receiving" exact="oseltamivir" post="according to the guidelines in relation to patients’ and"/>
   <result pre="and 2) what proportion of patients diagnosed with influenza received" exact="oseltamivir" post="and which factors determined this prescription. Methods Practices and"/>
   <result pre="the GPs were considered. First, patients having a prescription of" exact="oseltamivir" post="(ATC-code J05AH02) between August 8 and December 31, 2009"/>
   <result pre="8 and December 31, 2009 were considered. No prescriptions of" exact="zanamivir" post="were registered. When there was more than one oseltamivir"/>
   <result pre="of zanamivir were registered. When there was more than one" exact="oseltamivir" post="prescription, only the first one was taken into account."/>
   <result pre="to take into account registration delays. However, in 88% of" exact="oseltamivir" post="prescriptions, the diagnosis was registered at the same day."/>
   <result pre="illness outside the influenza season). Patients who did not receive" exact="oseltamivir" post="were evaluated for a diagnosis of influenza. When more"/>
   <result pre="consultation was taken. Recommended treatment of high risk patients with" exact="oseltamivir" post="was based on age (&amp;lt;2 years or ≥60 years),"/>
   <result pre="– within these days), or a third trimester pregnancy (an" exact="oseltamivir" post="prescription or an influenza diagnosis between 20 to 34"/>
   <result pre="child had to be no more than 14 weeks after" exact="oseltamivir" post="prescription or influenza diagnosis). Details on ICPC- and ATC-codes"/>
   <result pre="we evaluated the proportion of patients whom had been prescribed" exact="oseltamivir" post="and whom should have been prescribed it. Univariate logistic"/>
   <result pre="analyses were performed on the association between the prescription of" exact="oseltamivir" post="and a recommendation for a prescription, as well as"/>
   <result pre="associated with the prescription of oseltamivir. Likewise, we evaluated whether" exact="oseltamivir" post="was prescribed according to the guidelines among all patients"/>
   <result pre="all patients receiving oseltamivir. Because of the recommendation to prescribe" exact="oseltamivir" post="to both very young (under two years of age)"/>
   <result pre="enlisted patients) had been prescribed oseltamivir. The total number of" exact="oseltamivir" post="prescriptions ranged between practices from 0 (11 practices) to"/>
   <result pre="geometric mean = 0.9; geometric standard distribution = 3.4). Half of the patients receiving" exact="oseltamivir" post="had a diagnosis of influenza (n = 181; 51.6%). The most"/>
   <result pre="valid ICPC-code was recorded for 23 patients (6.6%). Of all" exact="oseltamivir" post="prescriptions, 241 (68.7%) were to patients belonging to the"/>
   <result pre="shows the distribution of the underlying reasons for qualification for" exact="oseltamivir" post="in these patients. Table 1 Characteristics of 241 patients"/>
   <result pre="at high risk of severe illness who had been prescribed" exact="oseltamivir" post="n of patients (%) High risk group description  Age"/>
   <result pre="age were associated with an increased chance of having an" exact="oseltamivir" post="prescription according to the recommendations. Independently of age, a"/>
   <result pre="number of prescriptions in general were positively associated with prescribing" exact="oseltamivir" post="according to the guidelines. Table 2 Factors influencing a"/>
   <result pre="to the guidelines. Table 2 Factors influencing a prescription of" exact="oseltamivir" post="according to clinical guidelines in 351 patients with antiviral"/>
   <result pre="to 6.42) 0.001 GP = general practitioner; OR = odds ratio; CI = confidence interval. *Excluding" exact="oseltamivir" post="prescriptions. A total of 3,293 patients (1.3% of the"/>
   <result pre="(1.3% of the study population) were diagnosed with influenza and" exact="oseltamivir" post="was prescribed to 181 (5.5%). The weekly number of"/>
   <result pre="of prescriptions in 2009 were determinants of the prescription of" exact="oseltamivir" post="among influenza patients (Table 3). Patients with underlying co-morbidity"/>
   <result pre="Patients with underlying co-morbidity had the highest chance of an" exact="oseltamivir" post="prescription. All of the designated high risk groups were"/>
   <result pre="the designated high risk groups were statistically significantly associated with" exact="oseltamivir" post="prescription, except children receiving chronic aspirin therapy. Taking into"/>
   <result pre="complicated course of illness, but this was not associated with" exact="oseltamivir" post="treatment. Practice characteristics were not associated with oseltamivir prescriptions."/>
   <result pre="associated with oseltamivir treatment. Practice characteristics were not associated with" exact="oseltamivir" post="prescriptions. Table 3 Potential factors influencing the prescription of"/>
   <result pre="oseltamivir prescriptions. Table 3 Potential factors influencing the prescription of" exact="oseltamivir" post="by general practitioners to 3,293 influenza patients Prescription of"/>
   <result pre="interval. *Reference group does not have the specific co-morbidity. †Excluding" exact="oseltamivir" post="prescriptions. The results of the multilevel model with age,"/>
   <result pre="60 years or above in itself was not associated with" exact="oseltamivir" post="prescription. Independently of a high risk for severe disease"/>
   <result pre="at high risk of severe illness were not associated with" exact="oseltamivir" post="prescription, nor were age, gender, and consultation rate or"/>
   <result pre="or practice characteristics (Table 4). The only significant determinant for" exact="oseltamivir" post="prescriptions was the total number of drug prescriptions in"/>
   <result pre="to 4.32). Table 4 Potential factors influencing the prescription of" exact="oseltamivir" post="to 2,242 influenza patients not at high risk Prescription"/>
   <result pre="(0.40 to 1.82) GP = general practitioner; OR = odds ratio; CI = confidence interval. *Excluding" exact="oseltamivir" post="prescriptions. Discussion This study showed that general practitioners in"/>
   <result pre="general practitioners in the Netherlands have been restrained in prescribing" exact="oseltamivir" post="during the influenza pandemic. Only 5% of all patients"/>
   <result pre="can be considered proxies for underlying morbidity, were determinants for" exact="oseltamivir" post="prescription in addition to the high risk factors of"/>
   <result pre="[14], who found that 85% of Dutch patients with an" exact="oseltamivir" post="prescription belonged to the high risk groups. Their study"/>
   <result pre="on telephone interviews with patients who filled a prescription for" exact="oseltamivir" post="through community pharmacists. Results from other countries on prescriptions"/>
   <result pre="through community pharmacists. Results from other countries on prescriptions of" exact="oseltamivir" post="during the A(H1N1)pdm09 pandemic are scarce. In a study"/>
   <result pre="Chicago hospital, 65% of high-risk patients with influenza-like illness received" exact="oseltamivir" post="treatment [17]. These figures are much higher than in"/>
   <result pre="our study. The results of our study show that if" exact="oseltamivir" post="was prescribed, it was in accordance with the guidelines"/>
   <result pre="fairly well. But they often did not prescribe, even when" exact="oseltamivir" post="was recommended. The availability of antiviral drugs was no"/>
   <result pre="available from the national stockpile. A possible explanation for withholding" exact="oseltamivir" post="to patients at higher risk of complications might have"/>
   <result pre="this is the first study in which recommendations for prescribing" exact="oseltamivir" post="in primary care has been evaluated in detail. More"/>
   <result pre="rate more so than practice featuresPrev Med20023540140610.1006/pmed.2002.108312453719 FietjéEHPhilbertDvan GeffenECWintersNABouvyMLAdherence to" exact="oseltamivir" post="guidelines during influenza pandemic, the NetherlandsEmerg Infect Dis20121853453510.3201/eid1803.11135122377063 HershALStaffordRSAntiviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4195804/results/search/drugs/results.xml">
   <result pre="initial outbreak of SARS, a number of medications that included" exact="ribavirin" post="with and without corticosteroids [81, 82, 83], interferon (alfacon-1)"/>
   <result pre="corticosteroids [81, 82, 83], interferon (alfacon-1) with corticosteroids [84], and" exact="ribavirin" post="with protease inhibitors [85] had some encouraging outcomes, but"/>
   <result pre="not clearly established. More recently, a combination of IFN-α2b and" exact="ribavirin" post="were shown to have some in vitro synergistic activities"/>
   <result pre="of drug abuse/overdose, bacterial infections and many others (Interferon and" exact="ribavirin" post="treatment side effects, http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp#S1X). Hence, with the new outbreak"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4247767/results/search/drugs/results.xml">
   <result pre="antiviral drug combination. Combining multiple drugs such as interferon-α and" exact="ribavirin" post="is a standard therapy for enhancing the antiviral effects"/>
   <result pre="Med2012181378138510.1038/nm.289222941277 14.ZeuzemSSchmidtJMLeeJHvon WagnerMTeuberGRothWKHepatitis C virus dynamics in vivo: effect of" exact="ribavirin" post="and interferon alfa on viral turnoverHepatology19982824525210.1002/hep.5102801329657119 15.NeumannAULamNPDahariHGretchDRWileyTELaydenTJPerelsonASHepatitis C viral"/>
   <result pre="vivo and the antiviral efficacy of interferon-alpha therapyScience199828210310710.1126/science.282.5386.1039756471 16.DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infectionNature200443292292410.1038/nature0315315602565"/>
   <result pre="decay profiles of hepatitis B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling" exact="amantadine" post="treatment of influenza A virus in vitroJ Theor Biol200825443945110.1016/j.jtbi.2008.05.03118653201"/>
   <result pre="infection dynamicsJ Theor Biol201026733034010.1016/j.jtbi.2010.08.03620831874 52.GuedjJDahariHRongLSansoneNDNettlesRECotlerSJLaydenTJUprichardSLPerelsonASModeling shows that the NS5A inhibitor" exact="daclatasvir" post="has two modes of action and yields a shorter"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4353273/results/search/drugs/results.xml">
   <result pre="signs of spiking in several parts of Canada. NI drugs," exact="oseltamivir" post="(Tamiflu®, Hoffmann-La Roche Ltd, Canada) and zanamivir (Relenza®, GlaxoSmithKline"/>
   <result pre="Canada. NI drugs, oseltamivir (Tamiflu®, Hoffmann-La Roche Ltd, Canada) and" exact="zanamivir" post="(Relenza®, GlaxoSmithKline Inc, Canada), are the antiviral medications to"/>
   <result pre="as follows: 1. Antiviral drug therapy i. Residents: Oseltamivir or" exact="zanamivir" post="treatment should be administered as soon as the clinical"/>
   <result pre="h after illness onset. The dosage regimens for adults are" exact="oseltamivir" post="75 mg PO BID or zanamivir two inhalations BID."/>
   <result pre="regimens for adults are oseltamivir 75 mg PO BID or" exact="zanamivir" post="two inhalations BID. The treatment dose for oral oseltamivir"/>
   <result pre="or zanamivir two inhalations BID. The treatment dose for oral" exact="oseltamivir" post="for infants (younger than one year) is 3 mg/kg"/>
   <result pre="is 3 mg/kg twice a day. Given that in Canada," exact="oseltamivir" post="is currently not approved for use in infants younger"/>
   <result pre="current seasonal vaccine should be started on chemoprophylaxis with either" exact="oseltamivir" post="or zanamivir. Generally, it is preferable to wait to"/>
   <result pre="until laboratory confirmation has been received. The prophylactic doses are" exact="oseltamivir" post="75 mg PO once daily or zanamivir two inhalations"/>
   <result pre="prophylactic doses are oseltamivir 75 mg PO once daily or" exact="zanamivir" post="two inhalations once daily for adults. The prophylactic dose"/>
   <result pre="inhalations once daily for adults. The prophylactic dose for oral" exact="oseltamivir" post="for infants three months to younger than one year"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4353274/results/search/drugs/results.xml">
   <result pre="FOR AN UPDATE? Clinical trials with the neuraminidase inhibitors (NIs)" exact="oseltamivir" post="and zanamivir and and meta-analyses of oseltamivir therapy administered"/>
   <result pre="UPDATE? Clinical trials with the neuraminidase inhibitors (NIs) oseltamivir and" exact="zanamivir" post="and and meta-analyses of oseltamivir therapy administered within 36"/>
   <result pre="neuraminidase inhibitors (NIs) oseltamivir and zanamivir and and meta-analyses of" exact="oseltamivir" post="therapy administered within 36 h to 48 h of"/>
   <result pre="treatment after onset of symptoms (4). Earlier therapy with oral" exact="oseltamivir" post="administered within 12 h of symptom onset was shown"/>
   <result pre="was shown to reduce symptoms by 3.6 days (5). Inhaled" exact="zanamivir" post="shortened the duration of major influenza symptoms by 3"/>
   <result pre="placebo in individuals who were febrile at enrollment and received" exact="zanamivir" post="within 30 h (3). In low-risk outpatients, NI treatment"/>
   <result pre="H3N2 subtype and H1N1 pandemic subtype treated in hospital with" exact="oseltamivir" post="clearly demonstrate reduction in mortality, and this benefit was"/>
   <result pre="reduction in mortality, and this benefit was still observed if" exact="oseltamivir" post="was started up to 4 to 5 days after"/>
   <result pre="the predominating H3N2 virus isolates of influenza are susceptible to" exact="oseltamivir" post="and zanamivir. All isolates of H1N1 are oseltamivir- and"/>
   <result pre="Almost all isolates of influenza B are also susceptible to" exact="oseltamivir" post="and zanamivir. C. WHAT INVESTIGATIONS ARE REQUIRED TO DIAGNOSE"/>
   <result pre="onset of influenza-like symptoms. However, in severe illness requiring hospitalization," exact="oseltamivir" post="treatment has been shown to reduce mortality even if"/>
   <result pre="virus testing, treatment should be started immediately, most frequently with" exact="oseltamivir" post="orally. For adults with normal renal function, the typical"/>
   <result pre="mg every 12 h for five days. In ventilated patients," exact="oseltamivir" post="should be administered by nasogastric tube. If zanamivir is"/>
   <result pre="ventilated patients, oseltamivir should be administered by nasogastric tube. If" exact="zanamivir" post="is required in a severely ill patient, intravenous zanamivir"/>
   <result pre="If zanamivir is required in a severely ill patient, intravenous" exact="zanamivir" post="is recommended at a dose of 600 mg every"/>
   <result pre="a dose of 600 mg every 12 h. If intravenous" exact="zanamivir" post="is needed, it can be obtained by request to"/>
   <result pre="(0830-1630 weekdays), 613-941-3061 (after hours and weekends), fax 613-941-3194). Inhaled" exact="zanamivir" post="is not advised in a severely ill patient because"/>
   <result pre="through ventilator circuits is contraindicated. The recommended dose of oral" exact="oseltamivir" post="suspension for pediatric patients is shown Table 1, as"/>
   <result pre="used by adult patients who cannot swallow a capsule. If" exact="oseltamivir" post="oral suspension is not available, oseltamivir capsules may be"/>
   <result pre="swallow a capsule. If oseltamivir oral suspension is not available," exact="oseltamivir" post="capsules may be opened and mixed with sweetened liquids"/>
   <result pre="should be sent for viral PCR and susceptibility testing for" exact="oseltamivir" post="resistance. Suspected oseltamivir resistance should prompt a switch to"/>
   <result pre="for viral PCR and susceptibility testing for oseltamivir resistance. Suspected" exact="oseltamivir" post="resistance should prompt a switch to intravenous zanamivir until"/>
   <result pre="resistance. Suspected oseltamivir resistance should prompt a switch to intravenous" exact="zanamivir" post="until results of antiviral susceptibility testing are available. Repeated"/>
   <result pre="case can be reduced by early institution of post-exposure prophylactic" exact="oseltamivir" post="or zanamivir (16). Hospitalized patients and HCW, regardless of"/>
   <result pre="be reduced by early institution of post-exposure prophylactic oseltamivir or" exact="zanamivir" post="(16). Hospitalized patients and HCW, regardless of their vaccine"/>
   <result pre="contact with a patient with ILI, may be offered either" exact="oseltamivir" post="at a dose of 75 mg once daily or"/>
   <result pre="oseltamivir at a dose of 75 mg once daily or" exact="zanamivir" post="inhalation, two puffs (10 mg) once daily for seven"/>
   <result pre="receive post-exposure antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either" exact="oseltamivir" post="or zanamivir for hospitalized patients or staff is not"/>
   <result pre="antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either oseltamivir or" exact="zanamivir" post="for hospitalized patients or staff is not routinely recommended."/>
   <result pre="Michel Laverdiere: None. References REFERENCES 1.NicholsonKAokiFYOsterhausADet al.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: A randomized controlled trialLancet200035518455010866439"/>
   <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983521877819863784"/>
   <result pre="virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301"/>
   <result pre="and summary of regulatory commentsBMJ2014348g254524811411 5.AokiFYMacleodMDPaggiaroPet al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Ther2003511239 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe"/>
   <result pre="and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and" exact="zanamivir" post="treatment of influenza Updated from: The use of antiviral"/>
   <result pre="prescription instructions match the dosing device. 2.The above dosage provides" exact="oseltamivir" post="exposure in children similar to that achieved by the"/>
   <result pre="for adults (13–15). The American Academy of Pediatrics recommended an" exact="oseltamivir" post="treatment dose of 3.5 mg/kg orally twice daily for"/>
   <result pre="in the case of premature infants for whom treatment with" exact="oseltamivir" post="is being considered. The current weight-based dosing recommendations are"/>
   <result pre="premature infants as they might have slower clearance of oral" exact="oseltamivir" post="because of immature renal function. The following dosing is"/>
   <result pre="disease that increase the risk of bronchospasm. TABLE 2 Recommended" exact="oseltamivir" post="regimens for prevention and treatment of adult patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4531042/results/search/drugs/results.xml">
   <result pre="to minimize immunosuppression. The current antiviral drugs against CMV, ie," exact="ganciclovir" post="(GCV), foscarnet (PFA), and cidofovir (CDV), are associated with"/>
   <result pre="antiviral drugs against CMV, ie, ganciclovir (GCV), foscarnet (PFA), and" exact="cidofovir" post="(CDV), are associated with significant adverse effects. Moreover, there"/>
   <result pre="treatment are the nucleoside analog GCV, and its valine-ester prod-rug" exact="valganciclovir" post="(VGCV), the nucleotide analog CDV, and the pyrophosphate analog"/>
   <result pre="CMV-related disease. Often, transplant patients are receiving other drugs (eg," exact="tacrolimus" post="and calcineurin inhibitors) that augment the risk for renal"/>
   <result pre="specific sites where viral DNA will be cleaved; it produces" exact="adenosine" post="triphosphate (ATP) necessary for DNA translocation; and it combines"/>
   <result pre="CMV disease with 240 mg daily of letermovir was on" exact="tacrolimus" post="as part of his immunosuppression regimen, and no dose"/>
   <result pre="Infect Dis20094981167116819751150 5HumarALebranchuYVincentiFet al.The efficacy and safety of 200 days" exact="valganciclovir" post="cytomegalovirus prophylaxis in high-risk kidney transplant recipientsAm J Transplant20101051228123720353469"/>
   <result pre="kidney transplant recipientsAm J Transplant20101051228123720353469 6PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="J Transplant20101051228123720353469 6PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="(only moderate increases in the levels of midazolam, tacrolimus, and" exact="cyclosporine" post="were observed among healthy volunteers) McCormick48 Potential future applications"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4539848/results/search/drugs/results.xml">
   <result pre="agents compared to the single agent. Acetylcysteine was superior to" exact="ursodeoxycholic acid" post="or silibinin to reduce ALT. Ursodeoxycholic acid was superior"/>
   <result pre="the single agent. Acetylcysteine was superior to ursodeoxycholic acid or" exact="silibinin" post="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine"/>
   <result pre="or silibinin to reduce ALT. Ursodeoxycholic acid was superior to" exact="acetylcysteine" post="or silibinin to reduce TBIL. Conclusions: Hepatoprotective agents combined"/>
   <result pre="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or" exact="silibinin" post="to reduce TBIL. Conclusions: Hepatoprotective agents combined with antiviral"/>
   <result pre="function. These mechanisms may be related to the ability of" exact="ursodeoxycholic acid" post="to regulate cell cycle, apoptosis and protein biosynthesis of"/>
   <result pre="and cholagogue (9). Results of long-term observational studies showed that" exact="ursodeoxycholic acid" post="can significantly reduce the development of hepatic fibrosis (8,"/>
   <result pre="with a large amount of silibinin. it is noteworthy that," exact="silibinin" post="is the main active ingredient of silymarin (14). In"/>
   <result pre="the main active ingredient of silymarin (14). In recent years," exact="silibinin" post="has been used to treat liver cirrhosis, hepatitis, liver"/>
   <result pre="of glutathione transferase and promote the detoxification of free radicals." exact="nitric oxide" post="(NO) and its metabolite can improve microcirculation, increase tissue"/>
   <result pre="not only effective to treat liver failure caused by excessive" exact="acetaminophen" post="(paracetamol), but is also useful for liver disease arising"/>
   <result pre="Using &quot;chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective," exact="silibinin" post="(silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)&quot;,"/>
   <result pre="hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine)," exact="acetylcysteine" post="and ursodeoxycholic bile acid (UDCA)&quot;, the study retrieved papers"/>
   <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
   <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
   <result pre="Fabris et al. (25) 40 39 UDCA (0.6 g/d) +" exact="lactulose" post="(100-200 g/d) Lactulose (100 - 200 g/d) 3 w"/>
   <result pre="Flisiak et al. (31) 25 25 Silibinin (0.21 g/d) +" exact="misoprostol" post="(0.8 g/d) Placebo (unclear) 24 w ALT, AST, GGT,"/>
   <result pre="compared to UDCA and silibinin. The impact of UDCA and" exact="silibinin" post="on ALT levels in patients with hepatitis B were"/>
   <result pre="(WMD = -22.32; P = 0.03, 95% CI [-42.28, -2.36])," exact="silibinin" post="(WMD = -22.40; P = 0.11, 95% CI [-49.52,"/>
   <result pre="95 % confidence intervals. UDCA was superior over NAC and" exact="silibinin" post="to reduce TBIL in patients with hepatitis B. Meta-analysis"/>
   <result pre="[-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31])," exact="silibinin" post="(WMD = -2.09; 95% CI [-8.70, 4.52]). However, the"/>
   <result pre="In 2006, Qureshi et al reported that large doses of" exact="ursodeoxycholic acid" post="reduces ALT levels in patients with hepatitis B (28)."/>
   <result pre="(28). The meta-analysis of the current study showed that acetylcysteine," exact="ursodeoxycholic acid" post="and silibinin significantly reduced ALT, and were a liver"/>
   <result pre="of the current study showed that acetylcysteine, ursodeoxycholic acid and" exact="silibinin" post="significantly reduced ALT, and were a liver function marker"/>
   <result pre="patients with hepatitis B. The reduction in ALT levels by" exact="acetylcysteine" post="was better than ursodeoxycholic acid and silibinin. This may"/>
   <result pre="The reduction in ALT levels by acetylcysteine was better than" exact="ursodeoxycholic acid" post="and silibinin. This may be related to the ability"/>
   <result pre="and silibinin. This may be related to the ability of" exact="acetylcysteine" post="to inhibit the expression of serum II-18, IFN-γ and"/>
   <result pre="in the patients with hepatitis B. Some studies stated that" exact="acetylcysteine" post="should be used, and that it was more beneficial"/>
   <result pre="liver disease.Clin Liver Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of" exact="adenosine" post="combine with ursodeoxycholic acid in the treatment of chronic"/>
   <result pre="Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of adenosine combine with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
   <result pre="Pharm Dis.2013143689 9JooSSKangHCWonTJLeeDIUrsodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and" exact="nitric oxide" post="in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of ursodeoxycholic"/>
   <result pre="nitric oxide in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of" exact="ursodeoxycholic acid" post="in liver functional restoration of patients with obstructive jaundice"/>
   <result pre="J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin extraction and" exact="silibinin" post="purification.Lishizhen Med Materia Med Res.20122336556 15FeherJLengyelG[Silymarin in the treatment"/>
   <result pre="paraquat-induced cytotoxicity.Toxicol Letters.199684171210.1016/0378-4274(95)03446-3 17HarrisonPWendonJWilliamsREvidence of increased guanylate cyclase activation by" exact="acetylcysteine" post="in fulminant hepatic failure.Hepatology.199623510677210.1053/jhep.1996.v23.pm00086211358621135 18McClainCJPriceSBarveSDevalarjaRShedlofskySAcetaminophen hepatotoxicity: An update.Curr Gastroenterol"/>
   <result pre="Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical efficacy observation of" exact="acetylcysteine" post="injection on 58 cases of chronic severe hepatitis B.West"/>
   <result pre="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation of" exact="acetylcysteine" post="injection on 40 cases of chronic hepatitis B.J Chongqing"/>
   <result pre="Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618 25FabrisPTosittiGMazzellaGZanettiARNicolinRPellizzerGet al.Effect of" exact="ursodeoxycholic acid" post="administration in patients with acute viral hepatitis: a pilot"/>
   <result pre="with acute viral hepatitis: a pilot study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term" exact="ursodeoxycholic acid" post="delays histological progression in primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation"/>
   <result pre="primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation on the clinical efficiency of" exact="adenosine" post="methionine combined with ursodeoxycholic acid in the treatment of"/>
   <result pre="al.Observation on the clinical efficiency of adenosine methionine combined with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
   <result pre="hepatitis B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of" exact="ursodeoxycholic acid" post="in lowering ALT in chronic liver disease.J Pak Med"/>
   <result pre="of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.J Hepatol.20115451011910.1016/j.jhep.2010.08.03021145828 30FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on serum beta2-microglobulin in the course of viral hepatitis"/>
   <result pre="course of viral hepatitis B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on the course of viral hepatitis B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect"/>
   <result pre="hepatitis B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of" exact="silibinin" post="phospholipid complex treat chronic hepatitis B in 86 cases.Shandong"/>
   <result pre="36WangHZhaoYLXuKC[Clinical and pathological study on effects of Qianggan Capsule combined" exact="lamivudine" post="on hepatic fibrosis in patients with chronic hepatitis B].Zhongguo"/>
   <result pre="Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical observation on the safety and efficacy of" exact="ursodeoxycholic acid" post="and fuzheng huayu capsule in the treatment of primary"/>
   <result pre="hepatitis B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of" exact="valsartan" post="on liver fibrosis indexes in patients with alcoholic liver"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4542094/results/search/drugs/results.xml">
   <result pre="a resistant HCT8 colon carcinoma subline was developed by serial" exact="etoposide" post="exposure. Endoretroviral elements were detected by immunocytochemical staining, qPCR"/>
   <result pre="produce antitumoral effects. The introduction of antiviral drugs such as" exact="ribavirin" post="into the therapy of tumors with high HERV expression"/>
   <result pre="Ruhr-University of Bochum, Medical School. IC50 values and induction of" exact="etoposide" post="resistance IC50 values were determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium"/>
   <result pre="nm. Both methods were formerly described [30, 31]. Resistance to" exact="etoposide" post="in HCT8 cells was induced in the same form"/>
   <result pre="and reported as the IC50 iCSCs/ IC50 parental ratio. Using" exact="etoposide" post="as chemoresistance-inducer it is feasible to induce a wide"/>
   <result pre="of antiviral and cytostatic drugs Amantadine, ribavirin, pleconaril, lamivudine, and" exact="doxorubicin" post="were purchased from Sigma-Aldrich, acyclovir and ganciclovir from HEXAL"/>
   <result pre="pleconaril, lamivudine, and doxorubicin were purchased from Sigma-Aldrich, acyclovir and" exact="ganciclovir" post="from HEXAL AG, Holzkirchen, Germany. Retrovir was obtained from"/>
   <result pre="Staffordshire, UK and brivudine from Berlin Chemie, Germany. Etoposide and" exact="cisplatin" post="were purchased from TEVA GmbH and 5FU from Medac,"/>
   <result pre="HERV proteins we exposure HCT8 cells to amantadine, pleconaril and" exact="ribavirin" post="alone or simultaneously at 1-fold their respective IC50-values for"/>
   <result pre="in medium containing the respective IC50 of amantadine, pleconaril, and" exact="ribavirin" post="alone or with all drugs simultaneously for 24 hours."/>
   <result pre="and HERV-FRD1 in HCT8RETO colorectal carcinoma cells The anticancer drug" exact="etoposide" post="is commonly not employed in the treatment of colorectal"/>
   <result pre="several tumors as previously described. In HCT8 colorectal carcinoma cells," exact="etoposide" post="induces characteristics for stemness, as judged by their self"/>
   <result pre="of antiproliferative effect, as defined by their IC50 values: amantadine," exact="ribavirin" post="and pleconaril (Fig. 4). All other drugs did not"/>
   <result pre="shown) and therefore were excluded from further analysis. In general," exact="amantadine" post="and pleconaril were the most active compounds in the"/>
   <result pre="cells (Fig. 4). Fig. 4 In vitro cytotoxicity of amantadine," exact="ribavirin" post="and pleconaril in HCT8WT/RETO cells. Cytotoxicity was measured over"/>
   <result pre="of at least n = 3 independent experiments Synergistic cytotoxic effects between" exact="amantadine" post="and anticancer drugs in HCT8WT/RETO cells We next questioned"/>
   <result pre="line (Fig. 5, panels a, c and e), interaction between" exact="amantadine" post="and doxorubicin was slightly synergistic (panel a), between amantadine"/>
   <result pre="5, panels a, c and e), interaction between amantadine and" exact="doxorubicin" post="was slightly synergistic (panel a), between amantadine and cisplatin"/>
   <result pre="between amantadine and doxorubicin was slightly synergistic (panel a), between" exact="amantadine" post="and cisplatin (CP) additive (panel c), and remarkable antagonistic"/>
   <result pre="and doxorubicin was slightly synergistic (panel a), between amantadine and" exact="cisplatin" post="(CP) additive (panel c), and remarkable antagonistic activity was"/>
   <result pre="additive (panel c), and remarkable antagonistic activity was observed between" exact="amantadine" post="and 5FU (panel e), respectively. In contrast, in the"/>
   <result pre="(Fig. 5, panels b, d and f), synergistic interaction between" exact="amantadine" post="and all three anticancer drugs was shown, although synergism"/>
   <result pre="(5FU) (panel f). These results indicate that antiviral compounds like" exact="amantadine" post="do not only exhibited substantial cytotoxic activity in chemoresistant"/>
   <result pre="vitro. Fig. 5 Isobologram showing the in vitro interaction between" exact="amantadine" post="and doxorubicin, cisplatin or 5FU in HCT8WT and HCT8RETO"/>
   <result pre="Isobologram showing the in vitro interaction between amantadine and doxorubicin," exact="cisplatin" post="or 5FU in HCT8WT and HCT8RETO cells. Dose-response curves"/>
   <result pre="by using their specific IC50. As expected, amantadine, pleconaril and" exact="ribavirin" post="as single drugs reduced cell survival by about 50"/>
   <result pre="%. Enhanced cytotoxicity in HCT8RETO cells was only detectable for" exact="amantadine" post="and pleconaril. In general, combination of antiviral compounds (Fig."/>
   <result pre="HCT8 colon carcinoma cells. Simultaneous incubation of HCT8WT/RETO with amantadine," exact="ribavirin" post="and pleconaril based on the IC50 values calculated for"/>
   <result pre="expressed different HERVs entities. We found that amantadine, pleconaril and" exact="ribavirin" post="alone or in combination applied simultaneously, significantly downregulated the"/>
   <result pre="upon exposure of chemo-resistant HCT8RETO cells to the antiviral compound" exact="amantadine" post="We have already shown enhanced cytotoxicity of antiviral compounds"/>
   <result pre="HCT8RETO cells in vitro (Fig. 4). Furthermore, we shown that" exact="amantadine" post="is able to reduce significantly the HERV protein expression"/>
   <result pre="c). Fig. 7 depicts the semi-quantification of the effect of" exact="amantadine" post="in HCT8WT/RETO cells as assayed by ELISA. As expected,"/>
   <result pre="the RNA levels (data not shown). Fig. 7 Effect of" exact="amantadine" post="on HERV protein expression in HCT8WT/RETO analyzed by ELISA."/>
   <result pre="of both HERV-WE1 and HERV-FRD1 is downregulated after incubation with" exact="amantadine" post="at 2 x IC50 for 24 hours. Expression is"/>
   <result pre="cancer cell lines. Among these compounds, the structurally unrelated amantadine," exact="ribavirin" post="and pleconaril were found to be the most active,"/>
   <result pre="phase of viral replication cycle. We focused our studies on" exact="amantadine" post="because we previously have been investigating several PPAP compounds"/>
   <result pre="promoters like Myc, Myb and Stat1/3 [44]. The combination of" exact="amantadine" post="with doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory"/>
   <result pre="Myb and Stat1/3 [44]. The combination of amantadine with doxorubicin," exact="cisplatin" post="and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e. amantadine"/>
   <result pre="doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e." exact="amantadine" post="boosts the cytotoxicity of these cytostatics in resistant cells."/>
   <result pre="in resistant cells. We also addressed the combination of amantadine," exact="ribavirin" post="and pleconaril on overall cytotoxicity in HCT8WT/RETO cells. Enhanced"/>
   <result pre="Melanoma Tumor Growth In vivoCancer Res20056525889110.1158/0008-5472.CAN-04-423115805254 25.KraljacicBCArguelloMAmriACormackGBordenKInhibition of eIF4E with" exact="ribavirin" post="cooperates with common chemotherapies in primary acute myeloid leukemia"/>
   <result pre="proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of" exact="ribavirin" post="and low-dose cytarabine for the treatment of relapsed and"/>
   <result pre="with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of ribavirin and low-dose" exact="cytarabine" post="for the treatment of relapsed and refractory acute myeloid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4865845/results/search/drugs/results.xml">
   <result pre="models of chikungunya infection. Two of them, the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, have a"/>
   <result pre="we tested the in vivo efficacy of the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, which have"/>
   <result pre="we combined drugs to improve antiviral activity. We focused on" exact="pimozide" post="and TOFA, since they both demonstrated an antiviral effect"/>
   <result pre="with CHIKV for 1 h. In comparison with monotherapy, TOFA and" exact="pimozide" post="combination resulted in increased inhibition of CHIKV infection rate"/>
   <result pre="drug combination in vivo, in adult mice therapeutically treated with" exact="pimozide" post="and TOFA alone or in combination. Importantly, pimozide and"/>
   <result pre="treated with pimozide and TOFA alone or in combination. Importantly," exact="pimozide" post="and TOFA combination caused a significant reduction in CHIKV"/>
   <result pre="the potential for broadly active, host-directed, antiviral therapies (for example," exact="pimozide" post="that had an antiviral effect both for CHIKV and"/>
   <result pre="by keeping cells under selection medium containing blasticidine (5 μg ml−1) and" exact="puromycin" post="(2 μg ml−1) for an additional 10 days. A549 cells depleted"/>
   <result pre="which were kept under selection medium containing blasticidine (10 μg ml−1) and" exact="puromycin" post="(2.5 μg ml−1) for an additional 10 days and subsequently analysed"/>
   <result pre="50 mM stock), KH-CB19 (R&amp;amp;D Systems, 10 mM stock), bafilomycin (50 μM stock)," exact="pimozide" post="(10 mM stock), W7 (53 mM stock), TOFA (10 mM stock), BMS-303141"/>
   <result pre="mice (0.5 mg kg−1, per os) were infected as described above, whereas" exact="pimozide" post="(20 mg kg−1, via os)- and TOFA (25 mg kg−1, via intraperitoneal)-treated mice"/>
   <result pre="first dissolved in DMSO (40 mg ml−1) and then diluted in 0.5%" exact="methylcellulose" post="to a final concentration of 0.25 mg ml−1; pimozide (Sigma) was"/>
   <result pre="diluted in 0.5% methylcellulose to a final concentration of 0.25 mg ml−1;" exact="pimozide" post="(Sigma) was dissolved (25 mg ml−1) in N-methyl-2-pyrrolidone (NMP) and then"/>
   <result pre="of 5 mg ml−1. For experiments shown in Fig. 7d,e, TOFA and" exact="pimozide" post="were dissolved in DMSO (independently or in combination) to"/>
   <result pre="Oncol. Rep.13, 103–111 (2011).21318618 NelsonE. A.et al.. The STAT5 inhibitor" exact="pimozide" post="displays efficacy in models of acute myelogenous leukemia driven"/>
   <result pre="50) for 1 h and treated with cerulenin (50 μM), TOFA (25 μM)," exact="pimozide" post="(pimo, 10 μM), W7 (20 μM), tivozanib (tivo, 5 μM) or vehicle"/>
   <result pre="used and viral titres measured in C57BL/6 mice treated with" exact="pimozide" post="(pimo, per os, n=15 for both data sets) or"/>
   <result pre="days; i.p., intraperitoneal; NS, not significant. Figure 7 Impact of" exact="pimozide" post="and TOFA combination on CHIKV replication in vitro and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5065164/results/search/drugs/results.xml">
   <result pre="costs of the two first generation direct-acting antiviral agents (DAA)," exact="boceprevir" post="and telaprevir as uncertainty existed regarding the drug of"/>
   <result pre="the two first generation direct-acting antiviral agents (DAA), boceprevir and" exact="telaprevir" post="as uncertainty existed regarding the drug of choice between"/>
   <result pre="controlled trial (RCT) at a VA Medical Center to either" exact="boceprevir" post="or telaprevir in combination with peginterferon and ribavirin, stratified"/>
   <result pre="(RCT) at a VA Medical Center to either boceprevir or" exact="telaprevir" post="in combination with peginterferon and ribavirin, stratified by the"/>
   <result pre="adjudication committee. The primary outcome was difference in tolerability between" exact="boceprevir" post="vs. telaprevir. Secondary outcomes included viral response rates and"/>
   <result pre="adverse events were seen in 10/25 (40%) patients randomized to" exact="telaprevir" post="compared to 2/25 (8%) patients randomized to boceprevir (RR:"/>
   <result pre="randomized to telaprevir compared to 2/25 (8%) patients randomized to" exact="boceprevir" post="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Cure rates"/>
   <result pre="an intention-to-treat basis, total cost per cure was $44,329 for" exact="boceprevir" post="vs. $57,115 for telaprevir. The significant side effect profile"/>
   <result pre="vs. $57,115 for telaprevir. The significant side effect profile of" exact="telaprevir" post="combined with the availability of highly efficacious second generation"/>
   <result pre="nearly 25 per 1000 person years.[9] Historically, pegylated-interferon (Peg-IFN) and" exact="ribavirin" post="(RBV) based combination therapy resulted in low cure rates"/>
   <result pre="and dose reductions.[14] The first generation nonstructural 3/4A protease inhibitors," exact="boceprevir" post="and telaprevir, were approved by the United States Food"/>
   <result pre="Peg-IFN with RBV (38–44%) in clinical trials, the addition of" exact="boceprevir" post="or telaprevir demonstrated improved cure rates between 63% to"/>
   <result pre="RBV (38–44%) in clinical trials, the addition of boceprevir or" exact="telaprevir" post="demonstrated improved cure rates between 63% to 75% for"/>
   <result pre="of these two direct-acting antiviral agents (DAA), clinicians largely preferred" exact="telaprevir" post="over boceprevir based on clinical judgment of data gathered"/>
   <result pre="two direct-acting antiviral agents (DAA), clinicians largely preferred telaprevir over" exact="boceprevir" post="based on clinical judgment of data gathered from placebo"/>
   <result pre="3 randomized controlled trials (RCT).[19, 20] The decision to use" exact="telaprevir" post="for some clinicians might have been influenced by its"/>
   <result pre="been influenced by its shorter treatment duration (12 weeks) vs." exact="boceprevir" post="(24/44 weeks). Alternatively, as direct head-to-head evidence comparing the"/>
   <result pre="guide clinicians, the Veterans Health Administration (VHA) decided to make" exact="boceprevir" post="the formulary choice presumably based on an acquisition cost"/>
   <result pre="primary objective of this RCT was to compare tolerability of" exact="boceprevir" post="vs. telaprevir in HCV treatment in treatment naïve and"/>
   <result pre="of this RCT was to compare tolerability of boceprevir vs." exact="telaprevir" post="in HCV treatment in treatment naïve and treatment experienced"/>
   <result pre="The secondary objectives were: a) to evaluate the effectiveness of" exact="boceprevir" post="vs. telaprevir in combination with peginterferon and ribavirin; b)"/>
   <result pre="objectives were: a) to evaluate the effectiveness of boceprevir vs." exact="telaprevir" post="in combination with peginterferon and ribavirin; b) to examine"/>
   <result pre="utilized to allocate subjects to one of two treatment groups," exact="boceprevir" post="or telaprevir. Allocation was concealed using serially numbered, opaque,"/>
   <result pre="eligible. Exclusion criteria were based on standard prescribing information for" exact="boceprevir" post="and telaprevir.[15, 16] These included: co-infection with Hepatitis B"/>
   <result pre="cancers), and current alcoholism or drug addiction. Treatments Boceprevir and" exact="telaprevir" post="were administered through regular clinical care without masking (open"/>
   <result pre="(375mg capsules, 750 mg TID p.o.) and Peg-IFN/RBV. Dosing for" exact="boceprevir" post="(according to product labeling): HCV treatment naïve patients and"/>
   <result pre="to product labeling): HCV treatment naïve patients and relapsers received" exact="boceprevir" post="for 24 to 44 weeks and 36 to 48"/>
   <result pre="of treatment. Prior non-responders or patients with compensated cirrhosis received" exact="boceprevir" post="for 44 weeks and Peg-IFN/RBV for 48 weeks. Dosing"/>
   <result pre="for 44 weeks and Peg-IFN/RBV for 48 weeks. Dosing for" exact="telaprevir" post="(according to product labeling): HCV treatment naïve patients/relapsers received"/>
   <result pre="telaprevir (according to product labeling): HCV treatment naïve patients/relapsers received" exact="telaprevir" post="for 12 weeks and Peg-IFN/RBV for 24 or 48"/>
   <result pre="of treatment. Non-responders and patients with compensated cirrhosis were prescribed" exact="telaprevir" post="for 12 weeks and Peg-IFN/RBV for 48 weeks. Additional"/>
   <result pre="groups: Peginterferon alfa-2a 180 mcg s.c. every week and weight-based" exact="ribavirin" post="1200 mg/day p.o. divided twice daily for patients ≥75kg"/>
   <result pre="data were used to determine cost per SVR for both" exact="boceprevir" post="and telaprevir. Statistical Analysis This study was projected to"/>
   <result pre="50 patients were randomized in a 1:1 fashion to either" exact="boceprevir" post="in combination with Peg-IFN/RBV or telaprevir and Peg-IFN/RBV. Of"/>
   <result pre="1:1 fashion to either boceprevir in combination with Peg-IFN/RBV or" exact="telaprevir" post="and Peg-IFN/RBV. Of the 50 patients randomized, 3 were"/>
   <result pre="patients randomized, 3 were lost to follow-up (1 in the" exact="boceprevir" post="group, 2 in the telaprevir group). The CONSORT study"/>
   <result pre="to follow-up (1 in the boceprevir group, 2 in the" exact="telaprevir" post="group). The CONSORT study flow diagram is shown in"/>
   <result pre="Table 1. 10.1371/journal.pone.0163945.t001Table 1 Demographic characteristics of patients randomized to" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="were seen in 10 of 25 (40%) patients randomized to" exact="telaprevir" post="compared to 2 of 25 (8%) patients randomized to"/>
   <result pre="telaprevir compared to 2 of 25 (8%) patients randomized to" exact="boceprevir" post="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Eight patients"/>
   <result pre="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Eight patients discontinued" exact="telaprevir" post="treatment early due to toxicity (mostly due to rashes);"/>
   <result pre="severe anemia (Hb ≤8 g/dL). Of the two patients on" exact="boceprevir" post="who stopped treatment early, one experienced a severe rash"/>
   <result pre="and the other had severe dysgeusia. Four patients (3 on" exact="boceprevir" post="and 1 on telaprevir) discontinued treatment early due to"/>
   <result pre="each treatment group) experienced mood disturbances while two patients on" exact="boceprevir" post="experienced nausea, vomiting and flu-like symptoms. Treatment tolerability data"/>
   <result pre="data are presented in Table 2. 10.1371/journal.pone.0163945.t002Table 2 Tolerability of" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="investigators decided to stop the trial early. Patients who tolerated" exact="telaprevir" post="poorly were given an option to either switch to"/>
   <result pre="3. 10.1371/journal.pone.0163945.t003Table 3 SVR24 rates based on treatment exposure to" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="SVR: sustained virologic response; RR: Relative Risk. Two patients on" exact="boceprevir" post="(8%) and 1 patient on telaprevir (4%) experienced viral"/>
   <result pre="Risk. Two patients on boceprevir (8%) and 1 patient on" exact="telaprevir" post="(4%) experienced viral relapse between weeks 4 and 12"/>
   <result pre="to futility criteria as per FDA package label, 6/25 in" exact="boceprevir" post="and 0/25 in telaprevir were considered to have met"/>
   <result pre="per FDA package label, 6/25 in boceprevir and 0/25 in" exact="telaprevir" post="were considered to have met the futility criteria due"/>
   <result pre="to viral breakthrough or non-response. Resource use Patients in the" exact="boceprevir" post="group had on average 13 outpatient visits related to"/>
   <result pre="HCV treatment vs. 9 outpatient visits for those in the" exact="telaprevir" post="group (mostly due to the high percentage of early"/>
   <result pre="telaprevir). Mean cost of standard triple therapy per patient with" exact="boceprevir" post="and Peg-IFN/RBV and routine care was $18,670 ($7,958 –$32,877)"/>
   <result pre="in comparison to $26,962 ($363 –$30,505) per patient in the" exact="telaprevir" post="and Peg-IFN/RBV group. Additionally, adverse event management (additional outpatient"/>
   <result pre="medications, such as growth factors) was $14,801 vs. $24,594 for" exact="boceprevir" post="and telaprevir respectively. In the boceprevir group, 6 patients"/>
   <result pre="as growth factors) was $14,801 vs. $24,594 for boceprevir and" exact="telaprevir" post="respectively. In the boceprevir group, 6 patients received epoetin-α,"/>
   <result pre="$14,801 vs. $24,594 for boceprevir and telaprevir respectively. In the" exact="boceprevir" post="group, 6 patients received epoetin-α, 1 received filgrastim, 4"/>
   <result pre="visits and 1 patient required an ED evaluation. In the" exact="telaprevir" post="group, 7 patients received epoetin-α, 1 received filgrastim, 3"/>
   <result pre="ITT basis, total cost per SVR achieved was $44,329 for" exact="boceprevir" post="vs. $57,115 for telaprevir (Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource"/>
   <result pre="per SVR achieved was $44,329 for boceprevir vs. $57,115 for" exact="telaprevir" post="(Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource use associated with boceprevir"/>
   <result pre="for telaprevir (Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource use associated with" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="SVR: Sustained virologic response. Discussion Compared to boceprevir, use of" exact="telaprevir" post="in standard triple antiviral regimens within a Midwestern VA"/>
   <result pre="not significantly different between the two treatment groups, but both" exact="telaprevir" post="and boceprevir showed substantially lower viral cure rates than"/>
   <result pre="different between the two treatment groups, but both telaprevir and" exact="boceprevir" post="showed substantially lower viral cure rates than observed in"/>
   <result pre="trials. Cost of treatment per cure was substantially higher for" exact="telaprevir" post="when compared to boceprevir. The approval of two novel"/>
   <result pre="C treatment when these drugs were approved, clinicians preferred using" exact="telaprevir" post="based triple therapy, presumably given its shorter treatment duration"/>
   <result pre="since real-world treatment experience reports were lacking.[19, 20] In contrast," exact="boceprevir" post="was the formulary choice in VHA based on its"/>
   <result pre="showed an increased incidence in SAEs including increased deaths with" exact="telaprevir" post="when compared to boceprevir, despite higher cure rates with"/>
   <result pre="side-effect profiles of the drugs in question are questionable. Although" exact="boceprevir" post="compared to telaprevir appeared attractive from an acquisition cost"/>
   <result pre="the drugs in question are questionable. Although boceprevir compared to" exact="telaprevir" post="appeared attractive from an acquisition cost perspective, implementing such"/>
   <result pre="or women. Additionally, the FDA approved two new DAAs, namely" exact="sofosbuvir" post="and simprevir in the fall of 2013, both of"/>
   <result pre="that it was unnecessary to continue treating patients with either" exact="telaprevir" post="or boceprevir. Nevertheless, our trial underscores the need for"/>
   <result pre="LeeWM, RustgiVK, et al.Interferon alfa-2b alone or in combination with" exact="ribavirin" post="as initial treatment for chronic hepatitis C. Hepatitis Interventional"/>
   <result pre="NiederauC, MinukGS, IdeoG, et al.Randomised trial of interferon alpha2b plus" exact="ribavirin" post="for 48 weeks or for 24 weeks versus interferon"/>
   <result pre="10.1056/NEJMoa101049421449783 19HezodeC, FontaineH, DorivalC, ZoulimF, LarreyD, CanvaV, et al.Effectiveness of" exact="telaprevir" post="or boceprevir in treatment-experienced patients with HCV genotype 1"/>
   <result pre="FontaineH, DorivalC, ZoulimF, LarreyD, CanvaV, et al.Effectiveness of telaprevir or" exact="boceprevir" post="in treatment-experienced patients with HCV genotype 1 infection and"/>
   <result pre="2008;337:a239010.1136/bmj.a239019001484 24AfdhalN, ZeuzemS, KwoP, ChojkierM, GitlinN, PuotiM, et al.Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
   <result pre=".24725239 25KowdleyKV, GordonSC, ReddyKR, RossaroL, BernsteinDE, LawitzE, et al.Ledipasvir and" exact="sofosbuvir" post="for 8 or 12 weeks for chronic HCV without"/>
   <result pre="SigalS, NelsonDR, CrawfordD, et al.Treatment of HCV with ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin. N Engl J Med. 2014;370(17):1594–603. 10.1056/NEJMoa1315722 .24720703"/>
   <result pre=".24720703 27FerenciP, BernsteinD, LalezariJ, CohenD, LuoY, CooperC, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with or without ribavirin for HCV. N Engl J"/>
   <result pre="CohenD, LuoY, CooperC, et al.ABT-450/r-ombitasvir and dasabuvir with or without" exact="ribavirin" post="for HCV. N Engl J Med. 2014;370(21):1983–92. 10.1056/NEJMoa1402338 .24795200"/>
   <result pre=".24795200 28PoordadF, HezodeC, TrinhR, KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin for hepatitis C with cirrhosis. N Engl"/>
   <result pre="HezodeC, TrinhR, KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and dasabuvir with" exact="ribavirin" post="for hepatitis C with cirrhosis. N Engl J Med."/>
   <result pre="LalezariJ, WangC, et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: a"/>
   <result pre="Cost-effectiveness and budget impact of hepatitis C virus treatment with" exact="sofosbuvir" post="and ledipasvir in the United States. Ann Intern Med."/>
   <result pre="32BackusLI, BelperioPS, ShahoumianTA, LoomisTP, MoleLA. Comparative effectiveness of ledipasvir/sofosbuvir +/-" exact="ribavirin" post="vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype"/>
   <result pre="MoleLA. Comparative effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir +" exact="dasabuvir" post="+/- ribavirin in 6961 genotype 1 patients treated in"/>
   <result pre="effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/-" exact="ribavirin" post="in 6961 genotype 1 patients treated in routine medical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5228644/results/search/drugs/results.xml">
   <result pre="Study Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="This study undertaken to identify suitable candidates for peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in"/>
   <result pre="CHC do not receive antiviral therapy.[1] Moreover, previous peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV)-based regimens are less effective and have higher side"/>
   <result pre="FDA approved of DAAs in 2011, new drugs, such as" exact="sofosbuvir" post="and daclatasvir/asunaprevir, were recently approved with much higher SVR"/>
   <result pre="C virus infection. Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="[3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
   <result pre="hepatitis C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
   <result pre="Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a randomized trial of peginterferon plus" exact="ribavirin" post="for the initial treatment of chronic hepatitis C genotype"/>
   <result pre="Clin Mol Hepatol2016;22:76–139.27044763 [10]HungCHLeeCMLuSNet al.Long-term effect of interferon alpha-2b plus" exact="ribavirin" post="therapy on incidence of hepatocellular carcinoma in patients with"/>
   <result pre="pegylated interferon and ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of" exact="peginterferon alfa-2b" post="and ribavirin on hepatocellular carcinoma prevention in older patients"/>
   <result pre="ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and" exact="ribavirin" post="on hepatocellular carcinoma prevention in older patients with chronic"/>
   <result pre="J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of pegylated interferon alpha-2b and" exact="ribavirin" post="treatment on the risk of hepatocellular carcinoma in patients"/>
   <result pre="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon plus" exact="ribavirin" post="and sustained virological response in HCV-related cirrhosis: outcomes and"/>
   <result pre="predicting response. Am J Gastroenterol2010;105:2164–72.20700116 [21]CardosoACMoucariRFigueiredo-MendesCet al.Impact of peginterferon and" exact="ribavirin" post="therapy on hepatocellular carcinoma: incidence and survival in hepatitis"/>
   <result pre="sonographic study of the liver surface. Radiology1989;172:389–92.2526349 [24]AfdhalNZeuzemSKwoPet al.Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
   <result pre="effects of therapy for chronic hepatitis C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral" exact="daclatasvir" post="plus asunaprevir for hepatitis C virus genotype 1b: a"/>
   <result pre="phase 3, multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of" exact="sofosbuvir" post="plus simeprevir in patients with advanced HCV cirrhosis. Hepatology2014;60:665a."/>
   <result pre="multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of sofosbuvir plus" exact="simeprevir" post="in patients with advanced HCV cirrhosis. Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy"/>
   <result pre="Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy of Ledipasvir plus Sofosobuvir with or without" exact="ribavirin" post="in hepatitis C genotype 1 patients who failed previous"/>
   <result pre="Hepatology2015;62:775a. [31]JinYJLeeJWLeeJIet al.Multicenter comparison of PEG-IFN alpha2a or alpha2b plus" exact="ribavirin" post="for treatment-naive HCV patient in Korean population. BMC Gastroenterol2013;13:74.23627926"/>
   <result pre="in Korean population. BMC Gastroenterol2013;13:74.23627926 [32]HondaTKatanoYShimizuJet al.Efficacy of peginterferon-alpha-2b plus" exact="ribavirin" post="in patients aged 65 years and older with chronic"/>
   <result pre="the elderly. Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of" exact="simeprevir" post="plus sofosbuvir with or without ribavirin in patients with"/>
   <result pre="Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of simeprevir plus" exact="sofosbuvir" post="with or without ribavirin in patients with decompensated genotype"/>
   <result pre="al.Safety and efficacy of simeprevir plus sofosbuvir with or without" exact="ribavirin" post="in patients with decompensated genotype 1 hepatitis C cirrhosis."/>
   <result pre="hepatitis C cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with" exact="simeprevir" post="+/− ribavirin in genotype 4 hepatitis C patients with"/>
   <result pre="cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with simeprevir +/−" exact="ribavirin" post="in genotype 4 hepatitis C patients with advanced fibrosis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5319548/results/search/drugs/results.xml">
   <result pre="Erratum Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="article &quot;Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="[1]LeeSHJinY-JShinJYet al.Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5440157/results/search/drugs/results.xml">
   <result pre="Erratum Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="article, &quot;Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="Reference [1]LeeS-HJinY-JShinJ-YAssessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5490823/results/search/drugs/results.xml">
   <result pre="are approved to treat other DNA virus infections, most frequently" exact="cidofovir" post="(CDV). CDV, however, has considerable nephrotoxicity, thus it is"/>
   <result pre="by virus replication to a larger extent. We show that" exact="valganciclovir" post="(VGCV), a drug that was shown to be active"/>
   <result pre="most serious cases [14]. Ribavirin and to a lesser extent" exact="ganciclovir" post="(GCV) have also been used (for reviews, see [3,5,6,7,8,9,10,11,15,16])."/>
   <result pre="Ad infection in immunocompromised patients, the animals are immunosuppressed by" exact="cyclophosphamide" post="[24] and then are infected intravenously (i.v.) with Ad5."/>
   <result pre="even reversed with the use of BCV [24,27], GCV [26]," exact="valganciclovir" post="(VGCV) [25], or CDV [27]. Previously, we have shown"/>
   <result pre="Infection of Hamsters with Adenovirus The animals were immunosuppressed using" exact="cyclophosphamide" post="(CP) as described before [24]. CP was administered intraperitoneally"/>
   <result pre="with human type 5 adenovirus in immunosuppressed syrian hamsters, while" exact="ribavirin" post="is largely ineffective in this modelAntivir. Res.2014112384610.1016/j.antiviral.2014.10.00525453340 28.ThomasM.A.SpencerJ.F.La ReginaM.C.DharD.TollefsonA.E.TothK.WoldW.S.Syrian"/>
   <result pre="adenovirus replication in immunocompetent syrian hamsters can be attenuated with" exact="chlorpromazine" post="or cidofovirJ. Gene Med.20101243544510.1002/jgm.145320440754 36.SoldinO.P.MattisonD.R.Sex differences in pharmacokinetics and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5549007/results/search/drugs/results.xml">
   <result pre="thymoglobulin, MMF: micophenolate mofetil, MPD: methylprednisolone, CSA: cyclosporine, TAC: tacrolimus,AZA:" exact="azathioprine" post="Fourteen (23%) of HCV-infected patients developed clinical hepatic disease"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5644647/results/search/drugs/results.xml">
   <result pre="infections despite aggressive management, additional treatment with antiviral drugs (e.g.," exact="plerixafor" post="and/or zidovudine) can be considered. Cats with no identifiable"/>
   <result pre="for treatment of HIV infection [13]. The anti-FIV activity of" exact="zidovudine" post="has been assessed in numerous in vitro studies in"/>
   <result pre="carried out in 1989, when North and coworkers showed that" exact="zidovudine" post="inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells."/>
   <result pre="Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to" exact="zidovudine" post="was similar to that of HIV [27]. There is"/>
   <result pre="the FIV gene is responsible for resistance [10]. In vivo," exact="zidovudine" post="can reduce plasma viral load, improve the immunologic and"/>
   <result pre="of life, and prolong life expectancy [16]. In placebo-controlled trials," exact="zidovudine" post="improved stomatitis and increased the CD4/CD8 ratio in naturally"/>
   <result pre="bone marrow suppression. Regular blood cell counts are necessary during" exact="zidovudine" post="treatment because non-regenerative anemia is a common side effect"/>
   <result pre="not be treated with zidovudine. Most FIV-infected cats treated with" exact="zidovudine" post="for as long as two years tolerated the drug"/>
   <result pre="in vitro [18,19,20,23,26,35,36]. Mutants of FIV that are resistant to" exact="stavudine" post="and cross-resistant to several other antivirals, including zidovudine, have"/>
   <result pre="is active against FIV in vitro [3,20,21,23,38,41]. A combination of" exact="zidovudine" post="and lamivudine had synergistic anti-FIV activities in cell cultures"/>
   <result pre="against FIV in vitro [3,20,21,23,38,41]. A combination of zidovudine and" exact="lamivudine" post="had synergistic anti-FIV activities in cell cultures [41]. FIV"/>
   <result pre="anti-FIV activities in cell cultures [41]. FIV mutants resistant to" exact="lamivudine" post="and containing a point mutation in the RT gene"/>
   <result pre="gene were selected in vitro and showed cross resistance to" exact="zidovudine" post="[23]. In one in vivo study, experimentally FIV-infected cats"/>
   <result pre="the cats with this high-dose dual-drug treatment [41]. Thus, high-dose" exact="lamivudine" post="treatment alone, or in combination with zidovudine, is not"/>
   <result pre="cats. 2.5. Emtricitabine Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to" exact="lamivudine" post="and was licensed by the FDA in 2003 [40]."/>
   <result pre="had higher levels of cytotoxicity than other compounds, such as" exact="didanosine" post="and amdoxovir [16,20]. There are no in vivo studies"/>
   <result pre="only approved NtARTi for the treatment of HIV infection is" exact="tenofovir" post="disoproxil fumarate (TDF), the prodrug of tenofovir ((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA),"/>
   <result pre="HIV infection is tenofovir disoproxil fumarate (TDF), the prodrug of" exact="tenofovir" post="((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA), which is also a member of the"/>
   <result pre="of the acyclic nucleoside phosphonates [43,45]. The antiviral spectrum of" exact="tenofovir" post="(2R-1-(6-amino-9H-purin-9-yl)-propan-2-yl-oxy-methyl-phosphonic acid, PMPA) is narrower than that of adefovir;"/>
   <result pre="thereby preventing nucleotide synthesis [66]. Others, such as ribavirin, inhibit" exact="inosine" post="monophosphate dehydrogenase after intracellular phosphorylation, which in turn leads"/>
   <result pre="variety of DNA and RNA viruses [71]. Systemic administration of" exact="ribavirin" post="is limited in cats because of side effects [72]."/>
   <result pre="limited in cats because of side effects [72]. Sequestration of" exact="ribavirin" post="within erythrocytes results in hemolysis, even when low doses"/>
   <result pre="primarily on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged" exact="ribavirin" post="treatment or at higher doses, the production of erythrocytes"/>
   <result pre="induce hepatic toxicity. An attempt to decrease the toxicity of" exact="ribavirin" post="by incorporating it into lecithin-containing liposomes and administering it"/>
   <result pre="vivo because of toxicity [74]. To date, the efficacy of" exact="ribavirin" post="has not been investigated in FIV-infected cats. 6. Receptor"/>
   <result pre="placebo-controlled double-blinded clinical trial, treatment of naturally FIV-infected cats with" exact="plerixafor" post="resulted in a significant decrease in proviral load in"/>
   <result pre="any clinical consequences. Development of resistance of FIV isolates to" exact="plerixafor" post="did not occur during treatment [53]. In cats, plerixafor"/>
   <result pre="to plerixafor did not occur during treatment [53]. In cats," exact="plerixafor" post="is administered at a dosage of 0.5 mg/kg every"/>
   <result pre="and further studies are needed to investigate the potential of" exact="tipranavir" post="in naturally infected cats. 7.2. Lopinavir Lopinavir (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhex-an-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide) is"/>
   <result pre="as an anti-HIV compound. Similar to lopinavir, some efficacy of" exact="atazanavir" post="was shown against FIV in vitro, but there are"/>
   <result pre="FIV in vitro [92], but FIV was less susceptible to" exact="raltegravir" post="than HIV [92]. No studies in FIV-infected cats exist"/>
   <result pre="there are no in vivo studies on the efficacy of" exact="raltegravir" post="in FIV-infected cats, the drug recently was shown to"/>
   <result pre="feline immunodeficiency virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of" exact="zidovudine" post="(ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in"/>
   <result pre="virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV)," exact="lamivudine" post="(3TC) and abacavir (ABC) antiretroviral therapy in suppressing in"/>
   <result pre="1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV), lamivudine (3TC) and" exact="abacavir" post="(ABC) antiretroviral therapy in suppressing in vitro FIV replicationAntivir."/>
   <result pre="inhibitors for the treatment of HIV: A brief history of" exact="stavudine" post="(D4T) and its comparison with other dideoxynucleosidesAntivir. Res.201085343810.1016/j.antiviral.2009.10.00619854224 35.BalzariniJ.EgberinkH.HartmannK.CahardD.VahlenkampT.ThormarH.de"/>
   <result pre="Immunol. Immunopathol.19923515516610.1016/0165-2427(92)90128-D1337395 53.HartmannK.StengelC.KleinD.EgberinkH.BalzariniJ.Efficacy and adverse effects of the antiviral compound" exact="plerixafor" post="in feline immunodeficiency virus-infected catsJ. Vet. Intern. Med./Am. Coll."/>
   <result pre="kinetic analysesProtein Sci.2007161728173710.1110/ps.07282900717656585 56.DasK.MartinezS.E.BaumanJ.D.ArnoldE.HIV-1 reverse transcriptase complex with DNA and" exact="nevirapine" post="reveals non-nucleoside inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with ribavirin in"/>
   <result pre="basis of ribavirin resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with" exact="ribavirin" post="in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on"/>
   <result pre="toxicity with ribavirin in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm. J. Vet."/>
   <result pre="calicivirus infection in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of" exact="ribavirin" post="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or"/>
   <result pre="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes."/>
   <result pre="antagonistBlood20031022728273010.1182/blood-2003-02-066312855591 85.NorelliS.El DakerS.D’OstilioD.MeleF.ManciniF.TagliaF.RuggieriA.CiccozziM.CaudaR.CiervoA.et al.Response of feline immunodeficiency virus (FIV) to" exact="tipranavir" post="may provide new clues for development of broad-based inhibitors"/>
   <result pre="Res.2007536538810.2174/15701620778102396517627500 89.MouscadetJ.F.AroraR.AndreJ.LambryJ.C.DelelisO.MaletI.MarcelinA.G.CalvezV.TchertanovL.HIV-1 in alternative molecular recognition of DNA induced by" exact="raltegravir" post="resistance mutationsJ. Mol. Recognit.20092248049410.1002/jmr.97019623602 90.CattoriV.WeibelB.LutzH.Inhibition of feline leukemia virus"/>
   <result pre="of the effect of short-term treatment with the integrase inhibitor" exact="raltegravir" post="(Isentress) on the course of progressive feline leukemia virus"/>
   <result pre="type-I interferon on retrovirusesViruses2009154557310.3390/v103054521994560 100.ZeidnerN.S.MylesM.H.Mathiason-DuBardC.K.DreitzM.J.MullinsJ.I.HooverE.A.Alpha interferon (2β) in combination with" exact="zidovudine" post="for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5753465/results/search/drugs/results.xml">
   <result pre="levels of IL-6, IL-10 and IFN-γ in mice treated with" exact="ribavirin" post="or the combination therapy of ribavirin and RDN were"/>
   <result pre="in mice treated with ribavirin or the combination therapy of" exact="ribavirin" post="and RDN were all significantly decreased than the untreated"/>
   <result pre="type I interferon and downstream interferon-stimulated responsesAntivir Res2017137495710.1016/j.antiviral.2016.11.01027847245 5.PandejpongDSaengsuriPRattarittamrongRRujipattanakulTChouriyaguneCIs excessive" exact="acetaminophen" post="intake associated with transaminitis in adult patients with dengue"/>
   <result pre="Severity of Dengue. J Infect Dis. 2015; 212(12):2011–2020. 50.YuexiaMWeiZZhongpengZMinLJianLYuguangWCombination of" exact="ribavirin" post="and reduning protects mice against severe pneumonia induced by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5923505/results/search/drugs/results.xml">
   <result pre="a newly emerging antiviral mechanism of nucleoside analogs. nucleoside analog" exact="gemcitabine" post="antiviral drugs innate immunity interferon-stimulated gene nucleos(t)ide synthesis 1."/>
   <result pre="nucleoside analog drugs targeting specific viral polymerases (acyclovir for herpesviruses," exact="zidovudine" post="for human immunodeficiency virus (HIV), and sofosbuvir for hepatitis"/>
   <result pre="(acyclovir for herpesviruses, zidovudine for human immunodeficiency virus (HIV), and" exact="sofosbuvir" post="for hepatitis C virus (HCV)) have been successful in"/>
   <result pre="IFN-α [6]. Importantly, extensive studies on the antiviral action of" exact="ribavirin" post="have established the underlying molecular framework of nucleoside analogs."/>
   <result pre="report [1]. In the present review, we focus more on" exact="gemcitabine" post="as a nucleoside analog, which is clinically relevant and"/>
   <result pre="cancers [11,12]. However, in recent years, the antiviral activity of" exact="gemcitabine" post="has also been reported against a broad range of"/>
   <result pre="(IAV), HIV, and enteroviruses (EV) [13,14,15,16,17,18]. The antiviral activities of" exact="gemcitabine" post="against the abovementioned viruses are summarized in Table 1."/>
   <result pre="290 FDA-approved drugs in virus-infected Vero E6 cells and identified" exact="gemcitabine" post="as one of drugs with antiviral activity against both"/>
   <result pre="of 1.2 μM and 4.9 μM, respectively) [13]. More recently," exact="gemcitabine" post="was shown to effectively suppress ZIKV infection and replication"/>
   <result pre="research and development into possible treatments. Effective antiviral activities of" exact="gemcitabine" post="were also found for the replication of HCV in"/>
   <result pre="therapy [20]. In the case of HIV, the combination of" exact="gemcitabine" post="with decitabine, another nucleoside analog in clinical use for"/>
   <result pre="study, Clouser et al. further reported the antiviral effect of" exact="gemcitabine" post="against HIV-related retrovirus, murine leukemia virus (MuLV), in vitro"/>
   <result pre="in murine AIDS model [17]. A significant antiviral effect of" exact="gemcitabine" post="on IAVs was also reported for RPE cells by"/>
   <result pre="al. (EC50 of 0.068 μM) [16]. They also tested whether" exact="gemcitabine" post="had an antiviral effect on several other viruses of"/>
   <result pre="virus (MeV), and vaccinia virus [16]. The antiviral effect of" exact="gemcitabine" post="on EVs, initially performed on Coxsackievirus B3 (CVB3), was"/>
   <result pre="respectively). In the case of HRV, the antiviral effect of" exact="gemcitabine" post="was further confirmed in a virus-infected mouse model [22]."/>
   <result pre="virus-infected mouse model [22]. In this study, intranasal administration of" exact="gemcitabine" post="significantly lowered the pulmonary viral load and inflammation by"/>
   <result pre="lung infiltrating lymphocytes. More recently, Zhang et al. also identified" exact="gemcitabine" post="as the best anti-PV inhibitor from a screen of"/>
   <result pre="[15]. As previously mentioned, accumulating evidence has definitively demonstrated that" exact="gemcitabine" post="is an effective broad-spectrum inhibitor of RNA viruses and"/>
   <result pre="treatment of various virus-associated diseases. Moreover, it is possible that" exact="gemcitabine" post="is effective for other untested RNA viruses. Because gemcitabine"/>
   <result pre="that gemcitabine is effective for other untested RNA viruses. Because" exact="gemcitabine" post="is a deoxycytidine analog that interferes with DNA as"/>
   <result pre="virus classified into the Herpesviridae family, was strongly affected by" exact="gemcitabine" post="[16]. Most of the abovementioned viruses have, at best,"/>
   <result pre="their early stages of infection. In this regard, repurposing of" exact="gemcitabine" post="for the treatment of patients infected with these deadly"/>
   <result pre="is an option to treat patients with a combination of" exact="gemcitabine" post="with other antiviral agents. In this manner, an effective"/>
   <result pre="used clinically. As an example, the synergistic antiviral effect of" exact="gemcitabine" post="in combination with ribavirin, an antiviral drug currently being"/>
   <result pre="CVB3 and EV71 [18]. As previously mentioned, the combination of" exact="gemcitabine" post="with decitabine synergistically suppressed HIV infectivity both in vitro"/>
   <result pre="EV71 [18]. As previously mentioned, the combination of gemcitabine with" exact="decitabine" post="synergistically suppressed HIV infectivity both in vitro and in"/>
   <result pre="vitro and in vivo [17,21]. However, the actual use of" exact="gemcitabine" post="in virus-infected patients necessitates prior in vivo animal studies"/>
   <result pre="studies, two recent studies have reported the antiviral effects of" exact="gemcitabine" post="in murine models [17,22]. More extensive analyses of gemcitabine"/>
   <result pre="of gemcitabine in murine models [17,22]. More extensive analyses of" exact="gemcitabine" post="in animal models in the near future will accelerate"/>
   <result pre="Pyrimidine Biosynthesis Inhibitors Most studies regarding the antiviral activity of" exact="gemcitabine" post="lack experimental evidence of the mode of action. However,"/>
   <result pre="mode of action. However, our group has recently reported that" exact="gemcitabine" post="had an anti-EV effect by targeting the salvage pathway"/>
   <result pre="by targeting the salvage pathway of pyrimidine biosynthesis [23]. Moreover," exact="gemcitabine" post="strongly induced the expression of several ISGs including CXCL10,"/>
   <result pre="infection. These results were consistent with a previous report that" exact="gemcitabine" post="stimulated the production of IFN-β and IFN-γ in IAV-infected"/>
   <result pre="as summarized in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors," exact="ribavirin" post="and mycophenolic acid (MPA) are inhibitors of inosine-5′-monophosphate (IMP)"/>
   <result pre="in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors, ribavirin and" exact="mycophenolic acid" post="(MPA) are inhibitors of inosine-5′-monophosphate (IMP) dehydrogenase (IMPDH), which"/>
   <result pre="the stimulation of ISGs [10,30]. For the antiviral activity of" exact="ribavirin" post="against HCV, ribavirin specifically induced the expression of IRF7,"/>
   <result pre="ISGs [10,30]. For the antiviral activity of ribavirin against HCV," exact="ribavirin" post="specifically induced the expression of IRF7, IRF9, and ISG15"/>
   <result pre="classical JAK/STAT system, which is similar to that observed with" exact="ribavirin" post="[30]. Similar results were obtained with several IMPDH1 or"/>
   <result pre="was not mediated by JAK [10]. Second, IRF7 induction by" exact="ribavirin" post="was not affected by knockdown of STAT1, while that"/>
   <result pre="under the same conditions [6]. Third, our recent study with" exact="gemcitabine" post="further confirmed IFN signal-independent ISG activation by parallel studies"/>
   <result pre="signal-independent ISG activation by parallel studies comparing the effects of" exact="gemcitabine" post="and IFN-α. In our study, the phosphorylation of STAT1"/>
   <result pre="dramatically triggered by IFN-α, did not occur when treated with" exact="gemcitabine" post="[23]. Moreover, the upregulation of DDX58 mRNAs induced by"/>
   <result pre="gemcitabine [23]. Moreover, the upregulation of DDX58 mRNAs induced by" exact="gemcitabine" post="was not affected by IRF9 knockdown, which was contrary"/>
   <result pre="classical IFN signal in the activation of ISGs induced by" exact="ribavirin" post="[6]. Despite the consensus of ISG activation, each purine/pyrimidine"/>
   <result pre="than one signaling pathway involved. The synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin observed in our study might be explained"/>
   <result pre="signaling pathway involved. The synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="observed in our study might be explained by the"/>
   <result pre="encephalitisN. Eng. J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued" exact="zidovudine" post="with didanosine in human immunodeficiency virus infection. The niaid"/>
   <result pre="J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued zidovudine with" exact="didanosine" post="in human immunodeficiency virus infection. The niaid aids clinical"/>
   <result pre="virus cell culture modelsHepatology201153324110.1002/hep.2398521254160 7.LeyssenP.BalzariniJ.de ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
   <result pre="virus replicationAntimicrob. Agents Chemother.2016602834284810.1128/AAC.02700-1526926637 11.HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG.A.ToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2′,2′-difluoro-2′-deoxycytidine)Cancer Res.199050441744222364394 12.CerqueiraN.M.FernandesP.A.RamosM.J.Understanding ribonucleotide reductase inactivation by gemcitabineChemistry2007138507851510.1002/chem.20070026017636467 13.DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.Jr.JahrlingP.B.LaidlawM.et"/>
   <result pre="respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit zika virus infection in vitro and differentially affect"/>
   <result pre="and metabolismAntivir. Res.201713911712810.1016/j.antiviral.2016.12.02228049006 15.ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.et al.Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax,"/>
   <result pre="a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infectionJ. Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of"/>
   <result pre="Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
   <result pre="17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et"/>
   <result pre="model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish"/>
   <result pre="HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish a cyclophilin"/>
   <result pre="of a novel HIV combination therapyJ. Virol.2010849301930910.1128/JVI.01006-1020610712 22.SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD.E.ChoS.ChangS.Y.YoonB.I.SeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.201714561310.1016/j.antiviral.2017.07.00328705625"/>
   <result pre="cultured mammalian cellsAntivir. Res.2011891810.1016/j.antiviral.2010.10.00921070810 27.TakhampunyaR.UbolS.HoungH.S.CameronC.E.PadmanabhanR.Inhibition of dengue virus replication by" exact="mycophenolic acid" post="and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and mycophenolic acid"/>
   <result pre="by mycophenolic acid and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and" exact="mycophenolic acid" post="markedly potentiate the anti-hepatitis B virus activity of entecavirAntivir."/>
   <result pre="activity of entecavirAntivir. Res.20077319219610.1016/j.antiviral.2006.10.00317098296 29.WangY.ZhouX.DebingY.ChenK.van der LaanL.J.NeytsJ.JanssenH.L.MetselaarH.J.PeppelenboschM.P.PanQ.Calcineurin inhibitors stimulate and" exact="mycophenolic acid" post="inhibits replication of hepatitis E virusGastroenterology20141461775178310.1053/j.gastro.2014.02.03624582714 30.PanQ.de RuiterP.E.MetselaarH.J.KwekkeboomJ.de JongeJ.TilanusH.W.JanssenH.L.van"/>
   <result pre="in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral activity of tiazofurin and" exact="mycophenolic acid" post="against grapevine leafroll-associated virus 3 in vitis vinifera explantsAntivir."/>
   <result pre="vitis vinifera explantsAntivir. Res.20077320621110.1016/j.antiviral.2006.10.00717125850 32.ShirakiK.IshibashiM.OkunoT.KokadoY.TakaharaS.YamanishiK.SonodaT.TakahashiM.Effects of cyclosporine, azathioprine, mizoribine, and" exact="prednisolone" post="on replication of human cytomegalovirusTransplant. Proc.199022168216852167528 33.FurutaY.TakahashiK.FukudaY.KunoM.KamiyamaT.KozakiK.NomuraN.EgawaH.MinamiS.WatanabeY.et al.In vitro"/>
   <result pre="cultureAntimicrob. Agents Chemother.2010543686369510.1128/AAC.00561-1020606073 35.SchlapferE.FischerM.OttP.SpeckR.F.Anti-HIV-1 activity of leflunomide: A comparison with" exact="mycophenolic acid" post="and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and cidofovir on replication"/>
   <result pre="leflunomide: A comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of" exact="leflunomide" post="and cidofovir on replication of BK virus in an"/>
   <result pre="comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and" exact="cidofovir" post="on replication of BK virus in an in vitro"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6025560/results/search/drugs/results.xml">
   <result pre="for treatment of EBV infections. Epstein–Barr virus maribavir antiviral acyclovir" exact="ganciclovir" post="1. Introduction Why is it that despite the profusion"/>
   <result pre="might be beneficial. However, in a multicenter, double-blind, placebo-controlled trial," exact="prednisolone" post="administered with ACV for treatment of IM inhibited oropharyngeal"/>
   <result pre="of the patients. 5. Ganciclovir and Valgancyclovir The effects of" exact="ganciclovir" post="(GCV) and valgancyclovir (VGCV) prophylaxis on EBV load was"/>
   <result pre="xenografts in nude mice, injection into the tumor tissue with" exact="cidofovir" post="suppressed growth of the NPC tissue [30,31]. The ribonucleotide"/>
   <result pre="of the NPC tissue [30,31]. The ribonucleotide reductase (RR) inhibitors" exact="hydroxyurea" post="and didox (3,4-dihydroxybenzohydroxamic acid) enhanced cidofovir-induced apoptosis in EBV-transformed"/>
   <result pre="authors declare no conflict of interest. References References 1.TynellE.AureliusE.BrandellA.JulanderI.WoodM.YaoQ.Y.RickinsonA.AkerlundB.AnderssonJ.Acyclovir and" exact="prednisolone" post="treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled"/>
   <result pre="Transplant.20022154755410.1016/S1053-2498(01)00407-711983544 13.HierroL.Diez-DoradoR.DiazC.De la VegaA.FraucaE.CamarenaC.Munoz-BartoloG.Gonzalez de ZarateA.Lopez SantamariaM.JaraP.Efficacy and safety of" exact="valganciclovir" post="in liver-transplanted children infected with Epstein-Barr virusLiver Transpl.2008141185119310.1002/lt.2149818668670 14.GreenM.MichaelsM.G.Epstein-Barr"/>
   <result pre="deep sequencingAntimicrob. Agents Chemother.2014584697470210.1128/AAC.03214-1424890586 23.ChouS.BowlinT.L.Cytomegalovirus UL97 mutations affecting cyclopropavir and" exact="ganciclovir" post="susceptibilityAntimicrob. Agents Chemother.20115538238410.1128/AAC.01259-1021041510 24.LurainN.S.ChouS.Antiviral drug resistance of human cytomegalovirusClin."/>
   <result pre="cytomegalovirusClin. Microbiol. Rev.20102368971210.1128/CMR.00009-1020930070 25.ChouS.Cytomegalovirus UL97 mutations in the era of" exact="ganciclovir" post="and maribavirRev. Med. Virol.20081823324610.1002/rmv.57418383425 26.WangF.Z.RoyD.GershburgE.WhitehurstC.B.DittmerD.P.PaganoJ.S.Maribavir inhibits epstein-barr virus transcription"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6027266/results/search/drugs/results.xml">
   <result pre="antagonist, such as maraviroc, or integrase inhibitors (INs), such as" exact="dolutegravir" post="[17,18,19,20]. It is important to remark that long-term exposure"/>
   <result pre="both P-gp and MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir," exact="indinavir" post="(PIs), and abacavir (NRTI) are known as P-gp substrates"/>
   <result pre="MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir, indinavir (PIs), and" exact="abacavir" post="(NRTI) are known as P-gp substrates [43], whereas zidovudine"/>
   <result pre="and abacavir (NRTI) are known as P-gp substrates [43], whereas" exact="zidovudine" post="and didanosine appear to be transported by MRP-4 and"/>
   <result pre="(NRTI) are known as P-gp substrates [43], whereas zidovudine and" exact="didanosine" post="appear to be transported by MRP-4 and MRP-5 [32,33,38]."/>
   <result pre="and MRP-5 [32,33,38]. Finally, zidovudine, lamivudine, abacavir, zalcitabine, stavudine, and" exact="efavirenz" post="appear as BCRP substrates [44], whereas ritonavir, saquinavir, and"/>
   <result pre="efavirenz appear as BCRP substrates [44], whereas ritonavir, saquinavir, and" exact="nelfinavir" post="are known as inhibitors of this transporter [34]. Maraviroc,"/>
   <result pre="suggested to be a P-gp substrate [45,46,47], whereas the IN" exact="dolutegravir" post="appears as a P-gp and BRCP substrate [20]. Cyclosporine-A,"/>
   <result pre="as a P-gp and BRCP substrate [20]. Cyclosporine-A, verapamil, and" exact="mefloquine" post="are P-gp inhibitors; some of them have been used"/>
   <result pre="primary human brain microvascular endothelial cells (HBMVEC) to HIV-1 and" exact="saquinavir" post="induces an increased MDR-1-mediated drug efflux [51]. Moreover, it"/>
   <result pre="efflux [51]. Moreover, it has been demonstrated that the PIs" exact="ritonavir" post="and atazinavir are able to induce P-gp expression in"/>
   <result pre="endothelial cells hCMEC/D3 demonstrated that amprenavir, atazanavir, efavirenz, ritonavir, and" exact="lopinavir" post="activate hPXR, whereas abacavir, efavirenz, and nepvirapine activate hCAR."/>
   <result pre="other words, a great number of PIs are hPXR ligands:" exact="abacavir" post="and nevirapine are hCAR ligands, and efavirenz is a"/>
   <result pre="a great number of PIs are hPXR ligands: abacavir and" exact="nevirapine" post="are hCAR ligands, and efavirenz is a ligand of"/>
   <result pre="are hPXR ligands: abacavir and nevirapine are hCAR ligands, and" exact="efavirenz" post="is a ligand of both PXR and hCAR. These"/>
   <result pre="enhancement of the cytotoxicity of some anticancer drugs induced by" exact="verapamil" post="(a vasodilator) and cyclosporin A (an immunosuppressant) was revealed."/>
   <result pre="large and fluid binding cavity, the HIV reverse transcriptase inhibitor" exact="abacavir" post="was converted into a dimeric prodrug able to act"/>
   <result pre="cells overexpressing the efflux transporter. The tether length between the" exact="abacavir" post="molecules in the prodrug dimers was able to modulate"/>
   <result pre="strategy of antiviral drugs demonstrating that the ester conjugation of" exact="zidovudine" post="(AZT) with ursodeoxycholic acid, a bile acid which can"/>
   <result pre="drugs demonstrating that the ester conjugation of zidovudine (AZT) with" exact="ursodeoxycholic acid," post="a bile acid which can permeate the CNS, results"/>
   <result pre="antiretroviral drug. In this regard, it has been reported that" exact="indinavir" post="(IDV)-loaded nanoparticles, obtained by coating an IDV suspension, prepared"/>
   <result pre="Very recently, a powder formulation of agglomerates constituted by micronized" exact="ribavirin" post="and α-cyclodextrin spray-dried microparticles was nasally administered to rats."/>
   <result pre="Regarding studies on innovative nasal formulations, the development of antiretroviral" exact="efavirenz" post="(EFV)-loaded nanoparticles based on poly(ε-caprolactone) (PCL), Eudragit® RS 100"/>
   <result pre="PVP compared to chitosan gels [104]. In addition to chitosan," exact="papaverine" post="(a phosphodiesterase inhibitor) has also been considered for its"/>
   <result pre="of nasal mucosa. In particular, after intranasal administration to rats," exact="papaverine" post="appeared to be able to induce a rapid and"/>
   <result pre="associated with an approximately four-fold increase in the amounts of" exact="gemcitabine" post="(chosen as a model drug) reaching the brain, which"/>
   <result pre="surfactant and co-surfactant, respectively, was developed for brain targeting of" exact="saquinavir" post="mesylate. This type of formulation was able to induce"/>
   <result pre="the drug in the brain after intranasal administration compared to" exact="saquinavir" post="amounts obtained after intravenous administration of plain drug suspension."/>
   <result pre="efficacy of this formulation in promoting the nose-to-brain delivery of" exact="saquinavir" post="mesylate [106]. 8.3.1. Nasal Formulations for Zidovudine Administration Several"/>
   <result pre="have been studied in order to induce the uptake of" exact="zidovudine" post="(AZT) in the central nervous system. It is well-known"/>
   <result pre="[110], resulting in a poor CNS/plasma ratio (about 0.1) of" exact="zidovudine" post="[111]. It is important to underline that AZT activity"/>
   <result pre="in the CSF increased when AZT was intravenously co-administered with" exact="probenecid" post="[114], even if it is known that the concomitant"/>
   <result pre="unwanted effects [27,115]. The first studies on nasal administration of" exact="zidovudine" post="to rats were performed using formulations constituted by an"/>
   <result pre="of AZT (20 µmol/kg) or a suspension of AZT and" exact="probenecid" post="[114]. Following nasal administration, AZT showed rapid absorption in"/>
   <result pre="lower than 1 and weakly increased in the presence of" exact="probenecid" post="[114]. A thermoreversible gel, based on Poloxamer 407 (thermoreversible"/>
   <result pre="the prodrug UDCA-AZT, obtained by means of ester conjugation of" exact="zidovudine" post="with ursodeoxycholic acid [71], was loaded in micro-particulate nasal"/>
   <result pre="UDCA-AZT, obtained by means of ester conjugation of zidovudine with" exact="ursodeoxycholic acid" post="[71], was loaded in micro-particulate nasal formulations. This prodrug"/>
   <result pre="P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of" exact="lopinavir" post="in cultured CD4 T cells and primary human lymphocytesJ."/>
   <result pre="primary human lymphocytesJ. Antimicrob. Chemother.20076098799310.1093/jac/dkm35317890284 25.DalpiazA.FogagnoloM.FerraroL.CapuzzoA.PavanB.RassuG.SalisA.GiunchediP.GaviniE.Nasal chitosan microparticles target a" exact="zidovudine" post="prodrug to brain HIV sanctuariesAntivir. Res.201512314615710.1016/j.antiviral.2015.09.01326427553 26.NamanjaH.A.EmmertD.DavisD.A.CamposC.MillerD.S.HrycynaC.A.ChmielewskiJ.Toward eradicating HIV"/>
   <result pre="the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug" exact="abacavir" post="dimersJ. Am. Chem. Soc.20121342976298010.1021/ja206867t21866921 27.PavanB.DalpiazA.Prodrugs and endogenous transporters: Are"/>
   <result pre="al.ATP binding cassette multidrug transporters limit the anti-HIV activity of" exact="zidovudine" post="and indinavir in infected human macrophagesAntivir. Ther.2004951952815456083 34.GuptaA.ZhangY.UnadkatJ.D.MaoQ.HIV protease"/>
   <result pre="cassette multidrug transporters limit the anti-HIV activity of zidovudine and" exact="indinavir" post="in infected human macrophagesAntivir. Ther.2004951952815456083 34.GuptaA.ZhangY.UnadkatJ.D.MaoQ.HIV protease inhibitors are"/>
   <result pre="Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein in the transport of" exact="saquinavir" post="and indinavir in rat brain microvessel endothelial and microglia"/>
   <result pre="Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein in the transport of saquinavir and" exact="indinavir" post="in rat brain microvessel endothelial and microglia cell linesPharm."/>
   <result pre="36.ParkS.SinkoP.J.P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of" exact="saquinavir" post="in miceJ. Pharmacol. Exp. Ther.20053121249125610.1124/jpet.104.07621615528451 37.BachmeierC.J.SpitzenbergerT.J.ElmquistW.F.MillerD.W.Quantitative assessment of HIV-1"/>
   <result pre="blood-brain barrierPharm. Res.2005221259126810.1007/s11095-005-5271-y16078135 38.EilersM.RoyU.MondalD.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs," exact="saquinavir" post="and zidovudine, from human endothelial cellsExp. Biol. Med.20082331149116010.3181/0802-RM-5918535159 39.DallasS.MillerD.S.BendayanR.Multidrug"/>
   <result pre="and chemotherapyAAPS Pharm. Sci.20024E1410.1208/ps04031412423063 41.JannehO.OwenA.ChandlerB.HartkoornR.C.HartC.A.BrayP.G.WardS.A.BackD.J.KhooS.H.Modulation of the intracellular accumulation of" exact="saquinavir" post="in peripheral blood mononuclear cells by inhibitors of MRP1,"/>
   <result pre="MRP2, P-gp and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced" exact="ritonavir" post="and saquinavir accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The"/>
   <result pre="and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced ritonavir and" exact="saquinavir" post="accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The transport of"/>
   <result pre="for HIVDrug Metab. Dispos.20053358759510.1124/dmd.104.00262615650075 46.WalkerD.K.BowersS.J.MitchellR.J.PotchoibaM.J.SchroederC.M.SmallH.F.Preclinical assessment of the distribution of" exact="maraviroc" post="to potential human immunodeficiency virus (HIV) sanctuary sites in"/>
   <result pre="(CNS) and gut-associated lymphoid tissue (GALT)Xenobiotica2008381330133910.1080/0049825080244740918853388 47.RamanathanS.AbelS.TweedyS.WestS.HuiJ.KearneyB.P.Pharmacokinetic interaction of ritonavir-boosted" exact="elvitegravir" post="and maravirocJ. Acquir. Immune Defic. Syndr.20105320921410.1097/QAI.0b013e3181ba453619851115 48.Ponte-SucreA.Availability and applications"/>
   <result pre="Biotechnol.20077627928610.1007/s00253-007-1017-617522856 49.OwenA.JannehO.HartkoornR.C.ChandlerB.BrayP.G.MartinP.WardS.A.HartC.A.KhooS.H.BackD.J.In vitro synergy and enhanced murine brain penetration of" exact="saquinavir" post="coadministered with mefloquineJ. Pharmacol. Exp. Ther.20053141202120910.1124/jpet.105.08627215923343 50.KruhG.D.BelinskyM.G.The MRP family"/>
   <result pre="following co-exposure to HIV-1 and saquinavirPLoS ONE20138e7537410.1371/journal.pone.007537424098380 52.PerloffM.D.von MoltkeL.L.GreenblattD.J.Ritonavir and" exact="dexamethasone" post="induce expression of CYP3A and P-glycoprotein in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von"/>
   <result pre="in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von MoltkeL.L.FaheyJ.M.GreenblattD.J.Induction of P-glycoprotein expression and activity by" exact="ritonavir" post="in bovine brain microvessel endothelial cellsJ. Pharm. Pharmacol.20075994795310.1211/jpp.59.7.000617637189 54.ZastreJ.A.ChanG.N.Y.RonaldsonP.T.RamaswamyM.CouraudP.O.RomeroI.A.WekslerB.BendayanM.BendayanR.Up-regulation"/>
   <result pre="of human pregnane X receptor tightens the blood-brain barrier to" exact="methadone" post="through P-glycoprotein up-regulationMol. Pharmacol.2006701212121910.1124/mol.106.02379616837625 58.OttM.FrickerG.BauerB.Pregnane X receptor (PXR) regulates"/>
   <result pre="molecular basis for poly-specific drug bindingScience20093231718172210.1126/science.116875019325113 70.NamanjaH.A.EmmertD.HrycynaC.A.ChmielewskiJ.Homodimers of the antiviral" exact="abacavir" post="as modulators of P-glycoprotein transport in cell culture: Probing"/>
   <result pre="P-glycoprotein transport in cell culture: Probing tether lengthMedchemcomm201341344134910.1039/c3md00196b24273637 71.DalpiazA.PaganettoG.PavanB.FogagnoloM.MediciA.BeggiatoS.PerroneD.Zidovudine and" exact="ursodeoxycholic acid" post="conjugation: Design of a new prodrug potentially able to"/>
   <result pre="of PLGA nanoparticles as delivery systems of a prodrug of" exact="zidovudine" post="obtained by its conjugation with ursodeoxycholic acidDrug Deliv.201421221123210.3109/10717544.2013.84474424134683 73.DalpiazA.FerraroL.PerroneD.LeoE.IannuccelliV.PavanB.PaganettoG.BeggiatoS.ScaliaS.Brain"/>
   <result pre="al.Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of" exact="indinavir" post="nanoparticles in human monocyte-derived macrophagesVirology200735814815810.1016/j.virol.2006.08.01216997345 76.GorantlaS.DouH.BoskaM.DestacheC.J.NelsonJ.PoluektovaL.RabinowB.E.GendelmanH.E.MosleyR.L.Quantitative magnetic resonance and"/>
   <result pre="deliveryActa Pharm. Sin. B2016626828610.1016/j.apsb.2016.05.01327471668 78.ManfrediniS.PavanB.VertuaniS.ScagliantiM.CompagnoneD.BiondiC.ScatturinA.TanganelliS.FerraroL.PrasadP.et al.Design, synthesis and activity of" exact="ascorbic acid" post="prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to"/>
   <result pre="virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy of" exact="ribavirin" post="against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of ribavirin"/>
   <result pre="of ribavirin against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of" exact="ribavirin" post="after intranasal administrationAntivir. Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery"/>
   <result pre="Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery of the hydrophilic antiviral" exact="ribavirin" post="by microparticle agglomeratesDrug Deliv.20182537638710.1080/10717544.2018.142824229382237 87.MistryA.StolnikS.IllumL.Nanoparticles for direct nose-to-brain delivery"/>
   <result pre="drugsInt. J. Pharm.200937914615710.1016/j.ijpharm.2009.06.01919555750 88.HoekmanJ.D.HoR.J.Effects of localized hydrophilic mannitol and hydrophobic" exact="nelfinavir" post="administration targeted to olfactory epithelium on brain distributionAAPS PharmSciTech.20111253454310.1208/s12249-011-9614-121519984"/>
   <result pre="N-trimethyl chitosan chlorideEur. J. Pharm. Biopharm.20117722523210.1016/j.ejpb.2010.11.02221130876 96.NakamuraK.MaitaniY.LowmanA.M.TakayamaK.PeppasN.A.NagaiT.Uptake and release of" exact="budesonide" post="from mucoadhesive, pH-sensitive copolymers and their application to nasal"/>
   <result pre="the sheep nasal cavityInt. J. Pharm.200121718319110.1016/S0378-5173(01)00602-011292554 98.ZakiN.M.AwadG.A.MortadaN.D.Abd ElhadyS.S.Enhanced bioavailability of" exact="metoclopramide" post="HCl by intranasal administration of a mucoadhesive in situ"/>
   <result pre="acyclovirDrug Dev. Ind. Pharm.20093535236210.1080/0363904080236051018770068 105.KrishanM.GudelskyG.A.DesaiP.B.GenterM.B.Manipulation of olfactory tight junctions using" exact="papaverine" post="to enhance intranasal delivery of gemcitabine to the brainDrug"/>
   <result pre="olfactory tight junctions using papaverine to enhance intranasal delivery of" exact="gemcitabine" post="to the brainDrug Deliv.20142181610.3109/10717544.2013.84001724116937 106.MahajanH.S.MahajanM.S.NerkarP.P.AgrawalA.Nanoemulsion-based intranasal drug delivery system"/>
   <result pre="to the brainDrug Deliv.20142181610.3109/10717544.2013.84001724116937 106.MahajanH.S.MahajanM.S.NerkarP.P.AgrawalA.Nanoemulsion-based intranasal drug delivery system of" exact="saquinavir" post="mesylate for brain targetingDrug Deliv.20142114815410.3109/10717544.2013.83801424128122 107.PardridgeW.M.Blood-brain barrier drug targeting:"/>
   <result pre="of brain drug developmentMol. Interv.200339010510.1124/mi.3.2.9014993430 108.WongS.L.Van BelleK.SawchukR.J.Distributional transport kinetics of" exact="zidovudine" post="between plasma and brain extracellular fluid/cerebrospinal fluid in the"/>
   <result pre="fluid in the rabbit: Investigation of the inhibitory effect of" exact="probenecid" post="utilizing microdialysisJ. Pharmacol. Exp. Ther.19932648999098437131 109.TakasawaK.TerasakiT.SuzukiH.SugiyamaY.In vivo evidence for"/>
   <result pre="brain during intravenous and intracerebroventricular infusionJ. Pharm. Sci.1995787187610.1002/jps.2600840717 111.WongS.L.WangY.SawchukR.J.Analysis of" exact="zidovudine" post="distribution to specific regions in rabbit brain using microdialysisPharm."/>
   <result pre="fluid cisterns via subarachnoid velae in ratNeuroscience1996751271128810.1016/0306-4522(96)00281-38938759 114.SekiT.SatoN.HasegawaT.KawaguchiT.JuniK.Nasal absorption of" exact="zidovudine" post="and its transport to cerebrospinal fluid in ratsPharm. Bull.1994171135113710.1248/bpb.17.1135"/>
   <result pre="oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal" exact="zidovudine" post="delivery to the brainInt. J. Pharm.20114111910.1016/j.ijpharm.2011.02.04021356294 117.Al-GhananeemA.M.SmithM.CoronelM.L.TranH.Advances in brain"/>
   <result pre="and organic compounds saquinavir, ritonavir, lopinavir, amprenavir, nelfinavir, indinavir, abacavir," exact="dolutegravir" post="cyclosporine-A, verapamil, mefloquine Multidrug Resistance Protein MRP-1 ABCC1 hydrophilic"/>
   <result pre="saquinavir, ritonavir, lopinavir, amprenavir, nelfinavir, indinavir, abacavir, dolutegravir cyclosporine-A, verapamil," exact="mefloquine" post="Multidrug Resistance Protein MRP-1 ABCC1 hydrophilic anion compounds, large"/>
   <result pre="Protein MRP-1 ABCC1 hydrophilic anion compounds, large molecules saquinavir, ritonavir," exact="lopinavir" post="paclitaxel, probenecid, MK-571 MRP-4 MRP-5 ABCC4 ABCC5 small polar"/>
   <result pre="MRP-4 MRP-5 ABCC4 ABCC5 small polar compounds, nucleoside analogues Zidovudine," exact="didanosine" post="Breast-Cancer-Resistance Protein BRCP ABCG2 partially overlap with those of"/>
   <result pre="with those of P-gp zidovudine, lamivudine, abacavir, zalcitabine, stavudine, efavirenz," exact="dolutegravir" post="ritonavir, saquinavir, nelfinavir"/>
   <result pre="P-gp zidovudine, lamivudine, abacavir, zalcitabine, stavudine, efavirenz, dolutegravir ritonavir, saquinavir," exact="nelfinavir" post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6439212/results/search/drugs/results.xml">
   <result pre="(Pol/RT) was modeled and docked with the active compounds, including" exact="lamivudine" post="as standard. Docking of lamivudine indicated strong interaction with"/>
   <result pre="with the active compounds, including lamivudine as standard. Docking of" exact="lamivudine" post="indicated strong interaction with the modeled HBV Pol active-site"/>
   <result pre="with HBV Pol inhibitors, the nucleot(s)ide analogs (e.g., lamivudine, adepovir," exact="entecavir" post="etc.) leads to the emergence of drug-resistance in the"/>
   <result pre="Wu, 2016, Parvez et al., 2016). Compared to interferons or" exact="lamivudine" post="treatment, some plant products are reported with similar or"/>
   <result pre="naringenin were purchased (Sigma-Aldrich, Germany). The approved anti-HBV nucleoside analog," exact="lamivudine" post="(3TC; Sigma-Aldrich, Germany) served as standard (positive control). 2.2"/>
   <result pre="grown over night. Compounds were first dissolved in 50 μl of" exact="dimethyl sulfoxide" post="(DMSO) following final preparation in culture media (1 mg/ml). Five"/>
   <result pre="for screening the binding modes of antiviral natural compounds, including" exact="lamivudine" post="(Fig. 1) in Autodock Vina and PyRx virtual screening"/>
   <result pre="used in the treatment of HIV/AIDS and CHB. Docking of" exact="lamivudine" post="(as control) to HBV Pol indicated that it was"/>
   <result pre="and two carbon-hydrogen bonds with Ala181. Other residues that surrounded" exact="lamivudine" post="were Gln182 and Ser185 as well as Tyr203 and"/>
   <result pre="delineate the binding mechanism of the anti-HBV active compounds and" exact="lamivudine" post="(ligands) to the modeled HBV Pol (receptor), we performed"/>
   <result pre="modeled HBV Pol (receptor), we performed molecular docking. Docking of" exact="lamivudine" post="indicated that it strongly interacted with the active site"/>
   <result pre="Pol ‘YMDD’ motif residues, Tyr203 and Met204 were among the" exact="lamivudine" post="surrounding amino acids. Quercetin, a widely distributed plant flavonol"/>
   <result pre="was lesser as compared to its reported higher activity to" exact="lamivudine" post="(Yi et al., 2015). In the docking analysis, menisdaurin-HBV"/>
   <result pre="in-vitro and molecular docking analysisJ. Biomol. Struct. Dyn.2017 RehmanM.T.AhmedS.KhanA.U.Interaction of" exact="meropenem" post="with 'N' and 'B' isoforms of human serum albumin:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6444013/results/search/drugs/results.xml">
   <result pre="The following reagents were purchased from Applichem: LB medium (powder)," exact="ampicillin" post="(used at 100 μg/mL) and chloramphenicol (used at 17 μg/mL), MnCl2,"/>
   <result pre="from Applichem: LB medium (powder), ampicillin (used at 100 μg/mL) and" exact="chloramphenicol" post="(used at 17 μg/mL), MnCl2, ammonium acetate, NaCl, MgCl2, ZnCl2,"/>
   <result pre="and pET16b expression vectors were obtained from Novagen. Nucleotide analogs" exact="ribavirin" post="5′-triphosphate and cordycepin 5′-triphosphate were obtained from Jena Bioscience"/>
   <result pre="E. coli cells were transformed by electroporation with pET16a-ZIKV-NS5RdRp. Single" exact="kanamycin" post="and chloramphenicol resistant colonies were cultured overnight in 10 mL"/>
   <result pre="cells were transformed by electroporation with pET16a-ZIKV-NS5RdRp. Single kanamycin and" exact="chloramphenicol" post="resistant colonies were cultured overnight in 10 mL of LB"/>
   <result pre="cordycepin 5′-triphosphate (3′dATP; a chain terminator analog of ATP48–50) and" exact="ribavirin" post="5′-triphosphate (RTP; a purine analog that inhibits but does"/>
   <result pre="and functions of RNA-directed RNA polymerasesTrends Plant Sci20061114215110.1016/j.tplants.2006.01.00316473542 22.YinZet al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc Natl Acad Sci USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="activity of ribavirinJ Biol Chem2001276460944609810.1074/jbc.C10034920011602568 53.CrottySet al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat Med200061375137910.1038/8219111100123 54.AriasAet al.Determinants of"/>
   <result pre="a broad-spectrum antiviral compoundSci Rep20177581610.1038/s41598-017-04449-328725041 67.VoNVYoungKCLaiMMMutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymeraseBiochemistry200342104621047110.1021/bi034468112950173 68.Bassi, M. R.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6702965/results/search/drugs/results.xml">
   <result pre="effect of three of these cell-targeting antivirals: lauryl gallate (LG)," exact="valproic acid" post="(VPA), and cerulenin (CRL) in the multiplication of viruses"/>
   <result pre="against porcine diseases is discussed. virus porcine antiviral lauryl gallate" exact="valproic acid" post="cerulenin Funding Spanish Ministerio de Ciencia e Innovación2011-20E112 Ministerio"/>
   <result pre="have focused our studies on three compounds: lauryl gallate (LG)," exact="valproic acid" post="(VPA), and cerulenin (CRL) (Table 1) that can interfere"/>
   <result pre="Inhibition of herpes virus infection in oligodendrocyte cultured cells by" exact="valproic acid." post="Virus Res.214, 71–79. 10.1016/j.virusres.2016.01.009, PMID: 26805038 CuypersL.SnoeckJ.KerremansL.LibinP.CrabbeR.Van DoorenS.et al.."/>
   <result pre="PMID: 11254174 TerbachN.WilliamsR. S. (2009). Structure-function studies for the panacea," exact="valproic acid." post="Biochem. Soc. Trans.37, 1126–1132. 10.1042/BST0371126, PMID: 19754465 UozakiM.YamasakiH.KatsuyamaY.HiguchiM.HigutiT.KoyamaA. H."/>
   <result pre="(2013). Inhibition of multiplication of the prototypic arenavirus LCMV by" exact="valproic acid." post="Antivir. Res.99, 172–179. 10.1016/j.antiviral.2013.05.012, PMID: 23735299 Vazquez-CalvoA.SaizJ. C.SobrinoF.Martin-AcebesM. A."/>
   <result pre="(2011). Inhibition of enveloped virus infection of cultured cells by" exact="valproic acid." post="J. Virol.85, 1267–1274. 10.1128/JVI.01717-10, PMID: 21106740 YamasakiH.UozakiM.KatsuyamaY.UtsunomiyaH.ArakawaT.HiguchiM.et al.. (2007)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6755163/results/search/drugs/results.xml">
   <result pre="different compared with that of PHHs, as the addition of" exact="dimethyl sulfoxide" post="(DMSO) plus polyethylene glycol 8000 (PEG8000) during infection does"/>
   <result pre="vena cava under anaesthesia by intraperitoneal injection of 30 mg/kg" exact="pentobarbital" post="sodium (7). Death was confirmed by respiratory arrest, cardiac"/>
   <result pre="plates pre-coated with collagen (Gibco; Thermo Fisher Scientific, Inc.) in" exact="dimethyl sulfoxide" post="(DMSO)-free primary human hepatocyte maintenance medium (PMM) (4) containing"/>
   <result pre="supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml" exact="streptomycin" post="maintained at 37°C in a 5% CO2 incubator. Huh7D"/>
   <result pre="(DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 µg/ml" exact="streptomycin" post="and 2.5% DMSO) for 24–72 h prior to HBV"/>
   <result pre="supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml" exact="streptomycin" post="maintained at 37°C in a 5% CO2 incubator. For"/>
   <result pre="penicillin and 100 µg/ml streptomycin, 5 µg/ml insulin, 18 ng/ml" exact="hydrocortisone" post="and 2–2.5% DMSO. The culture media was collected at"/>
   <result pre="~50 nM. The less effective inhibition of HBV infection by" exact="lamivudine" post="possibly occurred due to the failure of lamivudine to"/>
   <result pre="infection by lamivudine possibly occurred due to the failure of" exact="lamivudine" post="to block HBV entry. These results indicated that HBV-infected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6780377/results/search/drugs/results.xml">
   <result pre="for repressing Flaviviruses. Guanine biosynthesis can be inhibited through antiviral" exact="ribavirin" post="[69]. Dihydroorotate dehydrogenase (DHODH) is a mitochondrial protein that"/>
   <result pre="(HS) mimetic PI88 [80], α- d-glucan [84], GAG [85], and" exact="dextran" post="sulfate (DS, MW &amp;gt; 500,000 Da) [85] are also"/>
   <result pre="(MAPKAPK5) kinase activity and inhibit DENV propagation [108]. GNF-2 and" exact="imatinib" post="inhibit DENV but are mediated by cellular Abl kinases"/>
   <result pre="were non-detectable [142,143,144]. It has been demonstrated that IFN-γ controls" exact="nitric oxide" post="synthase II-mediated nitric oxide production that assists the host"/>
   <result pre="has been demonstrated that IFN-γ controls nitric oxide synthase II-mediated" exact="nitric oxide" post="production that assists the host in resistance against primary"/>
   <result pre="in Patients with Dengue Hemorrhagic FeverFEMS Immunol. Med. Microbiol.20002815115510.1111/j.1574-695X.2000.tb01470.x10799806 145.Neves-SouzaP.C.AzeredoE.L.ZagneS.M.Valls-de-SouzaR.ReisS.R.CerqueiraD.I.NogueiraR.M.KubelkaC.F.Inducible" exact="nitric oxide" post="synthase (iNOS) expression in monocytes during acute Dengue Fever"/>
   <result pre="Huh-7 [176] Isothiazolo[5,4-b] pyridines GAK DENV-2 Huh-7 [177] Sunitinib and" exact="erlotinib" post="AAK1 and GAK DENV-2 Huh7 [178] AR-12 PI3K/JAKT pathway"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6792045/results/search/drugs/results.xml">
   <result pre="HFMD is currently treated with broad-spectrum antiviral drugs, such as" exact="ribavirin" post="[19, 20] and glucocorticoids [21, 22], which can cause"/>
   <result pre="1.17 pg/mL (IL-6), 1.17 pg/mL (IL-10) and 1.63 pg/mL (TNF-α). Anti-viral effects of" exact="ribavirin" post="and cytokines in vitro and in vivo RD cells"/>
   <result pre="injected 1 h after infection. At 1 dpi, the same amount of" exact="ribavirin" post="and cytokines were re-injected. The body weights, clinical scores"/>
   <result pre="negative control. In vitro and in vivo antiviral effects of" exact="ribavirin" post="and cytokines RD cells were first i.m. inoculated with"/>
   <result pre="YT226R at an MOI of 0.01, and then treated with" exact="ribavirin" post="and a cytokine panel 48 hpi. The maximum inhibition rates"/>
   <result pre="and a cytokine panel 48 hpi. The maximum inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication were detected by"/>
   <result pre="IFN-γ and particularly IFN-α2a had comparable anti-CVA4 effects compared with" exact="ribavirin" post="in vitro. Figure 5. Anti-CVA4 effects of ribavirin and"/>
   <result pre="compared with ribavirin in vitro. Figure 5. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vitro. One hour after the RD"/>
   <result pre="One hour after the RD cells were challenged with YT226R," exact="ribavirin" post="and different cytokines were added, respectively. CCK8 and qRT-PCR"/>
   <result pre="and qRT-PCR were employed to determine the inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication (A), and the"/>
   <result pre="rate of the neonatal mice. Figure 6. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vivo. One hour after the 3-day-old"/>
   <result pre="after the 3-day-old neonatal mice (n = 10–15) were challenged with YT226R," exact="ribavirin" post="and different cytokines were administered for the first time."/>
   <result pre="monitoring in chronic Hepatitis C patients treated with interferon and" exact="ribavirin" post="combination therapy. Pak J Pharm Sci. 2017;30(1):11–16.28603106 [25]HuangLM, ChiuCH,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6843332/results/search/drugs/results.xml">
   <result pre="resistance in immunocompromised persons [22]. The nucleoside analogues acyclovir and" exact="ganciclovir" post="are the standard therapy for HHV-1 and CMV, respectively"/>
   <result pre="the viral kinase pUL97 and polymerase pUL54 mediate resistance to" exact="ganciclovir" post="and valganciclovir [25]. The prevalence of resistance against acyclovir"/>
   <result pre="kinase pUL97 and polymerase pUL54 mediate resistance to ganciclovir and" exact="valganciclovir" post="[25]. The prevalence of resistance against acyclovir is 5%"/>
   <result pre="marrow transplant patients [26], whereas the incidence of resistance to" exact="ganciclovir" post="is 5–10% in organ transplant recipients [27] and 40–50%"/>
   <result pre="acyclovir are typically cross-resistant to thymidine kinase-dependent drugs such as" exact="penciclovir" post="and famciclovir. They also may be cross-resistant to polymerase"/>
   <result pre="also may be cross-resistant to polymerase dependent drugs, foscarnet or" exact="cidofovir" post="[26]. Ganciclovir-resistant strains also have shown cross resistance to"/>
   <result pre="also have shown cross resistance to second-line treatments foscarnet and" exact="cidofovir" post="[28]. Targeting the DNA polymerase and thymidine kinase, while"/>
   <result pre="integrase inhibitor, exhibits efficiency against herpes viruses. The effect of" exact="raltegravir" post="on herpes viruses is attributed to an inhibition of"/>
   <result pre="as the HIV integrase [31]. Recently however, drug resistance to" exact="raltegravir" post="has been traced to HHV-1 UL42 coding for the"/>
   <result pre="not a part of the terminase, it was determined that" exact="raltegravir" post="likely inhibits DNA replication through the polymerase accessory factor"/>
   <result pre="analyzed, which may explain the resistance that has emerged against" exact="raltegravir" post="and acyclovir, respectively. Since pUL15 is one of the"/>
   <result pre="pathogenic virusesAntimicrob. Agents Chemother.2012561135113710.1128/AAC.05908-1122106211 45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous" exact="cidofovir" post="for life-threatening viral infections in pediatric hematopoietic stem cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6925545/results/search/drugs/results.xml">
   <result pre="MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HCT children was 19.3%. In 30.8% cases of"/>
   <result pre="which did not prevent development of EBV-DNA-emia with need of" exact="rituximab" post="treatment in 81.5% cases. In 47.7% of these cases,"/>
   <result pre="(GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV) nor" exact="cidofovir" post="(CDV) therapy/prophylaxis have any impact on development of EBV-PTLD,"/>
   <result pre="(81.8%) cases, a significant EBV-DNA-emia has occurred and treatment with" exact="rituximab" post="was required. In 44/54 (81.5%) of these cases viral"/>
   <result pre="were treated with antiviral drugs, including: CDV (n=18), GCV (n=17)," exact="aciclovir" post="(ACV) (n=1), oseltamivir (n=1) or drug combinations (FCV+GCV, n=5;"/>
   <result pre="antiviral drugs, including: CDV (n=18), GCV (n=17), aciclovir (ACV) (n=1)," exact="oseltamivir" post="(n=1) or drug combinations (FCV+GCV, n=5; FCV+CDV, n=2; GCV+CDV,"/>
   <result pre="FCV therapies, 1/12 (8.3%) ACV therapies and 1/13 (7.7%) of" exact="oseltamivir" post="therapies. Discussion The primary causes of morbidity and non-relapse"/>
   <result pre="risk of clinically significant CMV infection.18 We have shown that" exact="ganciclovir" post="and foscarnet were the most frequently used drugs in"/>
   <result pre="disease is a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir," exact="leflunomide" post="or artesunate can be considered in patients resistant or"/>
   <result pre="a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir, leflunomide or" exact="artesunate" post="can be considered in patients resistant or refractory to"/>
   <result pre="severity, and the selection of antibiotic resistance.19 In our study" exact="cidofovir" post="was the most frequently used drug in the treatment"/>
   <result pre="with available antiviral drugs is currently not recommended and intravenous" exact="cidofovir" post="is currently regarded as a standard of care in"/>
   <result pre="were acquired during hospitalization.17 In the case of CARV infections," exact="ribavirin" post="and intravenous immunoglobulin are recommended in hMPV, HPIV and"/>
   <result pre="from the respiratory tract, especially broncho-alveolar lavage.23 Neuraminidase inhibitors (oral" exact="oseltamivir" post="or inhalation of zanamivir) are currently the most effective"/>
   <result pre="RV- and NoV-related gastroenterocolitis is available; however, oral immunoglobulins and" exact="nitazoxanide" post="were used in some studies.24,27 In immunocompetent individuals primary"/>
   <result pre="cases in auto-HCT setting. In 80.3% (143/175) of EBV reactivations" exact="rituximab" post="was used and 93.3% of patients survived this infection."/>
   <result pre="prevent the development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment. This is clinically proven evidence that antiviral drugs"/>
   <result pre="immunoglobulins also have no impact in PTLD. Neither ganciclovir/foscarnet nor" exact="cidofovir" post="therapy/prophylaxis have any impact on the development of EBV-PTLD,"/>
   <result pre="PTLD.8 The following pre-emptive therapies are recommended after high-risk allo-HCT:" exact="rituximab" post="(375 mg/m2/weekly), reduction of immunosuppressive therapy (if possible), donor"/>
   <result pre="MSD. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HSCT children was 19.3%. In 30.8% of cases"/>
   <result pre="not prevent development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment in 81.5% of cases. This is clinically proven"/>
   <result pre="allogeneic hematopoietic cell transplant recipients: clinical course and experience using" exact="nitazoxanide" post="and enterally administered immunoglobulins. Pediatr Infect Dis J. 2018;37(2):176–181."/>
   <result pre="2013;6:94. doi:10.1186/1756-8722-6-9424341630 29.CzyzewskiK, StyczynskiJ, KrenskaA, et al. Intrathecal therapy with" exact="rituximab" post="in central nervous system involvement of post-transplant lymphoproliferative disorder."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7026129/results/search/drugs/results.xml">
   <result pre="or newly discovered agents in vitro and in vivo, with" exact="ribavirin" post="and favipiravir being the most promising candidates. While animal"/>
   <result pre="the limited efficacy of ribavirin, it was also speculated that" exact="ribavirin" post="would be effective in patients with a viral load"/>
   <result pre="load &amp;lt;1 × 106 copies/mL. Favipiravir showed higher efficacy than" exact="ribavirin" post="against SFTSV in in vitro assays and greater efficacy"/>
   <result pre="with thrombocytopenia syndrome severe fever with thrombocytopenia syndrome virus antiviral" exact="ribavirin" post="favipiravir Funding Ministry of Health, Labour and Welfare10.13039/501100003478H25-Shinko-Shitei-009 Japan"/>
   <result pre="U/mL IFNγ IC90 = 12 ng/ml &amp;gt;2,000 ng/mL *Combination with" exact="ribavirin" post="and IFNs, virus titers were reduced from 3.2–3.6 log."/>
   <result pre="a nebulizer (Snell, 2001). The proposed mechanisms of action of" exact="ribavirin" post="against viruses are indirect (inosine monophosphate dehydrogenase inhibition and"/>
   <result pre="2006). Shimojima et al. (2014) first reported the efficacy of" exact="ribavirin" post="in vitro using three cell lines: monkey kidney-derived Vero,"/>
   <result pre="hepatoma-derived Huh7, and human osteosarcoma-derived U2OS cells. When treated with" exact="ribavirin" post="before and during infection with SFTSV, the 99% inhibitory"/>
   <result pre="during infection with SFTSV, the 99% inhibitory concentration (IC99) of" exact="ribavirin" post="was 263, 83, and 78 μM in Vero, Huh7,"/>
   <result pre="respectively (Table 1). However, when Vero cells were treated with" exact="ribavirin" post="3 days after the inoculation, the inhibitory effect was"/>
   <result pre="the inoculation, the inhibitory effect was dramatically decreased, suggesting that" exact="ribavirin" post="could be used as post-exposure prophylaxis for the prevention"/>
   <result pre="prophylaxis for the prevention of SFTS and also mentioned that" exact="ribavirin" post="could be effective as part of a combination therapy"/>
   <result pre="treat SFTS patients (Shimojima et al., 2014). The efficacy of" exact="ribavirin" post="against SFTSV replication was also observed in another study,"/>
   <result pre="1). Despite several differences in viral strains and treatment procedure," exact="ribavirin" post="suppressed SFTS replication, suggesting that it was effective against"/>
   <result pre="Shimojima et al. (2015) investigated the improvement in efficacy when" exact="ribavirin" post="was used in combination with IFNs. All IFNs showed"/>
   <result pre="U/ml, 24 U/ml, and 12 ng/ml, respectively, and that of" exact="ribavirin" post="was 43 μg/mL (Table 1). When IFNs were combined"/>
   <result pre="was 43 μg/mL (Table 1). When IFNs were combined with" exact="ribavirin" post="at IC90, significant inhibitory effects were observed, with reductions"/>
   <result pre="in viral titers. This study suggested that the combination of" exact="ribavirin" post="with IFNs or other agents that function via different"/>
   <result pre="The Chinese Ministry of Health initially approved the use of" exact="ribavirin" post="to treat SFTS based on the results of in"/>
   <result pre="the case fatality rate was similar between patients who received" exact="ribavirin" post="and those who did not (Liu et al., 2013)."/>
   <result pre="311 patients, of whom 54 died; in those who received" exact="ribavirin" post="therapy, the platelet counts did not increase and the"/>
   <result pre="significant, it was unexpectedly observed that the patients who received" exact="ribavirin" post="therapy had lower platelet counts than those who did"/>
   <result pre="study reported that two patients, in whom plasma exchange and" exact="ribavirin" post="treatment were initiated early, recovered from rapidly progressing SFTS"/>
   <result pre="patients, the platelet counts began to gradually recover after initiating" exact="ribavirin" post="treatment. Furthermore, according to a large-scale epidemiological study in"/>
   <result pre="including 2096 patients with laboratory-confirmed SFTS between 2011 and 2017," exact="ribavirin" post="therapy was effective in reducing the case fatality rate"/>
   <result pre="cells (Tani et al., 2016) was lower than that of" exact="ribavirin" post="(263 μM) (Shimojima et al., 2014). The efficacy of"/>
   <result pre="On the other hand, ~40% of the mice treated with" exact="ribavirin" post="(i.p.) at a dose of 25 or 100 mg/kg/day"/>
   <result pre="aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them," exact="hexachlorophene" post="was the most potent, with an IC50 of 1.3"/>
   <result pre="antiviral drugs identified (Table 1). Furthermore, the results indicated that" exact="hexachlorophene" post="treatment interfered with SFTSV entry without affecting virus-host cell"/>
   <result pre="virus infectivity (Yuan et al., 2019). It was predicted that" exact="hexachlorophene" post="would bind to the deep hydrophobic pocket between domains"/>
   <result pre="cholinesterase inhibitor (Hsu et al., 2004). It was reported that" exact="hexachlorophene" post="inhibited the viral replication of severe acute respiratory syndrome-related"/>
   <result pre="of 700 FDA-approved drugs identified the CCBs benidipine hydrochloride and" exact="nifedipine" post="as inhibitors of SFTSV replication in vitro by impairing"/>
   <result pre="in vitro study suggested that treatment with benidipine hydrochloride or" exact="nifedipine" post="inhibited SFTSV replication by reducing virus induced Ca2+ influx."/>
   <result pre="and decreased fatality rate in the humanized mouse model. Notably," exact="nifedipine" post="is one of the most widely used drugs for"/>
   <result pre="of 2087 patients with SFTS comprising 83 nifedipine-treated, who received" exact="nifedipine" post="before admission and during hospitalization, 48 non-nifedipine-treated ones who"/>
   <result pre="before admission and during hospitalization, 48 non-nifedipine-treated ones who received" exact="nifedipine" post="before admission but not during hospitalization, and 249 general"/>
   <result pre="hospitalization, and 249 general SFTS patients who did not receive" exact="nifedipine" post="at all. The case fatality rate was decreased by"/>
   <result pre="authors clearly showed the inhibitory effect of benidipine hydrochloride or" exact="nifedipine" post="in cultured cells and an animal model. Most importantly,"/>
   <result pre="an animal model. Most importantly, it was found that the" exact="nifedipine" post="administration enhanced virus clearance and improved clinical recovery. 2′-Fluoro-2′-deoxycytidine"/>
   <result pre="(Table 1). This value was much lower than that of" exact="ribavirin" post="(49.7 μM) in the same study and favipiravir (22"/>
   <result pre="(Balasubramanian et al., 2017). The mechanism of inhibitory activity of" exact="amodiaquine" post="against malaria and those viruses remains unclear. Baba et"/>
   <result pre="remains unclear. Baba et al. (2017) investigated the effect of" exact="amodiaquine" post="and other halogen molecules (fluorine, bromine, and iodine) against"/>
   <result pre="bromine, and iodine, respectively (Table 1). Among the compounds tested," exact="amodiaquine" post="was identified as a selective inhibitor against SFTSV replication."/>
   <result pre="inhibitor against SFTSV replication. The CC50 and the IC50 of" exact="amodiaquine" post="was &amp;gt;100 and 19.1 μM, respectively. The IC50 of"/>
   <result pre="amodiaquine was &amp;gt;100 and 19.1 μM, respectively. The IC50 of" exact="amodiaquine" post="was lower than those of ribavirin (40.1 μM) and"/>
   <result pre="respectively. The IC50 of amodiaquine was lower than those of" exact="ribavirin" post="(40.1 μM) and favipiravir (25.0 μM). IFN-γ IFN-γ is"/>
   <result pre="China, 2011). The in vitro and in vivo studies on" exact="ribavirin" post="(Shimojima et al., 2014, 2015; Tani et al., 2016;"/>
   <result pre="study conducted by Liu et al. (2013), which showed that" exact="ribavirin" post="did not reduce the fatality rate of patients with"/>
   <result pre="fatality rate of patients with SFTS, discouraged us from considering" exact="ribavirin" post="treatment for treating patients with SFTS. However, Li et"/>
   <result pre="patients with SFTS. However, Li et al. (2018) reported that" exact="ribavirin" post="is effective for early-stage patients with a low viral"/>
   <result pre="for the pretreatment of exposed individuals. Nevertheless, in cases of" exact="ribavirin" post="administration, patients should be intensely monitored because of the"/>
   <result pre="intensely monitored because of the possible adverse events induced by" exact="ribavirin" post="such as anemia and hyperamylasemia (Lu et al., 2015)."/>
   <result pre="hyperamylasemia (Lu et al., 2015). Favipiravir exhibited higher effectiveness than" exact="ribavirin" post="in in vitro and in vivo studies (Tani et"/>
   <result pre="using an FDA-approved drug library (Yuan et al., 2019). Because" exact="hexachlorophene" post="can cause acute and subacute neurotoxicity in laboratory animals"/>
   <result pre="et al., 2019). Notably, retrospectively conducted clinical study suggested that" exact="nifedipine" post="remarkably reduced the case fatality rate in SFTS patients"/>
   <result pre="fatality rate in SFTS patients (Li et al., 2019). Although" exact="nifedipine" post="is administrated consistently for patients with cardiac disease, these"/>
   <result pre="therapeutics for SFTS. It is considered that the efficacy of" exact="nifedipine" post="in treating patients with SFTS should be evaluated in"/>
   <result pre="further studies are needed. Baba et al. (2017) showed that" exact="amodiaquine" post="and other halogen molecules effectively inhibited the propagation of"/>
   <result pre="can be administered at a low cost. The efficacy of" exact="amodiaquine" post="in vivo should be evaluated. The anti-SFTSV efficacy of"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance. Curr. Opin. Virol.8, 10–15. 10.1016/j.coviro.2014.04.01124846716 BoonyasuppayakornS.ReichertE. D.ManzanoM.NagarajanK.PadmanabhanR. (2014)."/>
   <result pre="10.1093/jac/dku20924951535 DewaldL. E.DyallJ.SwordJ. M.TorzewskiL.ZhouH.PostnikovaE.et al. (2018). The calcium channel blocker" exact="bepridil" post="demonstrates efficacy in the murine model of marburg virus"/>
   <result pre="e01942–e01916. 10.1128/JVI.01942-1627881648 GraciJ. D.CameronC. E. (2006). Mechanisms of action of" exact="ribavirin" post="against distinct viruses. Rev. Med. Virol.16, 37–48. 10.1002/rmv.48316287208 HsuJ."/>
   <result pre="J.ChoeP. G.ParkW. B.et al.. (2017). In vitro antiviral activity of" exact="ribavirin" post="against severe fever with thrombocytopenia syndrome virus. Korean J."/>
   <result pre="LiuW.LuQ. B.CuiN.LiH.WangL. Y.LiuK.et al.. (2013). Case-fatality ratio and effectiveness of" exact="ribavirin" post="therapy among hospitalized patients in china who had severe"/>
   <result pre="G.FanY. D.GuoC. T.et al.. (2015). Common adverse events associated with" exact="ribavirin" post="therapy for Severe fever with thrombocytopenia syndrome. Antiviral Res.119,"/>
   <result pre="S.HeoS. T.KimS. H.ChoiW. J.HanM. G.KimJ. Y. (2014). Plasma exchange and" exact="ribavirin" post="for rapidly progressive severe fever with thrombocytopenia syndrome. Int."/>
   <result pre="(2016). Longitudinal diffusion tensor imaging of the rat brain after" exact="hexachlorophene" post="exposure. Neurotoxicology56, 225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe"/>
   <result pre="disease treatment. Science. 347, 995–998. 10.1126/science.125875825722412 SakuraiY.SakakibaraN.ToyamaM.BabaM.DaveyR. A. (2018). Novel" exact="amodiaquine" post="derivatives potently inhibit Ebola virus infection. Antiviral Res.160, 175–182."/>
   <result pre="virus infection. Virology482, 19–27. 10.1016/j.virol.2015.03.01025817401 ShimojimaM.FukushiS.TaniH.TaniguchiS.FukumaA.SaijoM. (2015). Combination effects of" exact="ribavirin" post="and interferons on severe fever with thrombocytopenia syndrome virus"/>
   <result pre="virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of" exact="ribavirin" post="on severe fever with thrombocytopenia syndrome virus in vitro."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7032198/results/search/drugs/results.xml">
   <result pre="required dose. In this work, two poorly soluble antiviral drugs," exact="ritonavir" post="(RTV) and efavirenz (EFV), with solubility of 1.2 µg/L and"/>
   <result pre="this work, two poorly soluble antiviral drugs, ritonavir (RTV) and" exact="efavirenz" post="(EFV), with solubility of 1.2 µg/L and 8.85 µg/L at pH"/>
   <result pre="was observed near the melting point of ritonavir, indicating that" exact="ritonavir" post="was present in an amorphous state. Similar results were"/>
   <result pre="acceptable physical stability [13], [37]. In the absence of polymer," exact="indomethacin" post="recrystallized in less than six weeks at storage temperatures"/>
   <result pre="in PVP solid dispersions, the difference between the Tg of" exact="indomethacin" post="in the formulations and the storage temperature increased to"/>
   <result pre="and the storage temperature increased to 40–50 °C, and recrystallization of" exact="indomethacin" post="was suppressed [38]. Such low glass transitions may not"/>
   <result pre="Am Chem Soc200627829116390158 27AnsellS.M.JohnstoneS.A.TardiP.G.Modulating the therapeutic activity of nanoparticle delivered" exact="paclitaxel" post="by manipulating the hydrophobicity of prodrug conjugatesJ Med Chem5120083288329618465845"/>
   <result pre="of carboxymethyl cellulose acetate butyrate containing acyclovirAppl Nanosci62016197208 35MarsacP.J.KonnoH.RumondorA.C.F.Recrystallization of" exact="nifedipine" post="and felodipine from amorphous molecular level solid dispersions containing"/>
   <result pre="cellulose acetate butyrate containing acyclovirAppl Nanosci62016197208 35MarsacP.J.KonnoH.RumondorA.C.F.Recrystallization of nifedipine and" exact="felodipine" post="from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and"/>
   <result pre="time constants for amorphous pharmaceutical systemsJ Pharm Sci89200041742710707021 38YoshiokaM.HancockB.C.ZografiG.Inhibition of" exact="indomethacin" post="crystallization in poly(vinylpyrrolidone) coprecipitatesJ Pharm Sci8419959839867500284 39FedorsR.F.A method for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7091927/results/search/drugs/results.xml">
   <result pre="from marine sponges and subsequently contributed to the synthesis of" exact="vidarabine" post="(arabinosyladenine), which is used for the treatment of herpes"/>
   <result pre="2 (M2) inhibitors (amantadine and rimantadine), NA inhibitors (zanamivir, oseltamivir," exact="peramivir" post="and laninamivir octanoate) and viral RNA-dependent RNA polymerase inhibitors"/>
   <result pre="1966 to treat influenza A virus infections. The target of" exact="amantadine" post="is M2 integral membrane protein, which exhibits H+ ion"/>
   <result pre="of the viral genome into the cytoplasm35 (Figure 1). However," exact="amantadine" post="and rimantadine, a derivative of amantadine, are not currently"/>
   <result pre="with viral membrane proteins (HA, NA and M2). Amantadine and" exact="rimantadine" post="inhibit M2 ion channel activity, and therefore, inhibit release"/>
   <result pre="viral mRNA by binding to viral polymerase complex. Favipiravir and" exact="ribavirin" post="inhibit viral RNA synthesis. Zanamivir, oseltamivir, peramivir and laninamivir"/>
   <result pre="complex. Favipiravir and ribavirin inhibit viral RNA synthesis. Zanamivir, oseltamivir," exact="peramivir" post="and laninamivir octanoate all inhibit neuraminidase activity of NA"/>
   <result pre="various influenza A and B viruses.40 The guanidine group in" exact="zanamivir" post="is suggested to form salt bridges with Glu119 in"/>
   <result pre="interactions with Glu227 of NA. Because of poor oral bioavailability," exact="zanamivir" post="is administered by inhalation. To improve oral bioavailability, novel"/>
   <result pre="is an ethylester prodrug of GS4071. The oral bioavailability of" exact="oseltamivir" post="was improved compared with that of GS4071.42 After zanamivir"/>
   <result pre="of oseltamivir was improved compared with that of GS4071.42 After" exact="zanamivir" post="and oseltamivir, two NA inhibitors, peramivir and laninamivir octanoate,"/>
   <result pre="that of GS4071.42 After zanamivir and oseltamivir, two NA inhibitors," exact="peramivir" post="and laninamivir octanoate, were launched.43, 44 Peramivir is administered"/>
   <result pre="influenza A and influenza B virus infections. Two approved drugs," exact="ribavirin" post="and T-705 (favipiravir), inhibit influenza viral RNA synthesis (Figure"/>
   <result pre="(interferon-α and pegylated interferon-α) and nucleos(t)ide analogs (lamivudine, adefovir, telbivudine," exact="entecavir" post="and tenofovir), which are useful for therapeutic treatment to"/>
   <result pre="an indispensable drug target for HBV treatment. Indeed, a new" exact="tenofovir" post="derivative, tenofovir alafenamide (Vemlidy), was recently approved and its"/>
   <result pre="drug target for HBV treatment. Indeed, a new tenofovir derivative," exact="tenofovir" post="alafenamide (Vemlidy), was recently approved and its improved pharmacological"/>
   <result pre="and is currently in phase II clinical trials.79, 80 Recently," exact="cyclosporine" post="A, a fungal cyclic polypeptide, and its analogs have"/>
   <result pre="Hendra and Nipah viruses.88, 89, 90 The potential activity of" exact="ribavirin" post="against broad-spectrum RNA viruses can be exerted by both"/>
   <result pre="decreasing intracellular GTP levels.91 Nucleotide pool imbalances that result from" exact="ribavirin" post="treatment could cause a reduction of viral polymerase activity"/>
   <result pre="cyclophilins have been semi-synthesized.118 A CsA derivative, alisporivir (DEB025), with" exact="ribavirin" post="has been studied as an anti-HCV drug and is"/>
   <result pre="formycin BJ. Antibiot. (Tokyo)1966192862876013241 5SawaTFukagawaYHommaITakeuchiTUmezawaHMode of inhibition of coformycin on" exact="adenosine" post="deaminaseJ. Antibiot. (Tokyo)1967202272316072897 6ShimadaNOxanosine, a novel nucleoside from actinomycetesJ."/>
   <result pre="and its relativesJ. Antibiot. (Tokyo)1974278018044457528 19KunimotoTHoriMUmezawaHModes of action of phleomycin," exact="bleomycin" post="and formycin on HeLa S3 cells in synchronized cultureJ."/>
   <result pre="1,2,4-triazole- 3-carboxamideScience19721777057064340949 49ErikssonBInhibition of influenza virus ribonucleic acid polymerase by" exact="ribavirin" post="triphosphate inhibition of influenza virus ribonucleic acid polymerase by"/>
   <result pre="ribavirin triphosphate inhibition of influenza virus ribonucleic acid polymerase by" exact="ribavirin" post="triphosphateAntimicrob. Agents Chemother.197711946951879760 50FurutaYIn vitro and in vivo activities"/>
   <result pre="by quantitative real-time PCR of RNA accumulation, the effect of" exact="ribavirin" post="and the attenuation of transcriptionArch. Virol.200515052153215526144 89ChangK-OGeorgeDWInterferons and Ribavirin"/>
   <result pre="norwalk virus replication in replicon-bearing cellsJ. Virol.200781121111211817855555 90KoffWCElmJLHalsteadSBAntiviral effects if" exact="ribavirin" post="and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitroAntiviral Res.1982269797201778 91StreeterDGMechanism"/>
   <result pre="against Ebola virus in rhesus monkeysNature201653138138526934220 96EyerLAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntiviral"/>
   <result pre="their potential for combination therapy with interferonHepatology20064411712516799963 103PengJProtective effect of" exact="fluvastatin" post="on influenza virus infectionMol. Med. Rep.201492221222624676773 104GiguèreJTremblayMJStatin compounds reduce"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7104000/results/search/drugs/results.xml">
   <result pre="a recent possible exposure to SARS-CoV-2. For example, PEP with" exact="rifampicin" post="is given to people exposed to index cases of"/>
   <result pre="people exposed to index cases of invasive meningococcal infection, and" exact="oseltamivir" post="has been recommended by WHO for people at high"/>
   <result pre="concentrations and in vitro drug testing suggest that prophylaxis with" exact="hydroxychloroquine" post="at approved doses could prevent SARS-CoV-2 infection and ameliorate"/>
   <result pre="prevent SARS-CoV-2 infection and ameliorate viral shedding.5 Clinical trials of" exact="hydroxychloroquine" post="treatment for COVID-19 pneumonia are underway in China (NCT04261517"/>
   <result pre="anyone found to be infected, and the efficacy of prophylactic" exact="hydroxychloroquine" post="in preventing secondary SARS-CoV-2 infections and disease symptoms among"/>
   <result pre="1286 of their close contactsmedRxiv2020published online March 4.10.1101/2020.03.03.20028423(preprint). 3WelliverRMontoASCarewiczOEffectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March 9.10.1093/cid/ciaa237 5TettSECutlerDJDayROBrownKFBioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol2719897717792757893 6Henao-RestrepoAMCamachoALonginiIMEfficacy and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7114304/results/search/drugs/results.xml">
   <result pre="recruited by the GTase, transfers the methyl group from S-adenosyl-" exact="l-methionine" post="(AdoMet) to the cap guanine to form the cap-0"/>
   <result pre="PPi (II) PPPi (III) 6-chloropurine-ribose-5′-triphosphate. GTase inhibitors: (I) foscarnet (II)" exact="ribavirin" post="triphosphate. MTase inhibitors: (I) sinefungin (II) dAPPMA 2′-O MTase"/>
   <result pre="GTase inhibitors: (I) foscarnet (II) ribavirin triphosphate. MTase inhibitors: (I)" exact="sinefungin" post="(II) dAPPMA 2′-O MTase inhibitors: (III) aurintricaboxylic acid (IV)"/>
   <result pre="ribose 2′-OH position by 2′-O MTase (see Fig. 1). S-adenosyl-" exact="l-methionine" post="(SAM) is the methyl donor for both the N-7"/>
   <result pre="capping started in the dsDNA Poxviridae field. A SAM analogue," exact="sinefungin" post="(Fig. 6, MTase inhibitor I), was reported as the"/>
   <result pre="MTase activity was shown to be inhibited by the GTP-analogue" exact="ribavirin" post="triphosphate (Benarroch et al., 2004a), sinefungin, and SAH (Selisko"/>
   <result pre="antiviral therapy or prevention: a monoclonal antibody (Palivizumab, Synagis) and" exact="ribavirin" post="(Empey et al., 2010, Vigant and Lee, 2011). The"/>
   <result pre="of PRNTase inhibitors, but the precise mechanism of action of" exact="ribavirin" post="(i.e., capping, error catastrophe, IMP dehydrogenase, or else (Leyssen"/>
   <result pre="al., 2003). In the case of alphaviruses, resistance mutants to" exact="ribavirin" post="were mapped into the GTase domain of the nsP1"/>
   <result pre="protein (Scheidel et al., 1987, Scheidel and Stollar, 1991) suggesting" exact="ribavirin" post="interferes with the GTase activity. Nevertheless, the ribavirin action"/>
   <result pre="1991) suggesting ribavirin interferes with the GTase activity. Nevertheless, the" exact="ribavirin" post="action mode remains controversial. Ribavirin also reduces the intracellular"/>
   <result pre="The same group extended the family of interesting compounds with" exact="thalidomide" post="derivatives, active through their 3,4-dihydroxyphenethyl moieties, and later with"/>
   <result pre="inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by" exact="ribavirin" post="5′-triphosphateJ. Biol. Chem.2792004356383564315152003 BenarrochD.SeliskoB.LocatelliG.A.MagaG.RometteJ.-L.CanardB.The RNA helicase, nucleotide 5′-triphosphatase, and"/>
   <result pre="as multisubstrate adductsJ. Pharm. Sci.7519861421453958922 BougieI.BisaillonM.The broad spectrum antiviral nucleoside" exact="ribavirin" post="as a substrate for a viral RNA capping enzymeJ."/>
   <result pre="as a targetAntiviral Res.8020089410118674567 LeyssenP.BalzariniJ.De ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
   <result pre="IMP dehydrogenaseJ. Virol.7920051943194715650220 LeyssenP.De ClercqE.NeytsJ.The anti-yellow fever virus activity of" exact="ribavirin" post="is independent of error-prone replicationMol Pharmacol6920061461146716421290 LiY.I.ChenY.J.HsuY.H.MengM.Characterization of the"/>
   <result pre="polymeraseJ. Virol.792005131051311516189012 LivonesiM.C.De SousaR.L.BadraS.J.FigueiredoL.T.In vitro and in vivo studies of" exact="ribavirin" post="action on Brazilian OrthobunyavirusAm. J. Trop. Med. Hyg.7520061011101617124004 LugariA.BetziS.DecrolyE.BonnaudE.HermantA.GuillemotJ.-C.DebarnotC.BorgJ.-P.BouvetM.CanardB.MorelliX.LecineP.Molecular"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntiviral Res.912011899321616094 PlotchS.J.BouloyM.KrugR.M.Transfer"/>
   <result pre="for viral cap-dependent transcriptionPLoS Pathog.692010e100110120862319 ScheidelL.M.DurbinR.K.StollarV.Sindbis virus mutants resistant to" exact="mycophenolic acid" post="and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to mycophenolic acid"/>
   <result pre="to mycophenolic acid and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to" exact="mycophenolic acid" post="and ribavirin on Sindbis virus map to the nonstructural"/>
   <result pre="and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to mycophenolic acid and" exact="ribavirin" post="on Sindbis virus map to the nonstructural protein nsP1Virology18119914904991826574"/>
   <result pre="of viruses by cytoplasmic sensorsCurr. Opin. Immunol.222010414720061127 ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of" exact="ribavirin" post="and IMPDH inhibitors on hepatitis C virus subgenomic replicon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7118541/results/search/drugs/results.xml">
   <result pre="remdesivir, and Kaletra were predicted to inhibit SARS-CoV-2. •Rapamycin and" exact="tiotropium bromide" post="may also be effective for SARS-CoV-2. Abstract The infection"/>
   <result pre="against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM)," exact="efavirenz" post="(199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM)."/>
   <result pre="3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM)," exact="ritonavir" post="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir,"/>
   <result pre="remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and" exact="dolutegravir" post="(336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all"/>
   <result pre="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and" exact="darunavir" post="are all designed to target viral proteinases. However, in"/>
   <result pre="analysis. The SARS-CoV-2 3C-like proteinase was predicted to bind with" exact="atazanavir" post="(Kd 94.94 nM), followed by remdesivir, efavirenz, ritonavir, and"/>
   <result pre="studies have been identified. For example, a docking study of" exact="lopinavir" post="along with other HIV proteinase inhibitors of the CoV"/>
   <result pre="HIV proteinase inhibitors of the CoV proteinase (PDBID 1UK3) suggests" exact="atazanavir" post="and ritonavir, which are listed in the present prediction"/>
   <result pre="the CoV proteinase in line with the inhibitory potency of" exact="lopinavir" post="[27]. According to the prediction, viral proteinase-targeting drugs were"/>
   <result pre="O)N1CC2C(C1C( O)NC(CC1CCC1)C( O)C(N) O)C2(C)C)C(C)(C)C 433.93 101 Among the prediction results," exact="atazanavir" post="was predicted to have a potential binding affinity to"/>
   <result pre="of the COVID-19 replication complex may be inhibited simultaneously by" exact="atazanavir" post="(Table 2, Table 3, Table 4, Table 5, Table"/>
   <result pre="2, Table 3, Table 4, Table 5, Table 6). Also," exact="ganciclovir" post="was predicted to bind to three subunits of the"/>
   <result pre="anti-HIV drug, Prezcobix of Johnson &amp;amp; Johnson, which consists of" exact="darunavir" post="and cobicistat, was to be sent to China [29],"/>
   <result pre="and cobicistat, was to be sent to China [29], and" exact="darunavir" post="is also predicted to have a Kd of 90.38"/>
   <result pre="3). However, there was no current supporting literature found for" exact="darunavir" post="to be used as a CoV therapeutic. Although remdesivir"/>
   <result pre="by inhibiting some aspects of SARS-CoV-2. For example, remdesivir and" exact="chloroquine" post="showed inhibitory effects against SARS-CoV-2 in vitro[31]. Another in-vitro"/>
   <result pre="effects against SARS-CoV-2 in vitro[31]. Another in-vitro study showed that" exact="hydroxychloroquine" post="was found to be more potent than chloroquine for"/>
   <result pre="showed that hydroxychloroquine was found to be more potent than" exact="chloroquine" post="for inhibiting SARS-CoV-2 [32]. Remdesivir and lopinavir/ritonavir (Kaletra) also"/>
   <result pre="but some differences were observed. For example, atazanavir, remdesivir, and" exact="efavirenz" post="were the top three predicted drugs that may bind"/>
   <result pre="that these drugs may be effective in inhibiting SARS-CoV-2. Lastly," exact="atazanavir" post="appears to be effective in the treatment of COVID-19"/>
   <result pre="issue)17145705 15PaoliniG.V.ShaplandR.H.van HoornW.P.MasonJ.S.HopkinsA.L.Global mapping of pharmacological spaceNat Biotechnol247200680581516841068 16WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="treatment of SARS: initial virological and clinical findingsThorax593200425225614985565 31WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7127693/results/search/drugs/results.xml">
   <result pre="restrict HIV-1 infection by binding to the capsid core and" exact="cyclosporine" post="A (CsA), which can effectively turn off restriction (Hulme"/>
   <result pre="ganciclovir, penciclovir) (De Clercq and Li, 2016). In the body," exact="ganciclovir" post="is phosphorylated by cellular kinases and penciclovir and acyclovir"/>
   <result pre="In the body, ganciclovir is phosphorylated by cellular kinases and" exact="penciclovir" post="and acyclovir by virus-encoded thymidine kinases to the active"/>
   <result pre="in murine leukemia virusJ. Biol. Chem.291392016206302064227514744 DongH.ChangD.C.HuaM.H.C.LimS.P.ChionhY.H.HiaF.LeeY.H.KukkaroP.LokS.-M.DedonP.C.ShiP.-Y.2′-O methylation of internal" exact="adenosine" post="by flavivirus NS5 methyltransferasePLoS Pathog.842012e100264222496660 DriscollM.D.RentergentJ.HayS.A quantitative fluorescence-based steady-state"/>
   <result pre="simplex virus type 1 thymidine kinase mutants engineered for improved" exact="ganciclovir" post="or acyclovir activityProtein Sci.11920022267227212192082 KonvalinkaJ.KräusslichH.-G.MüllerB.Retroviral proteases and their roles"/>
   <result pre="activityJ. Virol.79212005133731338416227259 LiJ.ChorbaJ.S.WhelanS.P.Vesicular stomatitis viruses resistant to the methylase inhibitor" exact="sinefungin" post="upregulate RNA synthesis and reveal mutations that affect mRNA"/>
   <result pre="SOCS genes, the negative regulators of cytokine signalingMicrobiol. Immunol.615201715916728419615 SchäferlingM.WolfbeisO.S.Europium" exact="tetracycline" post="as a luminescent probe for nucleoside phosphates and its"/>
   <result pre="phosphorylated motifsJ. Biol. Chem.277422002393793938712151408 ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.ShenH.ShenL.ChenZ.W.Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.312017455327733043 ZhaoQ.LiS.XueF.ZouY.ChenC.BartlamM.RaoZ.Structure of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7171712/results/search/drugs/results.xml">
   <result pre="KYangJ JViral calciomics: Interplays between Ca2+ and virusCell Calcium20094611719535138 31WilsonLGagePEwartGHexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replicationVirology200635329430616815524"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7190394/results/search/drugs/results.xml">
   <result pre="Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram," exact="escitalopram" post="etc.), antipsychotics (i.e., olanzapine) and valproate can be considered"/>
   <result pre="interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and" exact="valproate" post="can be considered to be safe in combination with"/>
   <result pre="of stressor events. Because sedative and hypnotic drugs such as" exact="oxazepam" post="and lorazepam are not metabolised by the CYP system,"/>
   <result pre="events. Because sedative and hypnotic drugs such as oxazepam and" exact="lorazepam" post="are not metabolised by the CYP system, these are"/>
   <result pre="minimal P450 interactions, antidepressants (citalopram, escitalopram, etc.), antipsychotics (olanzapine) and" exact="valproate" post="can be considered to be safe in combination with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7201615/results/search/drugs/results.xml">
   <result pre="and were followed in the clinic. Clinic patients treated with" exact="ribavirin" post="or PEGylated interferon-based regimens were excluded from the study."/>
   <result pre="ago demonstrated that a SVR achieved with interferon alpha plus" exact="ribavirin" post="in patients with chronic hepatitis C could improve glycemic"/>
   <result pre="medications used to achieve a SVR, including hemolytic anemia from" exact="ribavirin" post="which can falsely lower HbA1C levels and interferon-mediated nausea,"/>
   <result pre="Gastrointestinal and Liver Diseases201827328128910.15403/jgld.2014.1121.273.daa30240472 10MoralesA. L.JungaZ.SinglaM. B.SjogrenM.TorresD.Hepatitis C eradication with" exact="sofosbuvir" post="leads to significant metabolic changesWorld Journal of Hepatology20168351557156310.4254/wjh.v8.i35.155728050236 11IkedaA.IkedaK.TakaiA.et"/>
   <result pre="metabolic changesWorld Journal of Hepatology20168351557156310.4254/wjh.v8.i35.155728050236 11IkedaA.IkedaK.TakaiA.et al.Hepatitis c treatment with" exact="sofosbuvir" post="and ledipasvir accompanied by immediate improvement in hemoglobin a1cDigestion201796422823010.1159/00048423729084399"/>
   <result pre="diabetes in type 2 diabetic patient treated with IFN-?? and" exact="ribavirin" post="for hepatitis CEuropean journal of gastroenterology &amp;amp; hepatology200618329129310.1097/00042737-200603000-0001116462544 20AraseY.SuzukiF.SuzukiY.et"/>
   <result pre="C.WoodY. A.Falsely low hemoglobin A1c levels in a patient receiving" exact="ribavirin" post="and peginterferon alfa-2b for hepatitis CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL."/>
   <result pre="low hemoglobin A1c levels in a patient receiving ribavirin and" exact="peginterferon alfa-2b" post="for hepatitis CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL. S.NaqviZ.BräuN.Decline in haemoglobin"/>
   <result pre="in haemoglobin A1c values in diabetic patients receiving interferon-alpha and" exact="ribavirin" post="for chronic hepatitis CJournal of Viral Hepatitis200613961361710.1111/j.1365-2893.2006.00729.x16907848 23StineJ. G.WynterJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7219522/results/search/drugs/results.xml">
   <result pre="pathogens via phagocytosis, the production of reactive oxygen species (ROS)," exact="nitric oxide" post="(NO), myeloperoxidase, and inflammatory cytokines [13]. Under specific conditions,"/>
   <result pre="and virologic relapse soon develop [35]. With the exception of" exact="etravirine" post="and rilpivirine, resistance develops with the substitution of a"/>
   <result pre="studies have shown doravirine does not affect the pharmacokinetics of" exact="dolutegravir" post="but may have its pharmacokinetics altered by rifampicin (rifampin)"/>
   <result pre="pharmacokinetics of dolutegravir but may have its pharmacokinetics altered by" exact="rifampicin" post="(rifampin) and other rifamycins (CYP3A inducers). No clinically significant"/>
   <result pre="study in treatment-naive adults, DOR at 100 mg QD with" exact="emtricitabine" post="(FTC) and tenofovir disoproxil fumarate (TDF) demonstrated comparable efficacy"/>
   <result pre="adults, DOR at 100 mg QD with emtricitabine (FTC) and" exact="tenofovir" post="disoproxil fumarate (TDF) demonstrated comparable efficacy to efavirenz with"/>
   <result pre="(FTC) and tenofovir disoproxil fumarate (TDF) demonstrated comparable efficacy to" exact="efavirenz" post="with FTC/TDF and had a favorable safety profile, with"/>
   <result pre="lower rates of drug-related adverse events and CNS events than" exact="efavirenz" post="[36]. In the phase 3 DRIVE-FORWARD trial, DOR at"/>
   <result pre="3′-processing [52]. There are totally three integrase inhibitors [raltegravir (RAL);" exact="elvitegravir" post="(EVG); dolutegravir (DTG)], which have been approved by FDA."/>
   <result pre="There are totally three integrase inhibitors [raltegravir (RAL); elvitegravir (EVG);" exact="dolutegravir" post="(DTG)], which have been approved by FDA. Scopelliti and"/>
   <result pre="cART including fostemsavir in comparison with a cART including ritonavir-boosted" exact="atazanavir" post="in a randomized active-controlled trial [71,73,74]. The chemokine receptor"/>
   <result pre="absence of preexisting X4 strains [79]. Rather, some cases of" exact="maraviroc" post="resistance in R5 HIV strains were reported in vitro"/>
   <result pre="of CCR5 as a coreceptor [80–82]. Recent clinical trials included" exact="maraviroc" post="in an intensified regimen consisting of four or five"/>
   <result pre="the concentration of circulating chemokines [84]. However, in another trial," exact="maraviroc" post="intensification was associated with an improvement of the CD4"/>
   <result pre="likely to respond to the drug. Later, BEV was renamed" exact="bevirimat" post="MPC-4326 and also is developing HIV maturation inhibitors of"/>
   <result pre="and a greatly improved preclinical profile compared to that of" exact="bevirimat" post="[108]. In our laboratory, projects related to the test"/>
   <result pre="group has developed long-acting/extended release nanoformulations of ritonavir, indinavir, and" exact="efavirenz" post="(nanoART) [114]. They reasoned that circulating macrophages traveling across"/>
   <result pre="II compartments. Traffic. 200210;3(10):718–729.12230470 [24]BorrajoA, RanazziA, PollicitaM, et alEffects of" exact="amprenavir" post="on HIV-1 maturation, production and infectivity following drug withdrawal"/>
   <result pre="et alEvaluation of the potential for pharmacokinetic drug-drug interaction between" exact="armodafinil" post="and carbamazepine in healthy adults. Clin Ther. 201521;37(2):325–337. Epub"/>
   <result pre="of the potential for pharmacokinetic drug-drug interaction between armodafinil and" exact="carbamazepine" post="in healthy adults. Clin Ther. 201521;37(2):325–337. Epub 2014 Oct"/>
   <result pre="of print DOI:10.1007/s13318-018-0497-3 [40]KhaliliehSG, YeeKL, SanchezRI, et alMultiple doses of" exact="rifabutin" post="reduce exposure of doravirine in healthy subjects. J Clin"/>
   <result pre="Ther. 2017;224:337–344.28206979 [44]MolinaJM, SquiresK, SaxPE, et al. Doravirine versus ritonavir-boosted" exact="darunavir" post="in antiretroviral-naive adults with hiv-1 (drive-forward): 96-week results of"/>
   <result pre="raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor" exact="dolutegravir" post="in human primary macrophages and lymphocytes. J Antimicrob Chemother."/>
   <result pre="et alA controlled Phase II trial assessing three doses of" exact="enfuvirtide" post="(T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz"/>
   <result pre="three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir," exact="ritonavir" post="and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults."/>
   <result pre="of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and" exact="efavirenz" post="in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther."/>
   <result pre="immunodeficiency virus type 1 gp41 amino acid substitutions selected during" exact="enfuvirtide" post="treatment on gp41 binding and antiviral potency of enfuvirtide"/>
   <result pre="during enfuvirtide treatment on gp41 binding and antiviral potency of" exact="enfuvirtide" post="in vitro. J Virol. 200510;79(19):12447–12454.16160172 [66]WeiX, DeckerJM, LiuH, et"/>
   <result pre="gp41 are associated with immunological success in HIV-1-infected patients receiving" exact="enfuvirtide" post="treatment. J Antimicrob Chemother. 200610;58(4):714–722. Epub 2006 Aug 5.16891628"/>
   <result pre="Signal. 201858;11(529):pii: eaal2869. [77]Garcia-PerezJ, RuedaP, AlcamiJ, et alAllosteric model of" exact="maraviroc" post="binding to CC chemokine receptor 5 (CCR5). J Biol"/>
   <result pre="assays indicates that viral strains resistant to the CCR5 antagonist" exact="maraviroc" post="utilize inhibitor-bound receptor for entry. J Virol. 20073;81(5):2359–2371. Epub"/>
   <result pre="[81]RocheM, JakobsenMR, EllettA, et alHIV-1 predisposed to acquiring resistance to" exact="maraviroc" post="(MVC) and other CCR5 antagonists in vitro has an"/>
   <result pre="61: 5557–564.22986949 [84]HuntPW, ShulmanNS, HayesTL, et alThe immunologic effects of" exact="maraviroc" post="intensification in treated HIV-infected individuals with incomplete CD4+ T-cell"/>
   <result pre="activation after treatment in acute HIV infection with and without" exact="raltegravir" post="and maraviroc intensification. J Virus Erad. 2015;1(2):116–122. Epub 2015"/>
   <result pre="treatment in acute HIV infection with and without raltegravir and" exact="maraviroc" post="intensification. J Virus Erad. 2015;1(2):116–122. Epub 2015 Apr 1.26835516"/>
   <result pre="[86]CilloAR, HilldorferBB, LalamaCM, et alVirologic and immunologic effects of adding" exact="maraviroc" post="to suppressive antiretroviral therapy in individuals with suboptimal CD4+"/>
   <result pre="2012 Oct 5. Review.23043111 [96]UranoE, AblanSD, MandtR, et alAlkyl amine" exact="bevirimat" post="derivatives are potent and broadly active HIV-1 maturation inhibitors."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7232887/results/search/drugs/results.xml">
   <result pre="Francis pmcid: 7232887 doi: 10.1080/07391102.2020.17658761765876 : Research Article Repurposing of" exact="chloroquine" post="and some clinically approved antiviral drugs as effective therapeutics"/>
   <result pre="putative inhibitory potential of lopinavir, remdesivir, oseltamir, azithromycin, ribavirin, and" exact="chloroquine" post="towards V-ATPase, protein kinase A, SARS-CoV spike glycoprotein/ACE-2 complex"/>
   <result pre="His374, and His345 were predicted as the key residues for" exact="lopinavir" post="binding to human SARS-CoV spike glycoprotein/ACE-2 complex while His378,"/>
   <result pre="and Tyr510, Phe504, Met62, Tyr50, and His378 were predicted for" exact="azithromycin" post="as the key residues for binding to SARS-CoV spike"/>
   <result pre="SARS-CoV spike glycoprotein/ACE-2 complex. Moreover, it was also observed that" exact="chloroquine" post="has appreciable binding affinities for 3-Chymotrpsin- like protease and"/>
   <result pre="coronavirus. Communicated by Ramaswamy H. Sarma Keywords Coronavirus antiviral drugs" exact="chloroquine" post="Autodock tool pkCSM tool fig-count: table-count: page-count: word-count: 1."/>
   <result pre="selected clinically approved drugs (lopinavir, remdesivir, oseltamir, azithromycin, ribavirin, and" exact="chloroquine" post="recently discovered) as inhibitors of V-ATPase, protein kinase A,"/>
   <result pre="The toxicity risks of azithromycin, chloroquine, lopinavir, oseltamivir, remdesivir, and" exact="ribavirin" post="were predicted based on their ADMET profile. The ADMET"/>
   <result pre="The SDF structures of azithromycin, chloroquine, lopinavir, oseltamivir, remdesivir, and" exact="ribavirin" post="were retrieved from the PubChem database (www.pubchem.ncbi.nlm.nih.gov) (Kim et"/>
   <result pre="pharmacodynamics properties of the azithromycin, chloroquine, lopinavir, oseltamivir, remdesivir, and" exact="ribavirin" post="are presented in Tables 1–5. The prediction was carried"/>
   <result pre="1997; Hughes et al., 2008) (Table 1). However, a negative" exact="ribavirin" post="logP value means the ribavirinis a hydrophilic drug that"/>
   <result pre="also contribute to poor permeability, all the screened drugs except" exact="ribavirin" post="could be maintained in the system at appropriate concentrations."/>
   <result pre="their subcellular localization in the lysosome are remdesivir, azithromycin, and" exact="chloroquine" post="as predicted by ADMETSAR1 (Cheng et al., 2012). Lopinavir,"/>
   <result pre="by ADMETSAR1 (Cheng et al., 2012). Lopinavir, remdesivir, azithromycin, and" exact="chloroquine" post="were predicted to be substrates of P-glycoprotein, an efflux"/>
   <result pre="transporter found primarily in epithelial cells. However, lopinavir, remdesivir, and" exact="azithromycin" post="were also predicted as P-glycoprotein inhibitors. Thus, lopinavir, remdesivir,"/>
   <result pre="were also predicted as P-glycoprotein inhibitors. Thus, lopinavir, remdesivir, and" exact="azithromycin" post="could modulate the physiological functions of P-glycoprotein in limiting"/>
   <result pre="steady-state volume of distribution (VDss) showed that lopinavir, azithromycin, and" exact="ribavirin" post="had lower theoretical dose required for uniform distribution in"/>
   <result pre="for uniform distribution in the plasma than remdesivir, oseltamivir, and" exact="chloroquine" post="while the degree of diffusing across plasma membrane increases"/>
   <result pre="roles in drug metabolism is the CYP isozymes. Oseltamivir and" exact="ribavirin" post="showed low CYP promiscuity while lopinavir, remdesivir, azithromycin, and"/>
   <result pre="ribavirin showed low CYP promiscuity while lopinavir, remdesivir, azithromycin, and" exact="chloroquine" post="are substrates of CYP3A4 (Table 3). The lipophilicity of"/>
   <result pre="it inhibits CYP2C19, CYP2C9, CYP2D6, and CYP3A4. This shows that" exact="lopinavir" post="could be involved in drug-drug interaction (Cheng et al.,"/>
   <result pre="could initiate oxidative stress (Williams et al., 2004). Also, only" exact="chloroquine" post="was a substrate of renal organic cation transporter while"/>
   <result pre="through AMES toxicity testing showed that all the drugs except" exact="chloroquine" post="could be considered as non-mutagenic agents. However, the toxicities"/>
   <result pre="occur within a short period after administration. Lopinavir, remdesivir, and" exact="chloroquine" post="were also shown to have low toxic dose threshold"/>
   <result pre="induce hepatotoxicity (Table 5). Thus, administration of lopinavir, remdesivir, and" exact="chloroquine" post="could result in delayed ventricular repolarisation through inhibition of"/>
   <result pre="the work of Nukoolkarn et al. (2008), who reported that" exact="lopinavir" post="showed a high binding ability to the pocket site"/>
   <result pre="site of SAR-CoV. It was observed that lopinavir, remdesivir, and" exact="azithromycin" post="have the highest docking scores with the highest number"/>
   <result pre="with the highest number of hydrogen bonds formed respectively while" exact="ribavirin" post="has the least docking score with the least hydrogen"/>
   <result pre="and His345 were predicted to be the key residues for" exact="lopinavir" post="binding to human SARS-CoV spike glycoprotein/ACE-2 complex while His378,"/>
   <result pre="and Tyr510, Phe504, Met62, Tyr50, and His378 were predicted for" exact="azithromycin" post="as the key residues for binding to SARS-CoV spike"/>
   <result pre="responsible for the high binding score in lopinavir, remdesivir, and" exact="azithromycin" post="(Elokely &amp;amp; Doerksen, 2013). Moreover, it was also observed"/>
   <result pre="(Elokely &amp;amp; Doerksen, 2013). Moreover, it was also observed that" exact="chloroquine" post="which was recently found to be effective in the"/>
   <result pre="A when compared to Oseltamivir and ribavirin. This implies that" exact="chloroquine" post="could limit the proliferation of coronavirus by enhancing the"/>
   <result pre="and His378 were predicted to be the key residues for" exact="chloroquine" post="binding to human SARS-CoV spike glycoprotein/ACE-2 complex. Analysis of"/>
   <result pre="Analysis of the results of the autodock software revealed that" exact="chloroquine" post="has a considerable binding affinity with coronavirus target protease."/>
   <result pre="main protease. Out of the five already established antiviral drugs," exact="lopinavir" post="had the highest binding affinity towards SARS-CoV protease while"/>
   <result pre="lopinavir had the highest binding affinity towards SARS-CoV protease while" exact="ribavirin" post="had the lowest binding affinity. Chloroquine recently discovered for"/>
   <result pre="of coronavirus thereby preventing its cellular entry and proliferation. Although" exact="chloroquine" post="could bind to the selected target proteins/enzymes, the result"/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular"/>
   <result pre="MalaisreeM., AruksakulwongO., &amp;amp; HannongbuaS. (2008). Molecular dynamic simulations analysis of" exact="ritonavir" post="and lopinavir as SARS-CoV 3CL(pro) inhibitors. Journal of Theoretical"/>
   <result pre="&amp;amp; HannongbuaS. (2008). Molecular dynamic simulations analysis of ritonavir and" exact="lopinavir" post="as SARS-CoV 3CL(pro) inhibitors. Journal of Theoretical Biology, 254(4),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7241459/results/search/drugs/results.xml">
   <result pre="doi: 10.1080/22221751.2020.1760145 : Letter Rheumotologitsts’ view on the use of" exact="hydroxychloroquine" post="to treat COVID-19 Emerging Microbes &amp;amp; Infections X. Sun"/>
   <result pre="coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine" exact="chloroquine" post="(CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have"/>
   <result pre="therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue" exact="hydroxychloroquine" post="(HCQ) have been recommended as promising candidate therapeutics that"/>
   <result pre="diverse opinions on this urgent topic. KEYWORDS COVID-19 SARS-CoV-2 therapy" exact="hydroxychloroquine" post="(HCQ) Chloroquine (CQ) Funding National Natural Science Foundation of"/>
   <result pre="the community. As originally an anti-malarial medicine applied for decades," exact="hydroxychloroquine" post="(HCQ) is one of the disease-modifying antirheumatic drugs (DMARDs),"/>
   <result pre="dynamic results of clinical trials. Gautret et al. reported that" exact="azithromycin" post="(AZM) added to HCQ was significantly more effective for"/>
   <result pre="Discov. 2020;6:10.1038/s41421-020-0156-0. eCollection 202. 2GautretP, LagierJC, ParolaP, et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="chloroquine. Lancet Infect Dis. 2006;10.1016/S1473-3099(06)70361-9. 5McChesneyEW.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfate. Am. J. Med. 1983;10.1016/0002-9343(83)91265-2. 6ZhouD, DaiSM, TongQ, et"/>
   <result pre="TongQ, et al.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression. J. Antimicrob. Chemother. 2020:10.1093/jac/dkaa114."/>
   <result pre="J. Antimicrob. Chemother. 2020:10.1093/jac/dkaa114. 7WangM, CaoR, ZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="erythematosus. A clinical study with determination of serum concentrations of" exact="chloroquine" post="and hydroxychloroquine. Scand. J. Rheumatol. 1974;3(2):103–108. 12FurstDE, LindsleyH, BaethgeB,"/>
   <result pre="Scand. J. Rheumatol. 1974;3(2):103–108. 12FurstDE, LindsleyH, BaethgeB, et al.Dose-loading with" exact="hydroxychloroquine" post="improves the rate of response in early, active rheumatoid"/>
   <result pre="Arthritis Rheum. 1999;42(2):357–365. 13IzmirlyPM, Costedoat-ChalumeauN, PisoniCN, et al.Maternal use of" exact="hydroxychloroquine" post="is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7292951/results/search/drugs/results.xml">
   <result pre="The most common treatment of influenza is the use of" exact="acetaminophen" post="to relieve fever and muscle pain associated with the"/>
   <result pre="reported [6]. The analytes included anti-influenza drugs (amantadine, rimantadine, oseltamivir," exact="oseltamivir" post="carboxylate, memantine, arbidol, and moroxydine), anti-herpes drugs (acyclovir, ganciclovir,"/>
   <result pre="memantine, arbidol, and moroxydine), anti-herpes drugs (acyclovir, ganciclovir, famciclovir, penciclovir," exact="ribavirin" post="and its main metabolite TCONH2), and an immunomodulator (imiquimod)."/>
   <result pre="of the antiviral agents against Herpes viruses is reviewed. As" exact="ribavirin" post="is also used in HCV treatment, it was already"/>
   <result pre="152.0577 [C5H6N5]+ [[6], [7], [8],[12], [13], [14]] 135.030 [C5H3N4O]+ [6,8,13]" exact="cidofovir" post="280.069 [C8H14N3O6P]+ 282.059 [C8H13N3O5P]+ [15] famciclovir 322.151 [C14H20N5O4]+ 280.140"/>
   <result pre="[14]] 135.030 [C5H3N4O]+ [6,8,13] cidofovir 280.069 [C8H14N3O6P]+ 282.059 [C8H13N3O5P]+ [15]" exact="famciclovir" post="322.151 [C14H20N5O4]+ 280.140 [C12H18N5O3]+ [6] 136.062 [C5H6N5]+ [6] ganciclovir"/>
   <result pre="[15] famciclovir 322.151 [C14H20N5O4]+ 280.140 [C12H18N5O3]+ [6] 136.062 [C5H6N5]+ [6]" exact="ganciclovir" post="256.104 [C9H14N5O4]+ 152.0577 [C5H6N5]+ [6,[12], [13], [14],16] 135.030 [C5H3N4O]+"/>
   <result pre="256.104 [C9H14N5O4]+ 152.0577 [C5H6N5]+ [6,[12], [13], [14],16] 135.030 [C5H3N4O]+ [6,13,17]" exact="idoxuridine" post="354.979 [C9H12IN2O5]+ 117.055 [C5H9O3]+ [18] letermovir 573.212 [C29H29F4N4O4]+ 383.101"/>
   <result pre="[C9H12IN2O5]+ 117.055 [C5H9O3]+ [18] letermovir 573.212 [C29H29F4N4O4]+ 383.101 [C18H15F4N2O3]+ [18]" exact="penciclovir" post="254.125 [C10H16N5O3]+ 152.0577 [C5H6N5]+ [6,20,21] 135.030 [C5H3N4O]+ [6] pritelivir"/>
   <result pre="[6,20,21] 135.030 [C5H3N4O]+ [6] pritelivir 403.089 [C18H19N4O3S2]+ 196.076 [C13H10NO]+ [22,23]" exact="ribavirin" post="245.088 [C8H12N4O5]+ 113.046 [C3H5N4O]+ [6,8,24,25] 96.019 [C3H2N3O]+ [6,8] ribavirin"/>
   <result pre="[22,23] ribavirin 245.088 [C8H12N4O5]+ 113.046 [C3H5N4O]+ [6,8,24,25] 96.019 [C3H2N3O]+ [6,8]" exact="ribavirin" post="– Met: TCONH2, triazole carboxamide 113.046 [C3H5N4O]+ 96.019 [C3H2N3O]+"/>
   <result pre="triazole carboxamide 113.046 [C3H5N4O]+ 96.019 [C3H2N3O]+ [6] 69.008 [C2HN2O]+ [6]" exact="trifluridine" post="297.069 [C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18] valaciclovir 325.162 [C13H21N6O4]+ 152.0577"/>
   <result pre="[6] 69.008 [C2HN2O]+ [6] trifluridine 297.069 [C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18]" exact="valaciclovir" post="325.162 [C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26] valganciclovir 355.172 [C12H23N6O5]+ 152.0577"/>
   <result pre="[C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18] valaciclovir 325.162 [C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26]" exact="valganciclovir" post="355.172 [C12H23N6O5]+ 152.0577 [C5H6N5]+ [14,17] vidarabine 268.104 [C10H14N5O4]+ 136.062"/>
   <result pre="[C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26] valganciclovir 355.172 [C12H23N6O5]+ 152.0577 [C5H6N5]+ [14,17]" exact="vidarabine" post="268.104 [C10H14N5O4]+ 136.062 [C5H6N5]+ [27] viramidine/taribavirin 244.104 [C8H14N5O4]+ 112.062"/>
   <result pre="SRM product-ion Formula Literature brivudine 330.994 [C11H12B5N2O5]– 78.919 [Br]– [29]" exact="cidofovir" post="278.055 [C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30] idoxuridine 352.964 [C9H10IN2O5]– 126.905"/>
   <result pre="[C11H12B5N2O5]– 78.919 [Br]– [29] cidofovir 278.055 [C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30]" exact="idoxuridine" post="352.964 [C9H10IN2O5]– 126.905 [I]– [18] trifluridine 295.055 [C10H10F3N2O5]– 179.007"/>
   <result pre="[C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30] idoxuridine 352.964 [C9H10IN2O5]– 126.905 [I]– [18]" exact="trifluridine" post="295.055 [C10H10F3N2O5]– 179.007 [CH2F3N2O2]– 3.1 Nucleoside analogues Most acyclic"/>
   <result pre="Herpes viruses are guanine-related compounds. Aciclovir ([M+H]+ with m/z 226)," exact="ganciclovir" post="([M+H]+ with m/z 256), penciclovir ([M+H]+ with m/z 254),"/>
   <result pre="Aciclovir ([M+H]+ with m/z 226), ganciclovir ([M+H]+ with m/z 256)," exact="penciclovir" post="([M+H]+ with m/z 254), valaciclovir ([M+H]+ with m/z 325),"/>
   <result pre="ganciclovir ([M+H]+ with m/z 256), penciclovir ([M+H]+ with m/z 254)," exact="valaciclovir" post="([M+H]+ with m/z 325), and valganciclovir ([M+H]+ with m/z"/>
   <result pre="([M+H]+ with m/z 254), valaciclovir ([M+H]+ with m/z 325), and" exact="valganciclovir" post="([M+H]+ with m/z 355) all show protonated guanine as"/>
   <result pre="to the loss of guanine N9-substituent (Fig. 1 ). For" exact="valaciclovir" post="and valganciclovir, the complementary ions due to the loss"/>
   <result pre="results in protonated 2-methylpropan-1-imine with m/z 72 ([C4H10N]+) for both" exact="valaciclovir" post="and valganciclovir (Fig. 1). Valaciclovir and valganciclovir are examples"/>
   <result pre="protonated 2-methylpropan-1-imine with m/z 72 ([C4H10N]+) for both valaciclovir and" exact="valganciclovir" post="(Fig. 1). Valaciclovir and valganciclovir are examples of amino-acid"/>
   <result pre="([C4H10N]+) for both valaciclovir and valganciclovir (Fig. 1). Valaciclovir and" exact="valganciclovir" post="are examples of amino-acid prodrugs of nucleoside antivirals. In"/>
   <result pre="in both positive-ion and negative-ion mode. In positive-ion mode for" exact="cidofovir" post="([M+H]+ with m/z 280), the product ion with m/z"/>
   <result pre="water is used in SRM. Based on similar structures, e.g.," exact="lamivudine" post="and zalcitabine, a product ion with m/z 112 ([C4H6N3O]+)"/>
   <result pre="ion with m/z 112 ([C4H6N3O]+) is most likely observed for" exact="cidofovir" post="as well. In negative-ion mode, cidofovir ([M−H]– with m/z"/>
   <result pre="most likely observed for cidofovir as well. In negative-ion mode," exact="cidofovir" post="([M−H]– with m/z 278) shows a product ion with"/>
   <result pre="the protonated 6-aminopurine or adenine ([C5H6N5]+) with m/z 136 for" exact="vidarabine" post="([M+H]+ with m/z 268), to the protonated 5-trifluoromethyl uracil"/>
   <result pre="268), to the protonated 5-trifluoromethyl uracil with m/z 181 for" exact="trifluridine" post="([M+H]+ with m/z 297) and to the protonated 5-iodouracil"/>
   <result pre="and to the protonated 5-iodouracil ([C4H4IN2O2]+) with m/z 239 for" exact="idoxuridine" post="([M+H]+ with m/z 355) (Fig. 2). However, for both"/>
   <result pre="idoxuridine ([M+H]+ with m/z 355) (Fig. 2). However, for both" exact="trifluridine" post="and idoxuridine, the 4-hydroxy-5-(hydroxymethyl)oxolan-2-ylium ion ([C5H9O3]+) with m/z 117"/>
   <result pre="next to two consecutive water losses [18]. In negative-ion MS–MS," exact="trifluridine" post="([M−H]– with m/z 295) shows the loss of the"/>
   <result pre="42 ([NCO]–), whereas for brivudine ([M−H]– with m/z 331) and" exact="idoxuridine" post="([M−H]– with m/z 353), a minor product ion due"/>
   <result pre="(I−) with m/z 127 (Fig. 2). Under ion-trap MS2 conditions," exact="idoxuridine" post="also shows the loss of hydrogen isocyanate (HNCO) to"/>
   <result pre="m/z of [M+H]+ Formula m/z of SRM product-ion Formula Literature" exact="amantadine" post="152.143 [C10H18N]+ 135.117 [C10H15]+ [[6], [7], [8],[32], [33], [34]]"/>
   <result pre="113.071 [C5H9N2O]+ [[4], [5], [6], [7], [8]] 69.045 [C3H5N2]+ [8]" exact="oseltamivir" post="313.212 [C16H29N2O4]+ 225.123 [C11H17N2O3]+ [6,7,36] 166.086 [C9H12NO2]+ [6,7] oseltamivir"/>
   <result pre="[8] oseltamivir 313.212 [C16H29N2O4]+ 225.123 [C11H17N2O3]+ [6,7,36] 166.086 [C9H12NO2]+ [6,7]" exact="oseltamivir" post="carboxylate 285.181 [C14H25N2O4]+ 138.055 [C7H8NO2]+ [6] 197.092 [C8H13N2O3]+ [6,36]"/>
   <result pre="oseltamivir carboxylate 285.181 [C14H25N2O4]+ 138.055 [C7H8NO2]+ [6] 197.092 [C8H13N2O3]+ [6,36]" exact="peramivir" post="329.218 [C15H29N4O4]+ 270.170 [C14H24NO4]+ [[37], [38], [39]] 100.112 [C6H14N]+"/>
   <result pre="329.218 [C15H29N4O4]+ 270.170 [C14H24NO4]+ [[37], [38], [39]] 100.112 [C6H14N]+ [40]" exact="rimantadine" post="180.175 [C12H22N]+ 163.148 [C12H19N]+ [[6], [7], [8],33] 135.117 [C10H15]+"/>
   <result pre="[C12H10BrNO2]+• [4] 479.082 [C22H2681BrN2O3S]+ 434.024 [C20H1981BrNO3S]+ [41] 280.986 [C12H1081BrNO2]+• [42]" exact="zanamivir" post="333.140 [C12H21N4O7]+ 60.056 [CH6N3]+ [[43], [44], [45]] 121.028 [C7H5O2]+"/>
   <result pre="[45] 4.1 M2 protein inhibitors against influenza A Amantadine and" exact="rimantadine" post="are inhibitors of the Matrix-2 protein, a proton-selective viroprotein,"/>
   <result pre="to prevent potential resistance issues in human, the use of" exact="amantadine" post="and rimantadine as antiviral agents during poultry farming has"/>
   <result pre="potential resistance issues in human, the use of amantadine and" exact="rimantadine" post="as antiviral agents during poultry farming has been banned"/>
   <result pre="Structures and the major product ions in positive-ion mode of" exact="amantadine" post="and rimantadine used against Influenza A viruses. Rimantadine ([M+H]+"/>
   <result pre="the major product ions in positive-ion mode of amantadine and" exact="rimantadine" post="used against Influenza A viruses. Rimantadine ([M+H]+ with m/z"/>
   <result pre="The initial fragmentation of the neuraminidase inhibitors laninamivir, peramivir, and" exact="zanamivir" post="is the loss of 59 Da, which can either"/>
   <result pre="guanidine [43], as also confirmed by accurate-m/z data, available for" exact="zanamivir" post="[47]. Either the ion with m/z 60 or the"/>
   <result pre="m/z 347) shows a product ion with m/z 60, whereas" exact="peramivir" post="([M+H]+ with m/z 329) shows a product ion with"/>
   <result pre="Structures and the major product ions in positive-ion mode of" exact="oseltamivir" post="and its carboxylate (desethyl) metabolite used against Influenza A"/>
   <result pre="Structures and the major product ions in positive-ion mode of" exact="peramivir" post="and zanamivir used against Influenza A viruses. The labeling"/>
   <result pre="the major product ions in positive-ion mode of peramivir and" exact="zanamivir" post="used against Influenza A viruses. The labeling position in"/>
   <result pre="as internal standard, is indicated with ∗. The fragmentation of" exact="zanamivir" post="is studied in detail in the course of an"/>
   <result pre="such as the small-molecule inhibitors camostat, nafamostat, as well as" exact="lopinavir" post="and ritonavir, known from HIV treatment. When SARS-CoV and"/>
   <result pre="in the discussion on the effectiveness of the antimalaria drugs" exact="chloroquine" post="and hydroxychloroquine in the treatment of Covid-19 [61]. Adequate"/>
   <result pre="discussion on the effectiveness of the antimalaria drugs chloroquine and" exact="hydroxychloroquine" post="in the treatment of Covid-19 [61]. Adequate clinical studies"/>
   <result pre="Compound class Compounds Status HIV-related agents lamuvidine, lopinavir, nelfinavir, ritonavir," exact="tenofovir" post="Discussed in part 1 [1]. HBV- or HCV-related agents"/>
   <result pre="part 2 [2]. Herpes-related agents aciclovir, brindicofovir, cidofovir, ganciclovir, letermovir," exact="valaciclovir" post="Discussed in this paper. Influenza-related agents umifenovir, zanamivir Discussed"/>
   <result pre="ganciclovir, letermovir, valaciclovir Discussed in this paper. Influenza-related agents umifenovir," exact="zanamivir" post="Discussed in this paper. Protein or peptide antiviral agents."/>
   <result pre="kDa), the cyclic peptide alisporivir (1215.9 Da), and the peptide" exact="thymalfasin" post="(3106.5 Da) Outside scope: no small-molecule antivirals. No MS–MS"/>
   <result pre="is attached to an aliphatic system, such as with peramivir," exact="zanamivir" post="and moroxydine (Fig. 6, Fig. 7). On the other"/>
   <result pre="small neutral losses. An illustrative example is the fragmentation of" exact="zanamivir" post="(Fig. 6). In yet other cases, the identity of"/>
   <result pre="in their generation. This is for instance the case for" exact="amantadine" post="and rimantadine (Fig. 4). The choices made in proposing"/>
   <result pre="generation. This is for instance the case for amantadine and" exact="rimantadine" post="(Fig. 4). The choices made in proposing structures for"/>
   <result pre="and heated electrospray ionization tandem mass spectrometryBiomed. Chromatogr.23200913214010.1002/bmc.109318823074 14SinghO.SaxenaS.MishraS.KhurooA.MonifT.Determination of" exact="valganciclovir" post="and ganciclovir in human plasma by liquid chromatography tandem"/>
   <result pre="electrospray ionization tandem mass spectrometryBiomed. Chromatogr.23200913214010.1002/bmc.109318823074 14SinghO.SaxenaS.MishraS.KhurooA.MonifT.Determination of valganciclovir and" exact="ganciclovir" post="in human plasma by liquid chromatography tandem mass spectrometric"/>
   <result pre="by liquid chromatography tandem mass spectrometric detectionClin. Biochem.44201190791510.1016/j.clinbiochem.2011.04.00321515246 15MomperJ.D.ZhangS.RandhawaP.S.ShapiroR.SchonderK.S.VenkataramananR.Determination of" exact="cidofovir" post="in human plasma after low dose drug administration using"/>
   <result pre="spectrometryJ. Pharmaceut. Biomed. Anal.5320101015102110.1016/j.jpba.2010.06.034 16RowerJ.E.NielsonC.ShiK.ParkA.H.Validation of an assay for quantifying" exact="ganciclovir" post="in dried blood spotsJ. Pharmaceut. Biomed. Anal.184202011318110.1016/j.jpba.2020.113181 17XuH.R.LiX.N.ChenW.L.LiuG.Y.ChuN.N.YuC.A sensitive"/>
   <result pre="17XuH.R.LiX.N.ChenW.L.LiuG.Y.ChuN.N.YuC.A sensitive assay for simultaneous determination of plasma concentrations of" exact="valganciclovir" post="and its active metabolite ganciclovir by LC/MS/MSJ. Chromatogr. B848200732933410.1016/j.jchromb.2006.10.053"/>
   <result pre="determination of plasma concentrations of valganciclovir and its active metabolite" exact="ganciclovir" post="by LC/MS/MSJ. Chromatogr. B848200732933410.1016/j.jchromb.2006.10.053 18KamelA.M.MunsonB.Collisionally-induced dissociation of substituted pyrimidine"/>
   <result pre="a high-performance liquid chromatography-tandem mass spectrometry for the determination of" exact="penciclovir" post="in human plasma: application to a bioequivalence studyJ. Chromatogr."/>
   <result pre="plasma: application to a bioequivalence studyJ. Chromatogr. B852200738238810.1016/j.jchromb.2007.01.044 21KannetiR.BhaveshD.ParamarD.ShivaprakashR.BhattP.A.Determination of" exact="penciclovir" post="in human plasma by liquid chromatography-electrospray ionization tandem mass"/>
   <result pre="accurate liquid chromatographic-tandem mass spectrometric method for the measurement of" exact="ribavirin" post="in rat and monkey plasmaJ. Chromatogr. B779200224124810.1016/s1570-0232(02)00379-3 25ShiX.ZhuD.LouJ.ZhuB.HuA.R.GanD.Evaluation of"/>
   <result pre="of a rapid method for the simultaneous quantification of ribavirin," exact="sofosbuvir" post="and its metabolite in rat plasma by UPLC-MS/MSJ. Chromatogr."/>
   <result pre="human plasma and its application to pharmacokinetic studiesChromatographia7320111089109510.1007/s10337-011-2001-y 30BreddemannA.HsienL.TotE.LäerS.Quantification of" exact="cidofovir" post="in human serum by LC-MS/MS for childrenJ. Chromatogr. B86120081910.1016/j.jchromb.2007.11.029"/>
   <result pre="nucleoside and nucleotide antiviralsMini Rev. Med. Chem.17201781883310.2174/138955751766617021615160128215138 32ArndtT.GuessregenB.HohlA.ReisJ.Determination of serum" exact="amantadine" post="by liquid chromatography-tandem mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination"/>
   <result pre="liquid chromatography-tandem mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination of amantadine," exact="rimantadine" post="and memantine in chicken muscle using multi-walled carbon nanotubes"/>
   <result pre="mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination of amantadine, rimantadine and" exact="memantine" post="in chicken muscle using multi-walled carbon nanotubes as a"/>
   <result pre="of a liquid chromatographic-tandem mass spectrometric method for determination of" exact="oseltamivir" post="and its metabolite oseltamivir carboxylate in plasma, saliva and"/>
   <result pre="mass spectrometric method for determination of oseltamivir and its metabolite" exact="oseltamivir" post="carboxylate in plasma, saliva and urineJ. Chromatogr. B8592007748310.1016/j.jchromb.2007.09.018 37LindegardhN.HanpithakpongW.PhakdeerajA.SinghasivanonP.FarrarJ.HienT.T.WhiteN.J.DayN.P.Development"/>
   <result pre="chromatography-tandem mass spectrometry method for determination of the anti-influenza drug" exact="peramivir" post="in plasmaJ. Chromatogr. A1215200814515110.1016/j.chroma.2008.11.00919026421 38LiY.WangZ.LiX.GongW.XieX.YangY.ZhongW.ZhengA.In vitro evaluation of absorption"/>
   <result pre="plasmaJ. Chromatogr. A1215200814515110.1016/j.chroma.2008.11.00919026421 38LiY.WangZ.LiX.GongW.XieX.YangY.ZhongW.ZhengA.In vitro evaluation of absorption characteristics of" exact="peramivir" post="for oral deliveryEur. J. Drug Metab. Pharmacokinet.42201775776510.1007/s13318-016-0390-x28000173 39LeiM.GanW.SunY.HPLC-MS/MS analysis"/>
   <result pre="for oral deliveryEur. J. Drug Metab. Pharmacokinet.42201775776510.1007/s13318-016-0390-x28000173 39LeiM.GanW.SunY.HPLC-MS/MS analysis of" exact="peramivir" post="in rat plasma: elimination of matrix effect using the"/>
   <result pre="using the phospholipid-removal solid-phase extraction methodBiomed. Chromatogr. Mar.323201810.1002/bmc.4103 40LiY.ZhangX.WangX.LiS.RuanJ.ZhangZ.Quantification of" exact="peramivir" post="(a novel anti-influenza drug) in human plasma by hydrophilic"/>
   <result pre="mass spectrometric method for the determination of the neuraminidase inhibitor" exact="zanamivir" post="(GG167) in human serumJ. Chromatogr. B732199938339310.1016/s0378-4347(99)00306-0 44BaughmanT.M.WrightW.L.HuttonK.A.Determination of zanamivir"/>
   <result pre="inhibitor zanamivir (GG167) in human serumJ. Chromatogr. B732199938339310.1016/s0378-4347(99)00306-0 44BaughmanT.M.WrightW.L.HuttonK.A.Determination of" exact="zanamivir" post="in rat and monkey plasma by positive ion hydrophilic"/>
   <result pre="compounds - application for the antiviral drug ZanamivirTalanta141201516416910.1016/j.talanta.2015.03.06625966397 46XuY.RenC.HanD.GongX.ZhangX.HuangH.JiangF.CuiY.ZhengW.TianX.Analysis of" exact="amantadine" post="in Laminaria Japonica and seawater of Daqin Island by"/>
   <result pre="spectrometryJ. Chromatogr. B1126–1127201912169710.1016/j.jchromb.2019.06.024 47ZonjaB.GonçalvesC.PérezS.DelgadoA.PetrovicM.AlpenduradaM.F.BarcelóD.Evaluation of the phototransformation of the antiviral" exact="zanamivir" post="in surface waters through identification of transformation productsJ. Hazard"/>
   <result pre="productsJ. Hazard Mater.265201429630410.1016/j.jhazmat.2013.10.00824211180 48JunwalM.SahuA.HandaT.ShahR.P.SinghS.ICH guidance in practice: degradation behaviour of" exact="oseltamivir" post="phosphate under stress conditionsJ. Pharmaceut. Biomed. Anal.6220124860 49WangY.ChenX.LiQ.ZhongD.Metabolite identification"/>
   <result pre="of safe-in-man broad-spectrum antiviral agentsInt. J. Infect. Dis.93202026827610.1016/j.ijid.2020.02.01832081774 61FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ3692020m143210.1136/bmj.m143232269046 62ZhangD.FuY.GaleJ.P.AubryA.F.ArnoldM.E.A sensitive method for the determination of"/>
   <result pre="hydroxychloroquine in covid-19BMJ3692020m143210.1136/bmj.m143232269046 62ZhangD.FuY.GaleJ.P.AubryA.F.ArnoldM.E.A sensitive method for the determination of" exact="entecavir" post="at picogram per milliliter level in human plasma by"/>
   <result pre="hepatic cytochrome P450 3A activity in healthy adults using intravenous" exact="midazolam" post="as a probeJ. Clin. Pharmacol.46200610310810.1177/009127000528328616397289 65AvataneoV.de NicolòA.CusatoJ.AntonucciM.MancaA.PalermitiA.WaittC.WalimbwaS.LamordeM.di PerriG.D’AvolioA.Development and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7308127/results/search/drugs/results.xml">
   <result pre="in MELD score. Conclusion Treatment of HCV-related LC patients with" exact="sofosbuvir" post="and daclatasvir with or without ribavirin for 3 or"/>
   <result pre="score. Conclusion Treatment of HCV-related LC patients with sofosbuvir and" exact="daclatasvir" post="with or without ribavirin for 3 or 6 months"/>
   <result pre="HCV-related LC patients with sofosbuvir and daclatasvir with or without" exact="ribavirin" post="for 3 or 6 months showed high SVR and"/>
   <result pre="Exposure and Outcome Medications The treated patients have been given" exact="sofosbuvir" post="400 mg plus daclatasvir 60 mg plus ribavirin daily"/>
   <result pre="The treated patients have been given sofosbuvir 400 mg plus" exact="daclatasvir" post="60 mg plus ribavirin daily for 3 months or"/>
   <result pre="been given sofosbuvir 400 mg plus daclatasvir 60 mg plus" exact="ribavirin" post="daily for 3 months or sofosbuvir 400 mg plus"/>
   <result pre="daclatasvir 60 mg plus ribavirin daily for 3 months or" exact="sofosbuvir" post="400 mg plus daclatasvir 60 mg daily for 6"/>
   <result pre="ribavirin daily for 3 months or sofosbuvir 400 mg plus" exact="daclatasvir" post="60 mg daily for 6 months in patients who"/>
   <result pre="apart from headache and fatigue in patients who responded to" exact="paracetamol" post="treatment. Rather, few patients who have received Ribavirin have"/>
   <result pre="the ALLY-1 trial looks at the effects of Daclatasvir/Sofosbuvir with" exact="ribavirin" post="on patients with advanced cirrhosis, including decompensated cirrhosis across"/>
   <result pre="colleague have said.27 Conclusion Treatment of HCV-related LC patients with" exact="sofosbuvir" post="and daclatasvir with or without ribavirin for 3 or"/>
   <result pre="said.27 Conclusion Treatment of HCV-related LC patients with sofosbuvir and" exact="daclatasvir" post="with or without ribavirin for 3 or 6 months"/>
   <result pre="HCV-related LC patients with sofosbuvir and daclatasvir with or without" exact="ribavirin" post="for 3 or 6 months shows high SVR and"/>
   <result pre="Gastroenterology. 2018;155(2):411–421. doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF, SchiffER, VierlingJM, et al. Daclatasvir with" exact="sofosbuvir" post="and ribavirin for hepatitis C virus infection with advanced"/>
   <result pre="doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF, SchiffER, VierlingJM, et al. Daclatasvir with sofosbuvir and" exact="ribavirin" post="for hepatitis C virus infection with advanced cirrhosis or"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7315692/results/search/drugs/results.xml">
   <result pre="molecule gs-5734 against Ebola virus in rhesus monkeysNature2016531759438138510.1038/nature1718026934220 7.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-ncov) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7318677/results/search/drugs/results.xml">
   <result pre="of RNA. Previously known nucleic acid catalysts attached fluorescently labeled" exact="adenosine" post="or guanosine derivatives through 2′,5′‐branched phosphodiester bonds to the"/>
   <result pre="units through a hydrolytically more stable phosphonate ester linkage. The" exact="tenofovir" post="transferase ribozymes were identified by in vitro selection and are"/>
   <result pre="RNA. antiviral nucleoside analogues in vitro selection ribozymes site-specific RNA labeling" exact="tenofovir" post="Funding European Research Council 10.13039/501100000781 682586 fig-count: table-count: ref-count:"/>
   <result pre="applications.7 Recently, we reported the FH14 ribozyme to attach N6‐labeled" exact="adenosine" post="to specific internal 2′‐OH groups through 2′,5′‐phosphodiester bonds.8 This"/>
   <result pre="as substrate and a structured RNA library with a bulged" exact="adenosine" post="as target site for labeling. The resulting ribozymes proved"/>
   <result pre="enzymes by attachment of non‐natural nucleotide analogues. Specifically, we considered" exact="tenofovir" post="diphosphate as a ribozyme substrate. Tenofovir is an FDA‐approved"/>
   <result pre="TDF),12 or phosphonamidate (tenofovir alafenamide, TAF).13 Upon release by esterases," exact="tenofovir" post="is phosphorylated by cellular nucleotide kinases to tenofovir diphosphate,"/>
   <result pre="by esterases, tenofovir is phosphorylated by cellular nucleotide kinases to" exact="tenofovir" post="diphosphate, which is the active drug metabolite that acts"/>
   <result pre="1 Ribozyme‐catalyzed site‐specific labeling of an RNA target using N6‐biotinylated" exact="tenofovir" post="diphosphate (biotin‐Ten‐DP), forming a phosphonate ester linkage with the"/>
   <result pre="a phosphonate ester linkage with the 2′‐OH of the bulged" exact="adenosine" post="(red) that is located in between two Watson–Crick base‐paired"/>
   <result pre="5′‐GGACAUACUGAGCCUUCAA. The previously identified adenylyl‐transferase ribozyme FH148 was tested with" exact="tenofovir" post="diphosphate, but it was not able to use the"/>
   <result pre="diphosphate, but it was not able to use the acyclic" exact="adenosine" post="derivative as a substrate for RNA labeling (Figure S1). Therefore,"/>
   <result pre="form a phosphonate ester with the 2′‐OH of the target" exact="adenosine" post="using N6‐modified tenofovir diphosphate as substrate (Figure 1). Using Watson–Crick"/>
   <result pre="ester with the 2′‐OH of the target adenosine using N6‐modified" exact="tenofovir" post="diphosphate as substrate (Figure 1). Using Watson–Crick base‐paired binding arms,"/>
   <result pre="Using Watson–Crick base‐paired binding arms, the ribozymes target a bulged" exact="adenosine" post="in the RNA of interest and catalyze labeling of"/>
   <result pre="interest and catalyze labeling of its 2′‐OH group. A biotinylated" exact="tenofovir" post="substrate was used for a bead‐based in vitro selection strategy"/>
   <result pre="procedure (with N6‐biotin‐ATP that resulted in FH ribozymes).8 The N6‐biotinylated" exact="tenofovir" post="diphosphate (biotin‐Ten‐DP) was synthesized from 6‐chloropurine in 7 steps"/>
   <result pre="for fluorescence spectroscopy or RNA imaging. In this respect, fluorescent" exact="tenofovir" post="analogues or derivatives with bioorthogonal functional groups for conjugation"/>
   <result pre="desirable as ribozyme substrates. Therefore, the respective N6‐hexynyl and N6‐azidohexyl‐modified" exact="tenofovir" post="diphosphates were synthesized and used for the attachment of"/>
   <result pre="fluorescein or Cy5 fluorophores through Cu‐catalyzed azide–alkyne cycloaddition (Scheme S2). Unmodified" exact="tenofovir" post="diphosphate (Ten‐DP) was tested as a reference.20 Gratifyingly, all"/>
   <result pre="fluorescently labeled RNA after 22 h. Figure 4 a) Structures of unmodified" exact="tenofovir" post="diphosphate, and analogues with N6‐hexynyl (alkyne) and N6‐azidohexyl (azide)"/>
   <result pre="mean of triplicates with standard error. Yields with fluorophore labeled" exact="tenofovir" post="analogues after 22 h. b) Labeling of mutated target RNAs with"/>
   <result pre="scope of FJC9. Next, the RNA substrate scope of the" exact="tenofovir" post="transferase ribozymes was investigated. Transition and transversion mutations were"/>
   <result pre="established RNA‐catalyzed labeling of RNA using the antiviral nucleoside analogue" exact="tenofovir" post="as scaffold for bioorthogonal ribozyme substrates. This work also"/>
   <result pre="Acids2015, 4, e230.25734917 18FJ is our laboratory nomenclature for the" exact="tenofovir" post="transferase ribozyme selection, and the numbers 1 and 8"/>
   <result pre="R.Miller, T.Wei, C. J.Fields, P.Sheng, M.Xie, RNA2018, 24, 1871–1877.30201850 20The" exact="tenofovir" post="analogues synthesized in this study were used as racemic"/>
   <result pre="revealed similar activity of FJ1 with enantiomerically pure and racemic" exact="tenofovir" post="diphosphate substrate (Figure S15)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7335219/results/search/drugs/results.xml">
   <result pre="[6] assessed the cost effectiveness of stockpiling the neuraminidase inhibitor" exact="oseltamivir" post="for a potential influenza pandemic in the UK in"/>
   <result pre="influenza pandemic in the UK in 2004. The study selected" exact="oseltamivir" post="because it was cheaper and easier to stockpile than"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7376526/results/search/drugs/results.xml">
   <result pre="world. Some drugs such as lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="have been recommended for COVID-19 treatment by some researchers,"/>
   <result pre="(MD) simulation indicates that binding of the combination therapy of" exact="simeprevir" post="and the candidate studied compounds to the receptors was"/>
   <result pre="a combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV2 receptor proteins to"/>
   <result pre="effective drug against SARS-CoV-2, but some previous studies reported that" exact="chloroquine" post="and remdesivir inhibited SARS-CoV-2 and the possibility of using"/>
   <result pre="and its derivatives along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 receptor proteins to"/>
   <result pre="performed to study the binding of the combination therapy of" exact="simeprevir" post="and the candidate studied compounds to the receptors and"/>
   <result pre="before docking. The structures of lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="were obtained from the PubChem database. The structural optimization"/>
   <result pre="highest binding complexes obtained from the molecular docking study of" exact="simeprevir" post="+ compound 7–6LU7, simeprevir + compound 19–6LU7, simeprevir +"/>
   <result pre="from the molecular docking study of simeprevir + compound 7–6LU7," exact="simeprevir" post="+ compound 19–6LU7, simeprevir + compound 7–6VYP, and simeprevir"/>
   <result pre="study of simeprevir + compound 7–6LU7, simeprevir + compound 19–6LU7," exact="simeprevir" post="+ compound 7–6VYP, and simeprevir + compound 7–6VYP complexes"/>
   <result pre="7–6LU7, simeprevir + compound 19–6LU7, simeprevir + compound 7–6VYP, and" exact="simeprevir" post="+ compound 7–6VYP complexes were prepared for MD simulation"/>
   <result pre="drugs. Hence, individual drugs like lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="may not be able to disrupt the stability of"/>
   <result pre="to all the chemical drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="as shown in Table 2 in the state of"/>
   <result pre="to all the chemical drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="as shown in Table 2 in the state of"/>
   <result pre="in molecular docking together with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 main protease and"/>
   <result pre="in combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="drugs which are actually used in the treatment of"/>
   <result pre="than those of the drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="against 6VYB and 6LU7. These results of molecular docking"/>
   <result pre="potent antiviral molecules along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="or other antiviral conventional drugs for disruption of the"/>
   <result pre="and 12 show the schematic presentation of combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
   <result pre="respectively. Fig. 11 Schematic presentation for the combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
   <result pre="cycle Fig. 12 Schematic presentation for the combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
   <result pre="simulations were carried out for the highest binding energy of" exact="simeprevir" post="with compounds 7 and 19 inside 6VYB and 6LU7"/>
   <result pre="solvated a 6LU7 and b 6VYB receptors in complex with" exact="simeprevir" post="+ compound 7 during molecular dynamics simulations at 10"/>
   <result pre="yellow atoms represented compound 7 in the bottom view and" exact="simeprevir" post="in the top view, the red and white colors"/>
   <result pre="the studied systems were 1.15 ± 0.04, 1.74 ± 0.08, 1.53 ± 0.03, and 1.30 ± 0.12 for" exact="simeprevir" post="+ compound 7–6LU7, simeprevir + compound 19–6LU7, simeprevir +"/>
   <result pre="1.15 ± 0.04, 1.74 ± 0.08, 1.53 ± 0.03, and 1.30 ± 0.12 for simeprevir + compound 7–6LU7," exact="simeprevir" post="+ compound 19–6LU7, simeprevir + compound 7–6VYP, and simeprevir"/>
   <result pre="1.30 ± 0.12 for simeprevir + compound 7–6LU7, simeprevir + compound 19–6LU7," exact="simeprevir" post="+ compound 7–6VYP, and simeprevir + compound 7–6VYP complexes,"/>
   <result pre="7–6LU7, simeprevir + compound 19–6LU7, simeprevir + compound 7–6VYP, and" exact="simeprevir" post="+ compound 7–6VYP complexes, respectively. Fig. 14 Plot of"/>
   <result pre="time for solvated 6LU7 and 6VYB receptors in complex with" exact="simeprevir" post="+ compounds 7 and 19 during molecular dynamics simulations"/>
   <result pre="of the complex indicates its stability with combination therapy of" exact="simeprevir" post="and the two candidate compounds and provided a suitable"/>
   <result pre="of solvated 6LU7 and 6VYB receptors, receptively, in complex with" exact="simeprevir" post="+ compounds 7 and 19 during 10 ns molecular"/>
   <result pre="for the complex indicates that binding of combination therapy of" exact="simeprevir" post="and the two candidate compounds to the receptors was"/>
   <result pre="RMSF values were 0.55 ± 0.07, 0.69 ± 0.09, and 0.87 ± 0.07 Å for 6LU7," exact="simeprevir" post="+ compound 7–6LU7, and simeprevir + compound 19–6LU7 complexes,"/>
   <result pre="and 0.87 ± 0.07 Å for 6LU7, simeprevir + compound 7–6LU7, and" exact="simeprevir" post="+ compound 19–6LU7 complexes, respectively, and 0.35 ± 0.03, 0.41 ± 0.07, and"/>
   <result pre="complexes, respectively, and 0.35 ± 0.03, 0.41 ± 0.07, and 0.58 ± 0.05 Å for 6VYB," exact="simeprevir" post="+ compound 7–6VYB, and simeprevir + compound 19–6VYB complexes,"/>
   <result pre="and 0.58 ± 0.05 Å for 6VYB, simeprevir + compound 7–6VYB, and" exact="simeprevir" post="+ compound 19–6VYB complexes, respectively. Fig. 15 The root"/>
   <result pre="(RMSF) values of 6LU7 protease alone and in complex with" exact="simeprevir" post="+ compounds 7 and 19 were plotted against residue"/>
   <result pre="(RMSF) values of 6VYB receptor alone and in complex with" exact="simeprevir" post="+ compounds 7 and 19 were plotted against residue"/>
   <result pre="in molecular docking along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 main protease and"/>
   <result pre="stability of the combination therapy between the studied compounds and" exact="simeprevir" post="inside 6LU7 and 6VYB receptors. Hence, the combination of"/>
   <result pre="6VYB receptors. Hence, the combination of the studied compounds and" exact="simeprevir" post="is highly effective against SARS-CoV-2 protease, and these drugs"/>
   <result pre="Finally, the antiviral activity of lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="could be increased against SARS-CoV-2 by using caulerpin and"/>
   <result pre="coronavirus pneumonia in Wuhan, China: a descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 6.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7391054/results/search/drugs/results.xml">
   <result pre="with promising early results in COVID-19 [1], including hydroxychloroquine, chloroquine," exact="nitazoxanide" post="and metformin, have also been previously explored as anticancer"/>
   <result pre="have also been previously explored as anticancer agents. The antimalarials" exact="hydroxychloroquine" post="and chloroquine are known to inhibit autophagic pathways in"/>
   <result pre="been previously explored as anticancer agents. The antimalarials hydroxychloroquine and" exact="chloroquine" post="are known to inhibit autophagic pathways in aggressive metastatic"/>
   <result pre="obstacle to effective cancer treatment [2]. Likewise, the antiparasitic drug" exact="nitazoxanide" post="induces cancer cell cytotoxicity under hypoxic conditions and could"/>
   <result pre="metabolism. Although the underlying mechanisms have not been completely characterised," exact="metformin" post="reduces tumour cell growth, inhibits the expression of microRNAs"/>
   <result pre="by affecting mitochondrial metabolism [4]. Moreover, cell starvation caused by" exact="metformin" post="triggers the release of cytokines such as interleukins IL-6"/>
   <result pre="antiviral and antitumour mechanisms, when considering other drugs such as" exact="lovastatin" post="and ivermectin. Development of host-based antiviral strategies is emerging"/>
   <result pre="in experimental mouse models at non-cytotoxic concentrations [7]. In particular," exact="lovastatin" post="holds promise for the clinical management of triple-negative breast"/>
   <result pre="of proinflammatory cytokines [10]. It appears that cholesterol depletion by" exact="lovastatin" post="causes the shutdown of host cell signals required for"/>
   <result pre="tumour cell signalling. Lovastatin and other lipophilic statins such as" exact="simvastatin" post="and atorvastatin also have profound effects on endothelial cell"/>
   <result pre="signalling. Lovastatin and other lipophilic statins such as simvastatin and" exact="atorvastatin" post="also have profound effects on endothelial cell biology, and"/>
   <result pre="lung disease associated with COVID-19 [12,16]. The well-known antiparasitic drug" exact="ivermectin" post="has been reported to possess antiviral activity against a"/>
   <result pre="the precise mechanisms are not completely understood. Among other actions," exact="ivermectin" post="affects tumour cell growth, induces caspase-dependent apoptosis, and causes"/>
   <result pre="and causes immunogenic cell death [19]. A few years ago," exact="ivermectin" post="was reported to affect the interaction between the integrase"/>
   <result pre="and could also explain part of the antitumour properties of" exact="ivermectin" post="[23]. In this regard, nuclear transport plays a central"/>
   <result pre="and potential mechanisms of action. Drugs such as lovastatin, ivermectin," exact="metformin" post="and nitazoxanide constitute promising therapeutic approaches that deserve clinical"/>
   <result pre="mechanisms of action. Drugs such as lovastatin, ivermectin, metformin and" exact="nitazoxanide" post="constitute promising therapeutic approaches that deserve clinical testing in"/>
   <result pre="ARDS, acute respiratory disease syndrome. aOther lipophilic statins such as" exact="simvastatin" post="and atorvastatin share similar antitumour and/or antiviral effects. References"/>
   <result pre="respiratory disease syndrome. aOther lipophilic statins such as simvastatin and" exact="atorvastatin" post="share similar antitumour and/or antiviral effects. References References 1SerafinMBBottegaAFolettoVSda"/>
   <result pre="therapyFront Pharmacol11202040810.3389/fphar.2020.0040832322202 3SenkowskiWZhangXOlofssonMHIsacsonRHöglundUGustafssonMThree-dimensional cell culture-based screening identifies the anthelmintic drug" exact="nitazoxanide" post="as a candidate for treatment of colorectal cancerMol Cancer"/>
   <result pre="Devel Ther14202028529610.2147/DDDT.S237393 19DraganovDGopalakrishna-PillaiSChenYRZuckermanNMoellerSWangCModulation of P2X4/P2X7/pannexin-1 sensitivity to extracellular ATP via" exact="ivermectin" post="induces a non-apoptotic and inflammatory form of cancer cell"/>
   <result pre="replication of HIV-1 and dengue virusBiochem J443201285185610.1042/BJ2012015022417684 21CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res178202010478710.1016/j.antiviral.2020.104787 22CalyLWagstaffKMJansDANuclear"/>
   <result pre="viruses: potential target for antivirals?Antiviral Res95201220220610.1016/j.antiviral.2012.06.00822750233 23KosynaFKNagelMKluxenLKraushaarKDeppingRThe importin α/β-specific inhibitor" exact="ivermectin" post="affects HIF-dependent hypoxia response pathwaysBiol Chem39620151357136710.1515/hsz-2015-017126351913 24KosynaFKDeppingR.Controlling the gatekeeper:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7392152/results/search/drugs/results.xml">
   <result pre="rather for a general mechanism of viral infection. For instance," exact="chloroquine" post="and hydroxychloroquine have been reported to affect endosomes, the"/>
   <result pre="a general mechanism of viral infection. For instance, chloroquine and" exact="hydroxychloroquine" post="have been reported to affect endosomes, the critical point"/>
   <result pre="antiviral activity [5]. Regardless, in a recent small clinical trial" exact="hydroxychloroquine" post="demonstrated moderate effectiveness in treatment of COVID-19 patients, and"/>
   <result pre="the effect was even more pronounced in co-treatment with antibacterial" exact="azithromycin" post="[6]. This led both drugs to numerous currently ongoing"/>
   <result pre="their potential benefits, mechanisms and safety. The mentioned drugs, chloroquine," exact="hydroxychloroquine" post="and azithromycin, highly accumulate in lysosomes/endosomes and their membranes,"/>
   <result pre="lysosomes). We propose that the antiviral activity of (hydroxy)chloroquine and" exact="azithromycin" post="is shared among all strong lysosomotropic drugs and is"/>
   <result pre="been extensively summarized by Salata et al. [22]. Chloroquine and" exact="amiodarone" post="have so far been amongst the most widely studied"/>
   <result pre="COVID-19 could be their potential anti-inflammatory effects, which was for" exact="azithromycin" post="and chloroquine as well as for a number of"/>
   <result pre="be their potential anti-inflammatory effects, which was for azithromycin and" exact="chloroquine" post="as well as for a number of tool drugs"/>
   <result pre="example antibacterial azithromycin, selective serotonin reuptake inhibitors (SSRI) antidepressants fluoxetine," exact="citalopram" post="and sertraline, as well as well-known antimalarial drug chloroquine."/>
   <result pre="are: promethazine, amodiaquine, chloroquine, mefloquine, tilorone, hydroxychloroquine, arbidol (umifenovir) and" exact="nelfinavir" post="[23] (https://drugvirus.info/). The drugs that passed all applied lysosomotropism"/>
   <result pre="applied lysosomotropism criteria are: azithromycin, promethazine, cyclizine, chloroquine, clemastine, hydroxyzine," exact="rifabutin" post="and vicriviroc, and drugs that do not have data"/>
   <result pre="and thereby preventing infection of the cell. The third antiviral," exact="nelfinavir" post="is a protease inhibitor drug approved for treatment of"/>
   <result pre="primary inclusion criteria. Three of them target respiratory system (bromhexine," exact="ambroxol" post="and formoterol), but should be cautiously assessed at which"/>
   <result pre="tested in numerous ongoing clinical trials on COVID-19, with chloroquine," exact="hydroxychloroquine" post="and azithromycin being most widely studied. FDA has recently"/>
   <result pre="numerous ongoing clinical trials on COVID-19, with chloroquine, hydroxychloroquine and" exact="azithromycin" post="being most widely studied. FDA has recently revoked the"/>
   <result pre="has recently revoked the emergency use authorization (EUA) to use" exact="hydroxychloroquine" post="and chloroquine to treat COVID-19 outside clinical trials due"/>
   <result pre="revoked the emergency use authorization (EUA) to use hydroxychloroquine and" exact="chloroquine" post="to treat COVID-19 outside clinical trials due to the"/>
   <result pre="CADs are also being clinically tested, such as amiodarone, fluoxetine," exact="chlorpromazine" post="and fluvoxamine, but also other drugs with possible CAD"/>
   <result pre="other drugs with possible CAD properties such as imatinib, bromhexine," exact="formoterol" post="[41]. The number of clinical trials and diversity of"/>
   <result pre="the past 50 yearsClin. Microbiol. Rev.29201669574727281742 2Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="the treatment of emerging viral diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="interaction map reveals targets for drug repurposingNature2020 6GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.ColsonP.ChabrièreE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="endo-/lysosomal system in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of" exact="azithromycin" post="and clarithromycin in rat alveolar macrophages (NR8383) in vitroBiol."/>
   <result pre="in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of azithromycin and" exact="clarithromycin" post="in rat alveolar macrophages (NR8383) in vitroBiol. Pharm. Bull.3620131494149923995662"/>
   <result pre="by decreasing autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujićK.BanjanacM.MunićV.PolančecD.Eraković HaberV.Impairment of lysosomal functions by" exact="azithromycin" post="and chloroquine contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions"/>
   <result pre="autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujićK.BanjanacM.MunićV.PolančecD.Eraković HaberV.Impairment of lysosomal functions by azithromycin and" exact="chloroquine" post="contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions involving lysosomes:"/>
   <result pre="Research Information on Drug-Induced Liver Injury [Online].Available: https://www.ncbi.nlm.nih.gov/books/NBK547852/ [Accessed]2012 37LentiniG.CavalluzziM.M.HabtemariamS.COVID-19," exact="chloroquine" post="repurposing, and cardiac safety concern: chirality might helpMolecules202025 38GriloL.S.CarruptP.A.AbrielH.Stereoselective"/>
   <result pre="stimulated Raman scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="during a five-year period. Incidence and prognosisActa Med. Scand.18219674915016054829 47ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin."/>
   <result pre="&amp;amp; immunology and dermatologyComprehensiv Med. Chem. II2007 52KrishnaS.WhiteN.J.Pharmacokinetics of quinine," exact="chloroquine" post="and amodiaquine. Clinical implicationsClin. Pharmacokinet.3019962632998983859 53O’maraE.KasserraC.HuddlestoneJ.R.WanY.SoniP.CaceresM.MedlockM.MorrisonR.DevinskyO.Effect of vicriviroc on"/>
   <result pre="K+ channelJ. Mol. Cell. Cardiol.40200610711816288909 55SchranH.F.PetrykL.ChangC.T.O’connorR.GelbertM.B.The pharmacokinetics and bioavailability of" exact="clemastine" post="and phenylpropanolamine in single-component and combination formulationsJ. Clin. Pharmacol.3619969119228930778"/>
   <result pre="single-component and combination formulationsJ. Clin. Pharmacol.3619969119228930778 56SchrezenmeierE.DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 57ShiJ.MontayG.BhargavaV.O.Clinical pharmacokinetics"/>
   <result pre="first ketolide antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of" exact="erythromycin" post="and clarithromycin on the HERG potassium channelMol. Cell. Biochem.25420031714674677"/>
   <result pre="antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of erythromycin and" exact="clarithromycin" post="on the HERG potassium channelMol. Cell. Biochem.25420031714674677 59TaylorG.HoustonJ.B.ShafferJ.MawerG.Pharmacokinetics of"/>
   <result pre="clarithromycin on the HERG potassium channelMol. Cell. Biochem.25420031714674677 59TaylorG.HoustonJ.B.ShafferJ.MawerG.Pharmacokinetics of" exact="promethazine" post="and its sulphoxide metabolite after intravenous and oral administration"/>
   <result pre="Drug Saf.4200542143115934850 61Van HaarstA.D.Van’ T KloosterG.A.Van GervenJ.M.SchoemakerR.C.Van OeneJ.C.BurggraafJ.CoeneM.C.CohenA.F.The influence of" exact="cisapride" post="and clarithromycin on QT intervals in healthy volunteersClin. Pharmacol."/>
   <result pre="61Van HaarstA.D.Van’ T KloosterG.A.Van GervenJ.M.SchoemakerR.C.Van OeneJ.C.BurggraafJ.CoeneM.C.CohenA.F.The influence of cisapride and" exact="clarithromycin" post="on QT intervals in healthy volunteersClin. Pharmacol. Ther.6419985425469834046 62WalkerR.B.KanferI.Pharmacokinetics"/>
   <result pre="on QT intervals in healthy volunteersClin. Pharmacol. Ther.6419985425469834046 62WalkerR.B.KanferI.Pharmacokinetics of" exact="cyclizine" post="following intravenous administration to human volunteersEur. J. Pharm. Sci.1996"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7399655/results/search/drugs/results.xml">
   <result pre="[7] 2 Chloroquine Image 2 Treatment of SARS-CoV-2 [45] 3" exact="hydroxychloroquine" post="Image 3 Treatment of SARS-CoV-2 [45] 4 Remdesivir Image"/>
   <result pre="with a score of −8.12, so it is expected that" exact="ritonavir" post="is a potent inhibitor for SARS-CoV-2 pneumonia. The results"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7403393/results/search/drugs/results.xml">
   <result pre="Inh. Index of 1.35 and 1.43 respectively. In addition to" exact="chloroquine" post="derivatives, two other hits are also currently evaluated in"/>
   <result pre="combinationsCurr. Opin. Pharmacol.201948929810.1016/j.coph.2019.07.00631454708 6.ManganaroRet al.Synthesis and antiviral effect of novel" exact="fluoxetine" post="analogues as enterovirus 2C inhibitorsAntiviral Res.202017810478110.1016/j.antiviral.2020.10478132234539 7.de WildeAHet al.Screening"/>
   <result pre="in inhibiting SARS-CoV-2 infection in vitroCell Discov.202061610.1038/s41421-020-0156-032194981 14.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Pneumonia (ALBERTA HOPE-Covid19). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04329611 (2020). 17.Efficacy and safety of" exact="darunavir" post="and cobicistat for treatment of pneumonia caused by 2019-nCoV."/>
   <result pre="HOPE-Covid19). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04329611 (2020). 17.Efficacy and safety of darunavir and" exact="cobicistat" post="for treatment of pneumonia caused by 2019-nCoV. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT042522745"/>
   <result pre="lung injuryCrit Care Med.2004321055106010.1097/01.CCM.0000120055.52377.BF15071401 30.MumtazNet al.Cell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntiviral Res.201714616116310.1016/j.antiviral.2017.09.00428912011 31.Maisonnasse, P. et al. Hydroxychloroquine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7404195/results/search/drugs/results.xml">
   <result pre="being approved in over a decade. While cholinesterase inhibitors and" exact="memantine" post="are FDA-approved drugs for AD, and do address some"/>
   <result pre="impairments. The study found that the co-administration of acyclovir with" exact="dexamethasone" post="attenuated impairments in spatial cognition. Furthermore, this combination reduced"/>
   <result pre="study found these effects to only occur when acyclovir and" exact="dexamethasone" post="were administered together [114]. 4.1.2. Penciclovir Penciclovir is another"/>
   <result pre="HSV-1 displayed a reduction of virus and Aβ accumulation when" exact="penciclovir" post="was administered. This was paralleled with a reduction in"/>
   <result pre="in AD. 4.2. Antimicrobial Drugs 4.2.1. Doxycycline Doxycycline is a" exact="tetracycline" post="antibiotic that has been studied for its therapeutic efficacy"/>
   <result pre="its therapeutic efficacy in AD models. Contrary to other tetracyclines," exact="doxycycline" post="has been determined to be safe and is able"/>
   <result pre="effect directly in the CNS. In vivo models, in which" exact="doxycycline" post="was administered to mice, observed its accumulation in amyloid"/>
   <result pre="and formation of Aβ oligomers, it was observed that although" exact="doxycycline" post="administration in transgenic mice did not cause a shift"/>
   <result pre="a reduction in microglia activation has also been associated with" exact="doxycycline" post="administration [132]. A drosophila model, which administered doxycycline to"/>
   <result pre="associated with doxycycline administration [132]. A drosophila model, which administered" exact="doxycycline" post="to Aβ1–42-expressing flies, observed that the treated group’s locomotor"/>
   <result pre="slower than the control group. The same study also observed" exact="doxycycline" post="administration to be associated with reduced Aβ fibrilization, suggesting"/>
   <result pre="the production of smaller amyloid structures [133]. Another study associated" exact="doxycycline" post="with the destabilization of Aβ fibrils [134]. Clinical trials,"/>
   <result pre="trials, however, were not as successful. One study, which administered" exact="doxycycline" post="and rifampicin, observed improvements in cognitive function, as assessed"/>
   <result pre="reduced microglial activation [141]. Studies by Tomiyama et al. found" exact="rifampicin" post="to protect neurons from cytotoxicity by scavenging free radicals"/>
   <result pre="scavenging free radicals [142,143]. In relation to the antimicrobial hypothesis," exact="rifampicin" post="has been previously studied for use in bacterial cerebral"/>
   <result pre="previously studied for use in bacterial cerebral infections [144]. As" exact="rifampicin" post="is able to cross the BBB [144], it can"/>
   <result pre="clearance [145]. A study by Umeda et al., in which" exact="rifampicin" post="was administered to APPOSK mice, found the treatment to"/>
   <result pre="reduce microglial activation [146]. Clinical studies exploring the impact of" exact="rifampicin" post="on cognitive function have also been investigated, as mentioned"/>
   <result pre="sections. Even with its many benefits, the oral intake of" exact="rifampicin" post="has also been associated with liver injury in humans."/>
   <result pre="with liver injury in humans. To circumvent this limitation, administering" exact="rifampicin" post="intranasally or subcutaneously has been suggested [147]. These routes"/>
   <result pre="intranasally or subcutaneously has been suggested [147]. These routes of" exact="rifampicin" post="administration have been shown to be more effective in"/>
   <result pre="in the brain, more so than other antibiotics, such as" exact="moxifloxacin" post="[153,154]. In addition, COR271 was found to provide some"/>
   <result pre="effects that could take away from its benefits. For example," exact="cefepime" post="is an antibiotic that has shown to be able"/>
   <result pre="virus type 1J. Alzheimer’s Dis.20081425926910.3233/JAD-2008-1430118599953 114.HuiZ.ZhijunY.YushanY.LipingC.YiyingZ.DifanZ.ChunglitC.T.WeiC.The combination of acyclovir and" exact="dexamethasone" post="protects against Alzheimer’s disease-related cognitive impairments in micePsychopharmacology202010.1007/s00213-020-05503-132221697 115.PrasadK.M.EackS.M.KeshavanM.S.YolkenR.H.IyengarS.NimgaonkarV.L.Antiherpes"/>
   <result pre="Alzheimer’s disease mouse modelsNeurobiol. Aging20187012813910.1016/j.neurobiolaging.2018.06.00230007162 133.CostaR.SperettaE.CrowtherD.C.CardosoI.Testing the therapeutic potential of" exact="doxycycline" post="in a Drosophila melanogaster model of Alzheimer diseaseJ. Biol."/>
   <result pre="Abeta42Int. J. Mol. Sci.201920464110.3390/ijms2018464131546787 135.LoebM.B.MolloyD.W.SmiejaM.StandishT.GoldsmithC.H.MahonyJ.SmithS.BorrieM.DecoteauE.DavidsonW.et al.A randomized, controlled trial of" exact="doxycycline" post="and rifampin for patients with Alzheimer’s diseaseJ. Am. Geriatr."/>
   <result pre="Geriatr. Soc.20045238138710.1111/j.1532-5415.2004.52109.x14962152 136.MolloyD.W.StandishT.I.ZhouQ.GuyattG.A multicenter, blinded, randomized, factorial controlled trial of" exact="doxycycline" post="and rifampin for treatment of Alzheimer’s disease: The DARAD"/>
   <result pre="antibiotic with brain protective functionBrain Res. Bull.2014107374210.1016/j.brainresbull.2014.05.00724905548 140.YulugB.HanogluL.OzansoyM.IsıkD.KilicU.KilicE.SchabitzW.R.Therapeutic role of" exact="rifampicin" post="in Alzheimer’s diseasePsychiatry Clin. Neurosci.20187215215910.1111/pcn.1263729315976 141.BiW.ZhuL.JingX.LiangY.TaoE.Rifampicin and Parkinson’s diseaseNeurol."/>
   <result pre="function as a hydroxyl radical scavengerJ. Biol. Chem.19962716839684410.1074/jbc.271.12.68398636108 144.MindermannT.LandoltH.ZimmerliW.RajacicZ.GratzlO.Penetration of" exact="rifampicin" post="into the brain tissue and cerebral extracellular space of"/>
   <result pre="space of ratsJ. Antimicrob. Chemother.19933173173710.1093/jac/31.5.7318335500 145.QosaH.AbuznaitA.H.HillR.A.KaddoumiA.Enhanced brain amyloid-β clearance by" exact="rifampicin" post="and caffeine as a possible protective mechanism against Alzheimer’s"/>
   <result pre="a candidate preventive medicine against amyloid-β and tau oligomersBrain20161391568158610.1093/brain/aww04227020329 147.UmedaT.TanakaA.SakaiA.YamamotoA.SakaneT.TomiyamaT.Intranasal" exact="rifampicin" post="for Alzheimer’s disease preventionAlzheimer’s Dement.2018430431310.1016/j.trci.2018.06.01230094330 148.LiN.CollyerC.A.Gingipains from Porphyromonas gingivalis—Complex"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7406694/results/search/drugs/results.xml">
   <result pre="respectively, a &amp;gt;10-fold increase in activity relative to the FDA-approved" exact="teriflunomide" post="(IC50 = 307.1 nmol/L). The X-ray crystal structure of"/>
   <result pre="10 505.88. It is much more potent than that of" exact="teriflunomide" post="or brequinar and is also by far the most"/>
   <result pre="animal models. In addition, the combination administration of S312 and" exact="oseltamivir" post="resulted in 100% protection of the infected mice, superior"/>
   <result pre="with an oseltamivir-resistant virus and had a remarkable advantage over" exact="oseltamivir" post="to treat the late phase of the infectious disease."/>
   <result pre="the DHODH inhibitor with DAA to overcome drug resistance. As" exact="leflunomide" post="and teriflunomide are used to treat autoimmune diseases such"/>
   <result pre="inhibitor with DAA to overcome drug resistance. As leflunomide and" exact="teriflunomide" post="are used to treat autoimmune diseases such as rheumatoid"/>
   <result pre="efficacy too. As anticipated, the combination use of S312 and" exact="oseltamivir" post="significantly reduced the levels of IL-6, MCP-1, IL-5, KC/GRO"/>
   <result pre="concept for the treatment of COVID-19, the clinical trial of" exact="leflunomide" post="has been initiated in England and founded by LifeArc"/>
   <result pre="ReisRAGCalilFAFelicianoPRPinheiroMPNonatoMCThe dihydroorotate dehydrogenases: past and presentArch Biochem Biophys201763217519110.1016/j.abb.2017.06.01928666740 WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7409489/results/search/drugs/results.xml">
   <result pre="for the prevention of cytomegalovirus infection, such as acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. Methods We searched relevant prospective and multi-armed"/>
   <result pre="in the analysis. In the case of cytomegalovirus infection, the" exact="ganciclovir" post="group (OR = 0.24, 95% CI 0.09–0.57) and the valacyclovir group"/>
   <result pre="0.04–0.69) provided significantly better outcomes than the control group. The" exact="ganciclovir" post="(OR = 0.37, 95% CI 0.13–0.86) and valacyclovir groups (OR = 0.31, 95%"/>
   <result pre="acyclovir group. As for cytomegalovirus disease, the ganciclovir, valacyclovir and" exact="valganciclovir" post="groups showed significant advantages compared with the control group"/>
   <result pre="OR = 0.17, 95% CI 0.07–0.31, valacyclovir group: OR = 0.08, 95% CI 0.01–0.33," exact="valganciclovir" post="group: OR = 0.14, 95% CI 0.02–0.45). Similarly, the ganciclovir group"/>
   <result pre="CI 0.01–0.33, valganciclovir group: OR = 0.14, 95% CI 0.02–0.45). Similarly, the" exact="ganciclovir" post="group (OR = 0.38, 95% CI 0.12–0.71) and the valacyclovir group"/>
   <result pre="symptoms of CMV infection after solid organ transplantation [7]. Although" exact="ganciclovir" post="and valganciclovir are recommended for CMV treatment according to"/>
   <result pre="CMV infection after solid organ transplantation [7]. Although ganciclovir and" exact="valganciclovir" post="are recommended for CMV treatment according to the third"/>
   <result pre="in use for CMV prevention and treatment, including acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. However, these antiviral drugs are associated with"/>
   <result pre="84 27 3 (11) 168 Cyclosporine, azathioprine, steroids Acyclovir vs" exact="ganciclovir" post="Singh [8] Liver Prophylaxis Acyclovir 3200 7 24 7"/>
   <result pre="Liver Prophylaxis Acyclovir 3200 7 24 7 (30) 168 Tacrolimus," exact="methylprednisolone" post="Preemptive Ganciclovir 10 mg/kg 168 23 8 (33) 168"/>
   <result pre="Preemptive Ganciclovir 10 mg/kg 168 23 8 (33) 168 Tacrolimus," exact="methylprednisolone" post="Duncan [9] Lung Prophylaxis Acyclovir 3200 90 12 742 ± 44"/>
   <result pre="Acyclovir 3200 90 12 742 ± 44 Azathioprine, cyclosporine, antilymphoblast globulin/antilymphocyt globulin," exact="methylprednisolone" post="Prophylaxis Ganciclovir 5 mg/kg 5 days/week 90 13 690 ± 85"/>
   <result pre="5 days/week 90 13 690 ± 85 Azathioprine, cyclosporine, antilymphoblast globulin/antilymphocyt globulin," exact="methylprednisolone" post="Rubin [10] Renal, heart, liver Prophylaxis Acyclovir 1200 84"/>
   <result pre="[11] Liver Prophylaxis Acyclovir 3200 100 109 365 Tacrolimus/cyclosporine, corticosteroids," exact="azathioprine" post="Prophylaxis Ganciclovir 3000 100 110 365 Tacrolimus/cyclosporine, corticosteroids, azathioprine"/>
   <result pre="corticosteroids, azathioprine Prophylaxis Ganciclovir 3000 100 110 365 Tacrolimus/cyclosporine, corticosteroids," exact="azathioprine" post="Acyclovir vs valacyclovir Egan [12] Heart Prophylaxis Acyclovir 800"/>
   <result pre="Prophylaxis Acyclovir 800 90 13 1 (7) 180 Azathioprine, cyclosporine," exact="prednisolone" post="Prophylaxis Valacyclovir 2000 90 14 0 (0) 180 Azathioprine,"/>
   <result pre="Prophylaxis Valacyclovir 2000 90 14 0 (0) 180 Azathioprine, cyclosporine," exact="prednisolone" post="Ganciclovir vs control Merigan [13] Heart Prophylaxis Ganciclovir 10"/>
   <result pre="Preemptive Ganciclovir 2.5 mg/kg/days 9 64 180 Azathioprine, cyclosporine, prednisone," exact="methylprednisolone" post="Preemptive Control 0 0 49 180 Azathioprine, cyclosporine, prednisone,"/>
   <result pre="methylprednisolone Preemptive Control 0 0 49 180 Azathioprine, cyclosporine, prednisone," exact="methylprednisolone" post="Gane [15] Liver Prophylaxis Ganciclovir 3000 98 150 21"/>
   <result pre="Renal Preemptive Ganciclovir 3000 49 42 5 (12) 365 Tacrolimus/cyclosporine," exact="prednisolone" post="Deferred Control 3000 28 38 3 (8) 365 Tacrolimus/cyclosporine,"/>
   <result pre="prednisolone Deferred Control 3000 28 38 3 (8) 365 Tacrolimus/cyclosporine," exact="prednisolone" post="Ganciclovir vs valacyclovir Pavlopoulou [18] Renal Prophylaxis Ganciclovir 3000"/>
   <result pre="Prophylaxis Ganciclovir 3000 90 40 6 (14) 180 Tacrolimus, MMF," exact="methylprednisolone" post="Prophylaxis Valacyclovir 8000 90 43 6 (15) 180 Tacrolimus,"/>
   <result pre="Prophylaxis Valacyclovir 8000 90 43 6 (15) 180 Tacrolimus, MMF," exact="methylprednisolone" post="Reischig [19] Renal Prophylaxis Ganciclovir 3000 90 36 5"/>
   <result pre="Prophylaxis Ganciclovir 3000 90 36 5 (14) 730 Tacrolimus, MMF," exact="azathioprine" post="Prophylaxis Valacyclovir 8000 90 35 4 (11) 730 Tacrolimus,"/>
   <result pre="Prophylaxis Valacyclovir 8000 90 35 4 (11) 730 Tacrolimus, MMF," exact="azathioprine" post="Ganciclovir vs valganciclovir Paya [20] Heart, liver, renal, pancreas"/>
   <result pre="90 35 4 (11) 730 Tacrolimus, MMF, azathioprine Ganciclovir vs" exact="valganciclovir" post="Paya [20] Heart, liver, renal, pancreas Prophylaxis Ganciclovir 3000"/>
   <result pre="outcomes of infection were not shown [11–13] (Fig. 3a). The" exact="ganciclovir" post="group (OR = 0.24, 95% CI 0.09–0.57) and the valacyclovir group"/>
   <result pre="0.04–0.69) performed significantly better than the control group, while the" exact="valganciclovir" post="group (OR = 0.31, 95% CI 0.06–1.49) and the acyclovir group"/>
   <result pre="no significant advantage compared to the control group. Moreover, the" exact="ganciclovir" post="(OR = 0.37, 95% CI 0.13–0.86) and valacyclovir groups (OR = 0.31, 95%"/>
   <result pre="group. However, the comparison between the valacyclovir group and the" exact="ganciclovir" post="group did not show significant differences in their efficacy"/>
   <result pre="we can observe in Fig. 3B, the ganciclovir, valacyclovir and" exact="valganciclovir" post="groups showed significant advantages over the control group (ganciclovir"/>
   <result pre="OR = 0.17, 95% CI 0.07–0.31; valacyclovir group: OR = 0.08, 95% CI 0.01–0.33;" exact="valganciclovir" post="group: OR = 0.14, 95% CI 0.02–0.45). There were still no"/>
   <result pre="and the control group (OR = 0.44, 95% CI 0.19–1.21). Furthermore, the" exact="ganciclovir" post="group results were moderately better than those obtained with"/>
   <result pre="superior to the acyclovir group (OR = 0.17, 95% CI: 0.03-0.72). The" exact="valganciclovir" post="group showed no significant advantages than the acyclovir group"/>
   <result pre="of the 17 studies were included [7, 14–22]. Both the" exact="ganciclovir" post="and valacyclovir groups showed significant advantages compared with the"/>
   <result pre="0.06–0.57; valacyclovir group: OR = 0.27, 95% CI 0.05–0.83). Of note, the" exact="valganciclovir" post="group also showed significant statistical differences compared to the"/>
   <result pre="compared to the control group (OR = 0.22, 95% CI 0.03–0.79). The" exact="ganciclovir" post="group showed better activity compared to the acyclovir group"/>
   <result pre="OR = 0.16, 95% CI 0.04–0.40; valacyclovir group: OR = 0.04, 95% CI 0.00–0.27;" exact="valganciclovir" post="group: OR = 0.15, 95% CI 0.02–0.89), while the acyclovir group"/>
   <result pre="differences (OR = 0.38, 95% CI 0.13–1.33). The results obtained with the" exact="ganciclovir" post="group were superior to those obtained for the acyclovir"/>
   <result pre="S3) showed that there is low-degree heterogeneity except when comparing" exact="valganciclovir" post="and valacyclovir. About the direct pairwise comparisons of CMV"/>
   <result pre="S5B), it was found a high degree of heterogeneity between" exact="valganciclovir" post="and valacyclovir in acute rejection. About the inconsistency analysis,"/>
   <result pre="still be valacyclovir (0.59). The second and third are respectively" exact="ganciclovir" post="(0.44) and valganciclovir (0.49), while the last one is"/>
   <result pre="(0.59). The second and third are respectively ganciclovir (0.44) and" exact="valganciclovir" post="(0.49), while the last one is acyclovir (0.71). As"/>
   <result pre="occurrence of CMV disease after solid organ transplantation, followed by" exact="valganciclovir" post="(0.53), ganciclovir (0.63) and acyclovir (0.92). In terms of"/>
   <result pre="CMV disease after solid organ transplantation, followed by valganciclovir (0.53)," exact="ganciclovir" post="(0.63) and acyclovir (0.92). In terms of acute rejection"/>
   <result pre="Figure S8A), the most probably induction order is acyclovir (0.57)," exact="ganciclovir" post="(0.60), valganciclovir (0.47) and valacyclovir (0.63). Concerning the inducement"/>
   <result pre="the most probably induction order is acyclovir (0.57), ganciclovir (0.60)," exact="valganciclovir" post="(0.47) and valacyclovir (0.63). Concerning the inducement of leukopenia"/>
   <result pre="S8B), the safest antiviral drug was acyclovir (0.92) followed by" exact="ganciclovir" post="(0.44), valacyclovir (0.46) and valganciclovir (0.56). In the subgroup"/>
   <result pre="was acyclovir (0.92) followed by ganciclovir (0.44), valacyclovir (0.46) and" exact="valganciclovir" post="(0.56). In the subgroup analysis of universal prophylaxis, the"/>
   <result pre="(Additional file 1: Figure S8D) is valacyclovir (0.89), followed by" exact="valganciclovir" post="(0.50), ganciclovir (0.54), acyclovir (0.86). It was not possible"/>
   <result pre="1: Figure S8D) is valacyclovir (0.89), followed by valganciclovir (0.50)," exact="ganciclovir" post="(0.54), acyclovir (0.86). It was not possible to assess"/>
   <result pre="downgraded our confidence in the network and for the comparison" exact="ganciclovir" post="versus valacyclovir about CMV disease after solid organ transplantation."/>
   <result pre="for the treatment of CMV infection, such as acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. But there is lack of head-to-head clinical"/>
   <result pre="and resistance effects of the CMV antiviral drugs -acyclovir, valacyclovir," exact="ganciclovir" post="and valganciclovir. 17 studies involving 2062 patients were included"/>
   <result pre="From the results obtained from our network meta-analysis, valacyclovir and" exact="ganciclovir" post="could effectively prevent CMV infection and disease after solid"/>
   <result pre="in the prevention of CMV disease. Although the comparison between" exact="valganciclovir" post="and control groups did not reach statistical significance. The"/>
   <result pre="valganciclovir and control groups did not reach statistical significance. The" exact="valganciclovir" post="group (CMV infection: p = 0.49) showed that it may have"/>
   <result pre="after solid organ transplantation, the preventive effect of valacyclovir and" exact="ganciclovir" post="was significantly better than that of acyclovir. No significant"/>
   <result pre="than that of acyclovir. No significant differences between valacyclovir and" exact="ganciclovir" post="were noted in prevention of CMV infection and disease"/>
   <result pre="after solid organ transplantation. Compared with the control group, valacyclovir," exact="valganciclovir" post="and ganciclovir play an active role in the prevention"/>
   <result pre="organ transplantation. Compared with the control group, valacyclovir, valganciclovir and" exact="ganciclovir" post="play an active role in the prevention of CMV"/>
   <result pre="one. Acyclovir had the lowest probability to induce leukocytopenia and" exact="valganciclovir" post="had the highest probability to induce. Considering the positive"/>
   <result pre="effect, with minimum chance of leukopenia occurrence. Compared to ganciclovir," exact="valganciclovir" post="is the most efficient in controlling CMV disease, but"/>
   <result pre="still likely to be our best choice, followed by valganciclovir," exact="ganciclovir" post="and acyclovir. However, valacyclovir did not show significant advantages"/>
   <result pre="acyclovir. However, valacyclovir did not show significant advantages compared to" exact="valganciclovir" post="and ganciclovir for the treatment of CMV infection. There"/>
   <result pre="valacyclovir did not show significant advantages compared to valganciclovir and" exact="ganciclovir" post="for the treatment of CMV infection. There are several"/>
   <result pre="highdegree: &amp;gt; 75%). There is a high-degree heterogeneity between the comparison between" exact="valganciclovir" post="and valacyclovir. Figure S4. Direct pairwise comparisons of CMV"/>
   <result pre="rejection, There is a low-degree heterogeneity between the comparison between" exact="ganciclovir" post="and valacyclovir and a high-degree heterogeneity between the comparison"/>
   <result pre="and valacyclovir and a high-degree heterogeneity between the comparison between" exact="valganciclovir" post="and valacyclovir. As for leukopenia, There is only a"/>
   <result pre="al.Multicenter evaluation of efficacy and safety of low-dose versus high-dose" exact="valganciclovir" post="for prevention of cytomegalovirus disease in donor and recipient"/>
   <result pre="renal transplant recipientsTransplant Infect Dis2016186904912 7.PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="Infect Dis2016186904912 7.PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="networks of interventionsInt J Epidemiol201342133234523508418 11.MeriganTCRenlundDGKeaySet al.A controlled trial of" exact="ganciclovir" post="to prevent cytomegalovirus disease after heart transplantationN Engl J"/>
   <result pre="randomized, comparative studyNephrol Dialysis Transplant200318918991908 13.WinstonDJBusuttilRWRandomized controlled trial of oral" exact="ganciclovir" post="versus oral acyclovir after induction with intravenous ganciclovir for"/>
   <result pre="of oral ganciclovir versus oral acyclovir after induction with intravenous" exact="ganciclovir" post="for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver"/>
   <result pre="in liver transplant patientsTransplant Infect Dis1999128997 16.DuncanSRGrgurichWFIaconoATet al.A comparison of" exact="ganciclovir" post="and acyclovir to prevent cytomegalovirus after lung transplantationAm J"/>
   <result pre="Med199415011461528025741 17.GaneESalibaFValdecasasGJet al.Randomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
   <result pre="of primary cytomegalovirus disease in organ transplant recipients with oral" exact="ganciclovir" post="or oral acyclovir prophylaxisTransplant Infect Dis200023112117 19.PavlopoulouIDSyriopoulouVPCheliotiHet al.A comparative"/>
   <result pre="Dis200023112117 19.PavlopoulouIDSyriopoulouVPCheliotiHet al.A comparative randomised study of valacyclovir vs. oral" exact="ganciclovir" post="for cytomegalovirus prophylaxis in renal transplant recipientsClin Microbiol Infect200511973674316104989"/>
   <result pre="the risk of acute renal allograft rejectionTransplantation200579331732415699762 22.ReischigTKacerMJindraPHesOLysakDBoudaMRandomized trial of" exact="valganciclovir" post="versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal"/>
   <result pre="Am Soc Nephrol CJASN201510229430425424991 23.SinghNYuVLMielesLWagenerMMMinerRCGayowskiTHigh-dose acyclovir compared with short-course preemptive" exact="ganciclovir" post="therapy to prevent cytomegalovirus disease in liver transplant recipients."/>
   <result pre="liver transplant recipients. A randomized trialAnn internal Med199412053753818304654 24.HibberdPLTolkoff-RubinNEContiDet al.Preemptive" exact="ganciclovir" post="therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal"/>
   <result pre="randomized controlled trialAnn Internal Med1995123118267762909 25.PayaCVWilsonJAEspyMJet al.Preemptive use of oral" exact="ganciclovir" post="to prevent cytomegalovirus infection in liver transplant patients: a"/>
   <result pre="randomized, placebo-controlled trialJ Infect Dis2002185785486011920308 26.ReischigTHribovaPJindraPet al.Long-term outcomes of pre-emptive" exact="valganciclovir" post="compared with valacyclovir prophylaxis for prevention of cytomegalovirus in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7436731/results/search/drugs/results.xml">
   <result pre="diphosphate (CQ; C6628) was purchased from Sigma‐Aldrich (St. Louis, MO)," exact="lopinavir" post="(LPV; S1380) was purchased from SelleckChem (Houston, TX), and"/>
   <result pre="Saline (DPBS; Welgene), and all other reagents were dissolved in" exact="dimethyl sulfoxide" post="(DMSO) for the screening. Anti‐SARS‐CoV‐2 N protein antibody was"/>
   <result pre="Vero and Calu‐3 cells. While the IC50 values of both" exact="chloroquine" post="and lopinavir increased by approcimately 10 folds and 2"/>
   <result pre="Calu‐3 cells. While the IC50 values of both chloroquine and" exact="lopinavir" post="increased by approcimately 10 folds and 2 folds, respectively"/>
   <result pre="IC50 (Figure 2B) (Table 2): nafamostat mesylate, camostat mesylate, remdesivir," exact="hydroxyprogesterone" post="caproate, digitoxin, and cyclosporine. Although nafamostat mesylate and camostat"/>
   <result pre="Microbiol. 2020;5(4):536‐544. 10.1038/s41564-020-0695-z32123347 3WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
   <result pre="bioRxiv. 202010.1101/2020.04.27.064279 7GelerisJ, SunY, PlattJ, et al. Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with COVID‐19. N Engl J Med."/>
   <result pre="SampaioVS, et al. Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7437450/results/search/drugs/results.xml">
   <result pre="± 3.22 μM was not prominent among the tested compounds," exact="lumefantrine" post="showed therapeutic promise due to high plasma and lung"/>
   <result pre="Further mode of action analysis revealed that arteannuin B and" exact="lumefantrine" post="acted at the post-entry step of SARS-CoV-2 infection. This"/>
   <result pre="and provides leading candidates for anti-SARS-CoV-2 drug research and development." exact="artemisinin" post="SARS-CoV-2 COVID-19 antiviral drug drug repurposing The COVID-19 pandemic"/>
   <result pre="a decades-old antimalarial drug with immune-modulation activities, and its derivative" exact="hydroxychloroquine" post="could efficiently inhibit SARS-CoV-2 in vitro.4,5 This raises an"/>
   <result pre="drugs derived from artemisinin.9−11 Arteannuin B and artemisinic acid are" exact="artemisinin" post="derivatives reported to have therapeutic efficacy against malaria in"/>
   <result pre="have reported the broad-spectrum antiviral potential of artemisinins. For example," exact="artesunate" post="effectively inhibits a wide range of DNA and RNA"/>
   <result pre="polyomavirus BK.14 Clinical trials focusing on the antiviral efficacy of" exact="artesunate" post="suggested that it shows promise for the treatment of"/>
   <result pre="most viral NP protein was inhibited when artesunate, dihydroartemisinin, and" exact="lumefantrine" post="were added at 25 μM, 25 μM, and 100"/>
   <result pre="were treated with 25 μM arteannuin B or 100 of" exact="lumefantrine" post="at different steps of infection (full-time, entry, and post-entry),"/>
   <result pre="when the drug was added at the post-entry step. Similarly," exact="lumefantrine" post="showed inhibitory effects when added during the full-time infection"/>
   <result pre="entry (Figure 4A,D,E). These data revealed that arteannuin B and" exact="lumefantrine" post="might function at a similar stage by interfering with"/>
   <result pre="treatment at different stages. (D) NP expression was visualized after" exact="lumefantrine" post="treatment at different stages. (E) NP expression was quantified"/>
   <result pre="(E) NP expression was quantified by Western blot assays after" exact="lumefantrine" post="treatment at different stages. Results are representative of n"/>
   <result pre="doses of 480 mg over 3 days, the EC50 of" exact="lumefantrine" post="was reached both in plasma and in the lungs."/>
   <result pre="and in the lungs. These results suggest the potential of" exact="lumefantrine" post="as a potential anti-SARS-CoV-2 agent. Figure 5 Predictive performance"/>
   <result pre="drug distribution of lumefantrine. (A) Simulated plasma concentration–time profile of" exact="lumefantrine" post="following six oral doses of 480 mg over 3"/>
   <result pre="95th percentiles of prediction. (B) Predicted lung concentration–time profile of" exact="lumefantrine" post="following six oral doses of 480 mg over 3"/>
   <result pre="dengue virus and HSV-1.23,24 Artesunate is a structural derivative of" exact="artemisinin" post="characterized by its broad-spectrum antiviral potential against DNA and"/>
   <result pre="potential of artemisinins against SARS-CoV-2 in vitro and discovered that" exact="artesunate" post="could inhibit SARS-CoV-2 replication in a dose-dependent manner. Arteannuin"/>
   <result pre="SARS-CoV-2 replication in a dose-dependent manner. Arteannuin B is another" exact="artemisinin" post="derivative that had an ideal EC50 value, suggesting its"/>
   <result pre="an important reference for estimating clinical efficacy. The Cmax of" exact="artesunate" post="was 42 μM following a single intravenous injection dose"/>
   <result pre="of 13.31 ± 1.24 μM (the in vivo metabolite of" exact="artesunate" post="was dihydroartemisinin) against SARS-CoV-2, indicating that artesunate is a"/>
   <result pre="vivo metabolite of artesunate was dihydroartemisinin) against SARS-CoV-2, indicating that" exact="artesunate" post="is a potential countermeasure against COVID-19.25 Coartem is a"/>
   <result pre="is a pharmaceutical compound preparation composed of artemether–lumefantrine (20 mg" exact="artemether" post="and 120 mg lumefantrine per tablet). The Cmax of"/>
   <result pre="preparation composed of artemether–lumefantrine (20 mg artemether and 120 mg" exact="lumefantrine" post="per tablet). The Cmax of artemether was found to"/>
   <result pre="artemether and 120 mg lumefantrine per tablet). The Cmax of" exact="artemether" post="was found to be low (0.28 μM); however, the"/>
   <result pre="found to be low (0.28 μM); however, the Cmax of" exact="lumefantrine" post="was much higher. Moreover, the plasma half-life of lumefantrine"/>
   <result pre="of lumefantrine was much higher. Moreover, the plasma half-life of" exact="lumefantrine" post="was determined to be 119 h, and the long"/>
   <result pre="the future optimization of artemisinins as anti-SARS-CoV-2 agents. Artemisinins, especially" exact="artesunate" post="and its active metabolite dihydroartemisinin, have been shown to"/>
   <result pre="the present and previous studies. Accumulating studies have suggested that" exact="artesunate" post="is likely to impair viral infection by modulating host"/>
   <result pre="host cell metabolic pathways. In particular, the anti-HCMV efficacy of" exact="artesunate" post="is associated with the PI3-K/Akt/p70S6K signaling pathway. Artesunate was"/>
   <result pre="of artemisinins against SARS-CoV-2 in vitro. Artesunate, arteannuin B, and" exact="lumefantrine" post="showed promise as anti-SARS-CoV-2 agents in vitro. Combined with"/>
   <result pre="safety and potential immunoregulatory activities of artemisinins, we believe that" exact="artemisinin" post="might represent a potential medical countermeasure against COVID-19. Methods"/>
   <result pre="0.05 was considered statistically significant. Materials Artemisinin (CAS No. 63968-64-9)," exact="artemether" post="(CAS No. 71963-77-4), artesunate (CAS No. 88495-63-0), dihydroartemisinin (CAS"/>
   <result pre="significant. Materials Artemisinin (CAS No. 63968-64-9), artemether (CAS No. 71963-77-4)," exact="artesunate" post="(CAS No. 88495-63-0), dihydroartemisinin (CAS No. 71939-50-9), artemisinic acid"/>
   <result pre="artemisinic acid (CAS No. 80286-58-4), arteether (CAS No. 75887-54-6), and" exact="lumefantrine" post="(CAS No. 82186-77-4) were purchased from Selleck. Arteannuin B"/>
   <result pre="YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG. (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="TanD. W. S.; WongF. W. S.; TranT. (2020) Anti-malarial drug," exact="artemisinin" post="and its derivatives for the treatment of respiratory diseases."/>
   <result pre="UzunT.; ToptasO. (2020) Artesunate: could be an alternative drug to" exact="chloroquine" post="in COVID-19 treatment?. Chin. Med.15, 5410.1186/s13020-020-00336-8.32514287 HoW. E.; PehH."/>
   <result pre="in Artemisia annua L. leading to enhanced antiplasmodial potency of" exact="artemisinin" post="via regulation of its metabolism. J. Ethnopharmacol.207, 86–91. 10.1016/j.jep.2017.06.025.28642094"/>
   <result pre="G.; StammingerT.; MarinJ. J.; MarschallM. (2008) The antiviral activities of" exact="artemisinin" post="and artesunate. Clin. Infect. Dis.47, 804–811. 10.1086/591195.18699744 RaffetinA.; BruneelF.;"/>
   <result pre="RaffetinA.; BruneelF.; RousselC.; ThellierM.; BuffetP.; CaumesE.; JaureguiberryS. (2018) Use of" exact="artesunate" post="in non-malarial indications. Med. Mal. Infect.48, 238–249. 10.1016/j.medmal.2018.01.004.29422423 ShapiraM."/>
   <result pre="SchnepfN. (2014) Stability and antiviral activity against human cytomegalovirus of" exact="artemisinin" post="derivatives. J. Antimicrob. Chemother.69, 34–40. 10.1093/jac/dkt346.24003183 HanY.; PhamH. T.;"/>
   <result pre="LefèvreG.; KernS. E. (2010) The effect of food consumption on" exact="lumefantrine" post="bioavailability in African children receiving artemether-lumefantrine crushed or dispersible"/>
   <result pre="GhavamiS.; LankaraniK. B. (2016) New use of an old drug:" exact="chloroquine" post="reduces viral and ALT levels in HCV non-responders (a"/>
   <result pre="HungN. C.; DavisT. M. (2002) The pharmacokinetic properties of intramuscular" exact="artesunate" post="and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J."/>
   <result pre="HauberI.; OlbrichA.; KronschnablM.; StammingerT.; HuangE. S. (2002) Antiviral activity of" exact="artesunate" post="towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol."/>
   <result pre="KalmerM.; BruggemanC. A.; VinkC.; StammingerT.; MarschallM. (2006) The anti-malaria drug" exact="artesunate" post="inhibits replication of cytomegalovirus in vitro and in vivo."/>
   <result pre="A.; VallejoM.; EfferthT.; AlvarezM.; MarinJ. J. (2006) Antiviral effect of" exact="artemisinin" post="from Artemisia annua against a model member of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7438026/results/search/drugs/results.xml">
   <result pre="ACE inhibitors, angiotensin II type-I receptor blockers (ARBs), thiazolidinediones and" exact="ibuprofen" post="have been reported to increase the expression of ACE2,"/>
   <result pre="and angina. Compounds blocking L-type calcium channels such as nimodipine," exact="diltiazem" post="etc., and a blocker of voltage gated calcium channel"/>
   <result pre="2019). A very recent report had re-proposed the use of" exact="verapamil" post="as modulators of endosomal trafficking, by inhibition of both"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7441766/results/search/drugs/results.xml">
   <result pre="HossainM. K., UllahM. O., &amp;amp; HalimM. A. (2019). Metal based" exact="donepezil" post="analogues designed to inhibit human acetylcholinesterase for Alzheimer’s disease."/>
   <result pre="Multiple receptor conformers based molecular docking study of fluorine enhanced" exact="ethionamide" post="with mycobacterium enoyl ACP reductase (InhA). Journal of Molecular"/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7441777/results/search/drugs/results.xml">
   <result pre="J., OlaoyeI. F., TijjaniH., &amp;amp; AdebayoA. I. (2020). Repurposing of" exact="chloroquine" post="and some clinically approved antiviral drugs as effective therapeutics"/>
   <result pre="KarP., &amp;amp; KnechtV. (2012d). Origin of decrease in potency of" exact="darunavir" post="and two related antiviral inhibitors against HIV-2 compared to"/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7448857/results/search/drugs/results.xml">
   <result pre="in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of" exact="gemcitabine" post="was suppressed efficiently by the cytidine nucleosides. Additionally, combination"/>
   <result pre="was suppressed efficiently by the cytidine nucleosides. Additionally, combination of" exact="gemcitabine" post="with oxysophoridine had an additive antiviral effect against SARS-CoV-2."/>
   <result pre="to cause epidemics worldwide. Different compounds, such as remdesivir and" exact="chloroquine" post="have been reported to inhibit SARS-CoV-2 replication effectively in"/>
   <result pre="lycorine and oxysophoridine against SARS-CoV-2 infection in cell culture, and" exact="chloroquine" post="was used as a positive control [1]. Vero-E6 cells"/>
   <result pre="exhibited dose-dependent inhibition of 2019-CoV replication in infected cells as" exact="chloroquine" post="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine"/>
   <result pre="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine and" exact="chloroquine" post="were 1.24, 0.31, 0.18 and 1.36 μM, respectively. To confirm"/>
   <result pre="treatment of HIV and enterovirus infection, the antiviral effect of" exact="gemcitabine" post="in combination with increased concentrations of oxysophoridine was also"/>
   <result pre="expected additive inhibitory effects were observed with the combination of" exact="gemcitabine" post="and oxysophoridine. Figure 1. The antiviral activities of gemcitabine,"/>
   <result pre="n.s. indicates no statistical differences. (E) Additive anti-SARS-CoV-2 effect of" exact="gemcitabine" post="in combination with different concentrations of oxysophoridine. The asterisks"/>
   <result pre="no statistical differences. (F) Suppression of the antiviral activity of" exact="gemcitabine" post="by cytidine. Vero-E6 cells were infected with SARS-CoV-2 and"/>
   <result pre="cells were infected with SARS-CoV-2 and simultaneously treated with 10 μM" exact="gemcitabine" post="plus different concentrations of cytidine or uridine. The asterisks"/>
   <result pre="treatment of various cancers [3]. Increasing evidence has shown that" exact="gemcitabine" post="is an effective broad spectrum antiviral agent against multiple"/>
   <result pre="of SARS-CoV-2 (1.24 μM) in our study. It is thought that" exact="gemcitabine" post="might exert its antiviral activities by targeting the salvage"/>
   <result pre="SARS-CoV-2, we added additional natural nucleosides (C and U) with" exact="gemcitabine" post="in cell culture. Similar to the previous results observed"/>
   <result pre="addition of exogenous cytidine significantly inhibited the antiviral activity of" exact="gemcitabine" post="against SARS-CoV-2 (Figure 1(F)). Our results thus indicated that"/>
   <result pre="gemcitabine against SARS-CoV-2 (Figure 1(F)). Our results thus indicated that" exact="gemcitabine" post="may inhibit SARS-CoV-2 replication through the modulation of nucleotide"/>
   <result pre="are unable to draw definitive conclusions regarding the efficacy of" exact="gemcitabine" post="against SARS-CoV-2 due to the lack of in vivo"/>
   <result pre="virus (HIV) [7]. Additionally, the mean peak plasma concentration of" exact="gemcitabine" post="observed in patients with advanced non-small cell lung cancer"/>
   <result pre="Vero-E6 cell. Altogether, these results support the therapeutic potential of" exact="gemcitabine" post="as effective antivirals with low toxicity against SARS-CoV-2. Further"/>
   <result pre="SARS-CoV-2. Further in vivo evaluation about the antiviral activity of" exact="gemcitabine" post="against SARS-CoV-2 infection is going to be carried out"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG.2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Chemother58:4885-93. doi: 10.1128/AAC.03036-1424841273 5KuivanenS, BespalovMM, NandaniaJ, et al.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="2017;139:117–128. doi: 10.1016/j.antiviral.2016.12.02228049006 6DenisovaOV, KakkolaL, FengL, et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infection. J Biol Chem. 2012;287:35324–32."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7451411/results/search/drugs/results.xml">
   <result pre="of cancer [4]. There have also been attempts to repurpose" exact="metformin" post="for cardiovascular diseases [5], and even for bacterial infections"/>
   <result pre="in oncology. Eur. J. Pharmacol.866, 172784 (2020).31730760 5.RenaG , LangCCRepurposing" exact="metformin" post="for cardiovascular disease. Circulation137(5), 422–424 (2018).29378754 6.KapoorY , SharmaR"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7452913/results/search/drugs/results.xml">
   <result pre="and proposed few potential inhibitors such as antibacterial drugs- lymecycline," exact="cefsulodine" post="and rolitetracycline, anti-fungal drug itraconazole, anti-human immunodeficiency virus-1 (HIV-1)"/>
   <result pre="immunodeficiency virus-1 (HIV-1) drug saquinavir, anti-coagulant drug dabigatran, diuretic drug" exact="canrenoic acid" post="and few flavonoids and xanthones (Wu et al., 2020a)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7461398/results/search/drugs/results.xml">
   <result pre="NCT04310228 (Not Applicable) 2 CHLOROQUINE AND HYDROXYCHLOROQUINE The synthesis of" exact="chloroquine" post="(CQ) backs to 1943 in Germany. During World War"/>
   <result pre="disorders. In 1955, one important analogue of CQ known as" exact="hydroxychloroquine" post="(HCQ) was employed for the treatment of rheumatologic and"/>
   <result pre="the antiviral mechanism of HCQ and CQ. CQ, chloroquine; HCQ," exact="hydroxychloroquine" post="Based on Figure 3, they concluded that HCQ could"/>
   <result pre="outcome follow‐up, but the obtained results especially using HCQ with" exact="azithromycin" post="were useful and could open a new window to"/>
   <result pre="inhibitor which is rapidly metabolized in vitro. However, co‐administration with" exact="ritonavir" post="(RTV; an inhibitor of the cytochromeP450 3A isoenzyme) inhibits"/>
   <result pre="point of view, 75 (76%) patients received antiviral treatment, including" exact="oseltamivir" post="(75 mg every 12 hours, orally), 500 mg LPV, 500 mg RTV and"/>
   <result pre="500 mg LPV, 500 mg RTV and the intravenous administration of 0.25 g" exact="ganciclovir" post="for 3 to 14 days. Most patients were given antibiotic"/>
   <result pre="calculated by AutoDock Vina and RosettaCommons. Their results suggested that" exact="indinavir" post="and remdesivir possessed the best docking scores, and the"/>
   <result pre="et al. The diagnostic utility of multifocal electroretinography in detecting" exact="chloroquine" post="and hydroxychloroquine retinal toxicity. Am J Ophthalmol. 2019;206:132‐139.31078540 8CortegianiA,"/>
   <result pre="The diagnostic utility of multifocal electroretinography in detecting chloroquine and" exact="hydroxychloroquine" post="retinal toxicity. Am J Ophthalmol. 2019;206:132‐139.31078540 8CortegianiA, IngogliaG, IppolitoM,"/>
   <result pre="EinavS. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID‐19. J Crit Care. 2020;57:279‐283.32173110"/>
   <result pre="J Crit Care. 2020;57:279‐283.32173110 9SchrezenmeierE, DörnerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:1‐12.31784724"/>
   <result pre="Rev Rheumatol. 2020;16:1‐12.31784724 10ColsonP, RolainJ‐M, LagierJ‐C, BrouquiP, RaoultD. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID‐19. Int J Antimicrob"/>
   <result pre="COVID‐19. Int J Antimicrob Agents. 2020;55:105932.32145363 11GaoJ, TianZ, YangX. Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID‐19"/>
   <result pre="DaiS‐M, TongQ. COVID‐19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression. J Antimicrob Chemother. 2020;75:1667‐1670.32196083"/>
   <result pre="Antimicrob Chemother. 2020;75:1667‐1670.32196083 14GautretP, LagierJ‐C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID‐19: results of an open‐label"/>
   <result pre="Commun. 2020;11(1):1‐14.31911652 16OuedraogoHG, MatteelliA, SulisG, et al. Pharmacokinetics of plasma" exact="lopinavir" post="and ritonavir in tuberculosis–HIV co‐infected African adult patients also"/>
   <result pre="16OuedraogoHG, MatteelliA, SulisG, et al. Pharmacokinetics of plasma lopinavir and" exact="ritonavir" post="in tuberculosis–HIV co‐infected African adult patients also receiving rifabutin"/>
   <result pre="and ritonavir in tuberculosis–HIV co‐infected African adult patients also receiving" exact="rifabutin" post="150 or 300 mg three times per week. Ann"/>
   <result pre="Commun. 2020;526(2):381‐388. 32223926 23WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7463888/results/search/drugs/results.xml">
   <result pre="(approved) drugs. A famous example in ophthalmology is represented by" exact="bevacizumab" post="(Avastin®, Roche, Genentech, South San Francisco, CA, USA) for"/>
   <result pre="[10]. The most widely used preservatives in the market are" exact="benzalkonium chloride" post="(BAK; a detergent frequently used in concentration varying from"/>
   <result pre="disinfectants, such as quaternary ammoniums compounds, hexamidine, phenolic compounds, or" exact="chlorhexidine" post="[17]. With regards to the formulations available for ophthalmological"/>
   <result pre="the most common and potentially interesting are those based on" exact="povidone" post="iodine and sodium hypochlorite. Of note, some authors demonstrated"/>
   <result pre="in suspension tests and for contact times of 5 min," exact="povidone" post="iodine (&amp;gt;0.75% free iodine) can inactivate SARS-CoV-2 infectivity in"/>
   <result pre="number of patients. On the other hand, topical application of" exact="chloroquine" post="may also have a repurposing potential. Chloroquine is an"/>
   <result pre="(e.g., retroviruses, flaviviruses, and coronaviruses), including SARS-CoV-2. In eye drops," exact="chloroquine" post="has been recently used at a concentration of 0.03%"/>
   <result pre="to affect the clinical course of viral infections. For example," exact="latanoprost" post="has been associated with herpes virus keratitis, potentially increasing"/>
   <result pre="[53,54]. Similar behavior has been observed with tafluprost, bimatoprost, and" exact="travoprost" post="[55,56,57]. Conversely, timolol maleate acts as an antiviral agent"/>
   <result pre="has been observed with tafluprost, bimatoprost, and travoprost [55,56,57]. Conversely," exact="timolol" post="maleate acts as an antiviral agent and it is"/>
   <result pre="viral infections, such as herpes simplex infections [58]. Of interest," exact="dorzolamide" post="showed antiviral action against oseltamivir-resistant influenza by an in"/>
   <result pre="aminoglycosides (e.g., on Japanese encephalitis and influenza A virus infection)," exact="chloramphenicol" post="(e.g., on human Herpesviridae family), Colistin (polymyxin E, for"/>
   <result pre="family), Colistin (polymyxin E, for example on mycobacteriophage D29 infection),and" exact="fusidic acid" post="(e.g., on human immunodeficiency virus and John Cunningham virus"/>
   <result pre="and Cuevavirus), and Influenza A virus infection [78,79,80]. Of note," exact="ketotifen" post="fumarate has proven to attenuate dengue virus infection [81]."/>
   <result pre="and respiratory syncytial virus (RSV). Some topical immunomodulators, such as" exact="cyclosporine" post="(also used in dry eye therapy), have also shown"/>
   <result pre="effect of interferon (IFN) on replication HSV. In this sense," exact="indometacin" post="and bromfenac has proven to inhibit HSV-1 replication as"/>
   <result pre="interferon (IFN) on replication HSV. In this sense, indometacin and" exact="bromfenac" post="has proven to inhibit HSV-1 replication as they depress"/>
   <result pre="of PrestoBlue® and plating method to evaluate antimicrobial activity of" exact="ascorbic acid," post="boric acid and curcumin in an in vitro gastrointestinal"/>
   <result pre="in vitroInt. J. Mol. Med.19982254154510.3892/ijmm_00000053 47.BrinkevichS.D.BorekoE.SavinovaO.V.PavlovaN.I.ShadyroO.I.Radical-regulating and antiviral properties of" exact="ascorbic acid" post="and its derivativesBioorg. Med. Chem. Lett.2012222424242710.1016/j.bmcl.2012.02.02222390834 48.HoviT.HirvimiesA.StenvikM.VuolaE.PippuriR.Topical treatment of"/>
   <result pre="Ophthalmol. Soc.201354195010.3341/jkos.2013.54.12.1950 56.KrollD.M.SchumanJ.S.Reactivation of herpes simplex virus keratitis after initiating" exact="bimatoprost" post="treatment for glaucomaAm. J. Ophthalmol.200213340140310.1016/S0002-9394(01)01360-511860979 57.YangH.S.ParkH.G.ChoiS.Reactivation of Herpetic Keratitis"/>
   <result pre="Broadly Effective Influenza A AntiviralsPLoS ONE20105e1316910.1371/journal.pone.001316920957181 61.JuurlinkD.N.Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCan. Med."/>
   <result pre="Influenza A AntiviralsPLoS ONE20105e1316910.1371/journal.pone.001316920957181 61.JuurlinkD.N.Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCan. Med. Assoc. J.2020192E450E45310.1503/cmaj.20052832269021"/>
   <result pre="influenza a virus RNA promoterMol. BioSyst.201282857285910.1039/c2mb25333j22990985 66.TopnoR.KhanS.A.ChowdhuryP.MahantaJ.Pharmacodynamics of aminoglycosides and" exact="tetracycline" post="derivatives against Japanese encephalitis virusAsian Pac. J. Trop. Med.2016924124610.1016/j.apjtm.2016.01.03326972394"/>
   <result pre="69.ChanJ.F.-W.MaM.K.-M.ChanG.S.-W.ChanG.C.-W.ChoiG.K.-Y.ChanK.-H.ChengV.C.-C.ChoyB.-Y.YuenK.-Y.ChanK.-W.Rapid reduction of viruria and stabilization of allograft function by" exact="fusidic acid" post="in a renal transplant recipient with JC virus-associated nephropathyInfection20154357758110.1007/s15010-015-0721-x25944568"/>
   <result pre="Acid in HIV InfectionAnn. N. Y. Acad. Sci.199368534134310.1111/j.1749-6632.1993.tb35885.x7689807 71.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles" exact="itraconazole" post="and posaconazole exhibit potent in vitro antiviral activity against"/>
   <result pre="HIV InfectionAnn. N. Y. Acad. Sci.199368534134310.1111/j.1749-6632.1993.tb35885.x7689807 71.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles itraconazole and" exact="posaconazole" post="exhibit potent in vitro antiviral activity against clinical isolates"/>
   <result pre="B Methyl EsterAntimicrob. Agents Chemother.19781319920410.1128/AAC.13.2.199206201 73.SchloerS.GoretzkoJ.KühnlA.BrunotteL.LudwigS.RescherU.The clinically licensed antifungal drug" exact="itraconazole" post="inhibits influenza virus in vitro and in vivoEmerg. Microbes"/>
   <result pre="the Treatment of Ocular DiseasesBioDrugs2011258910310.2165/11587010-000000000-0000021443273 78.HeS.LinB.ChuV.HuZ.HuX.XiaoJ.WangA.Q.SchweitzerC.J.LiQ.ImamuraM.et al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
   <result pre="of antiviral therapy for hepatitis C after liver transplantation with" exact="cyclosporine" post="and tacrolimus: A systematic review and meta-analysisLiver Transplant.201219364810.1002/lt.23516 86.QingM.YangF.ZhangB.ZouG.RobidaJ.M.YuanZ.TangH.ShiP.-Y.Cyclosporine"/>
   <result pre="Host Cyclophilins and Viral NS5 ProteinAntimicrob. Agents Chemother.2009533226323510.1128/AAC.00189-0919451286 87.MaC.LiF.MusharrafiehR.G.WangJ.Discovery of" exact="cyclosporine" post="A and its analogs as broad-spectrum anti-influenza drugs with"/>
   <result pre="Binding of Two Different CoronavirusesJ. Virol.2011855331533710.1128/JVI.02274-1021411533 107.ItoM.BabaM.SatoA.PauwelsR.De ClercqE.ShigetaS.Inhibitory effect of" exact="dextran" post="sulfate and heparin on the replication of human immunodeficiency"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7464166/results/search/drugs/results.xml">
   <result pre="acid (ATA) could easily be polymerized in water by reacting" exact="salicylic acid" post="with formaldehyde, sulphuric acid, and sodium nitrite [49]. Reymen"/>
   <result pre="water by reacting salicylic acid with formaldehyde, sulphuric acid, and" exact="sodium nitrite" post="[49]. Reymen et al. displayed that owing to an"/>
   <result pre="Other neutral antiviral molecules are ascorbic and dehydroascorbic acids [52]," exact="triclosan" post="[53] and the camphor imine derivatives. Various studies conducted"/>
   <result pre="effect increased. Chen et al. studied the use of poly-" exact="l-glutamine" post="(PGN) conjugated with Zanamivir and demonstrated that this system"/>
   <result pre="studied the consequence of adding 3% sodium pentaborate pentahydrate, 0.03%" exact="triclosan" post="and 7% glucapon solution to cotton textile [90]. They"/>
   <result pre="were demonstrated by Orsi et al. [143]. They revealed that" exact="dextran" post="sulphate, scleroglucan, and lambda carrageenan have antiviral effects on"/>
   <result pre="gum. Furthermore, these polymers influence HSV-2, with similar effect like" exact="dextran" post="sulphate, glyloid sulphate 4324 and lambda carrageenan which is"/>
   <result pre="delivery: Development, characterization and optimizationSaudi Pharm. J.201725324310.1016/j.jsps.2015.06.00328223860 58.YueI.C.PoffJ.CortésM.E.SinisterraR.D.FarisC.B.HildgenP.LangerR.ShastriV.P.A novel polymeric" exact="chlorhexidine" post="delivery device for the treatment of periodontal diseaseBiomaterials2004253743375010.1016/j.biomaterials.2003.09.11315020150 59.TalluryP.AirrabeelliR.LiJ.PaquetteD.KalachandraS.Release"/>
   <result pre="of cell-targeting groups for influenza A virus treatmentPolym. Chem.201892116212310.1039/C8PY00116B 62.LeeC.M.WeightA.K.HaldarJ.WangL.KlibanovA.M.ChenJ.Polymer-attached" exact="zanamivir" post="inhibits synergistically both early and late stages of influenza"/>
   <result pre="Sci.2019717818610.1039/C8BM01221K 66.SmithA.A.A.KrygerM.B.L.WohlB.M.Ruiz-SanchisP.ZuwalaK.TolstrupM.ZelikinA.N.Macromolecular (pro)drugs in antiviral researchPolym. Chem.201456407642510.1039/C4PY00624K 67.KrygerM.B.L.WohlB.M.SmithA.A.A.ZelikinA.N.Macromolecular prodrugs of" exact="ribavirin" post="combat side effects and toxicity with no loss of"/>
   <result pre="infected by influenza virusAntiviral Res.20056811612310.1016/j.antiviral.2005.07.00816214231 71.RonerM.R.CarraherC.E.DhanjiS.BarotG.Antiviral and anticancer activity of" exact="cisplatin" post="derivatives of tiloroneJ. Inorg. Organomet. Polym. Mater.20081837438310.1007/s10904-008-9219-732214933 72.RonerM.R.CarraherC.E.Cisplatin derivatives"/>
   <result pre="against infection of tobacco mosaic virusMacromol. Symp.19959923924210.1002/masy.19950990125 137.SanoY.Antiviral activity of" exact="chondroitin sulfate" post="against infection by tobacco mosaic virusCarbohydr. Polym.19973312512910.1016/S0144-8617(97)00029-5 138.WeiyueS.YingL.KanamotoT.AsaiD.TakemuraH.Elucidation of"/>
   <result pre="CE, Dhanji S, Barot G. Antiviral and anticancer activity of" exact="cisplatin" post="derivatives of Tilorone. J Inorg Organomet Polym Mater 2008;18:374–83"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7465925/results/search/drugs/results.xml">
   <result pre="receptors, 5-HT2A and 5-HT2C receptors and others. Notable examples include" exact="oseltamivir" post="which may act as MAO inhibitor and efavirenz, which"/>
   <result pre="which may be similar to those of the psychedelic hallucinogen" exact="lysergic acid diethylamide" post="(LSD). Other antiviral drugs with prominent nervous system effects"/>
   <result pre="they occur and manage them appropriately. central nervous system antiviral" exact="efavirenz" post="peripheral neuropathy monoamine oxidase The content published in Cureus"/>
   <result pre="individual agents, were searched separately using multiple search strings (e.g.," exact="ribavirin" post="AND neurotoxicity, efavirenz psychiatric effects, efavirenz AND psychosis, acyclovir"/>
   <result pre="searched separately using multiple search strings (e.g., ribavirin AND neurotoxicity," exact="efavirenz" post="psychiatric effects, efavirenz AND psychosis, acyclovir AND nervous system)."/>
   <result pre="multiple search strings (e.g., ribavirin AND neurotoxicity, efavirenz psychiatric effects," exact="efavirenz" post="AND psychosis, acyclovir AND nervous system). The search retrieved"/>
   <result pre="authors. Neuropsychiatric effects of antiviral therapy in influenza Oseltamivir and" exact="zanamivir" post="are neuraminidase inhibitors, used for treating influenza by shortening"/>
   <result pre="in the USA, Spain, Japan, China and South Korea associate" exact="oseltamivir" post="with many neuropsychiatric adverse events and abnormal behaviors such"/>
   <result pre="for conversion to the active form of the neuraminidase inhibitor" exact="oseltamivir" post="carboxylate (OC). Oseltamivir inhibits human monoamine oxidase‐A (MAO‐A), which"/>
   <result pre="to be other candidates for investigation. Another study reported that" exact="oseltamivir" post="sialylates a serum glycolipid that stimulates D2 dopaminergic receptor."/>
   <result pre="to abnormal behavior reported in some children taking oseltamivir. Unchanged" exact="oseltamivir" post="phosphate is suggested to be related to central nervous"/>
   <result pre="Health, Labour and Welfare (MHLW) warned against the use of" exact="oseltamivir" post="in children aged 10-19 years because of the possible"/>
   <result pre="Food and Drug Administration (FDA) added a warning to the" exact="oseltamivir" post="label in 2006 to draw attention to the risk"/>
   <result pre="of neuropsychiatric adverse events (NPAEs). However, a causal association between" exact="oseltamivir" post="use and abnormal behaviors or sudden death has not"/>
   <result pre="is no evidence, nor plausible mechanism of action, to link" exact="oseltamivir" post="with neuropsychiatric adverse events. They concluded that the risk"/>
   <result pre="of abnormal behavior was increased by influenza, and not by" exact="oseltamivir" post="use [4]. As far as the use of zanamivir"/>
   <result pre="by oseltamivir use [4]. As far as the use of" exact="zanamivir" post="is concerned, no major neuropsychiatric adverse events have been"/>
   <result pre="of antiviral therapy in herpes and cytomegalovirus (CMV) Aciclovir, valacyclovir," exact="famciclovir" post="are medications used for the treatment of herpes infections."/>
   <result pre="days of administration. Cessation of the gancyclovir and administration of" exact="haloperidol" post="resulted in recovery. Most patients with psychosis due to"/>
   <result pre="for the treatment of hepatitis B include lamivudine, telbivudine, and" exact="entecavir" post="(classified as nucleoside analogues), and the nucleotide analogues adefovir"/>
   <result pre="(classified as nucleoside analogues), and the nucleotide analogues adefovir dipivoxil," exact="tenofovir" post="disoproxil fumarate and tenofovir alafenamide [10]. Lamivudine and telbivudine"/>
   <result pre="and the nucleotide analogues adefovir dipivoxil, tenofovir disoproxil fumarate and" exact="tenofovir" post="alafenamide [10]. Lamivudine and telbivudine have been associated with"/>
   <result pre="dipivoxil, tenofovir disoproxil fumarate and tenofovir alafenamide [10]. Lamivudine and" exact="telbivudine" post="have been associated with myopathy and peripheral neuropathy, with"/>
   <result pre="mitochondrial DNA [11]. An interesting report of two cases of" exact="lamivudine" post="induced dystonia has been reported, which responded to prompt"/>
   <result pre="prompt administration of anticholinergic agents and did not recur after" exact="lamivudine" post="discontinuation [12]. The clinical presentation was similar to the"/>
   <result pre="dystonic reactions associated with antipsychotic drugs, which are mediated by" exact="dopamine" post="D2 receptor antagonism in the striatum. At present, there"/>
   <result pre="in the striatum. At present, there is no evidence that" exact="lamivudine" post="interacts with dopamine receptors, so this could be regarded"/>
   <result pre="At present, there is no evidence that lamivudine interacts with" exact="dopamine" post="receptors, so this could be regarded as an extremely"/>
   <result pre="idiosyncratic reaction. In another study, three of six patients with" exact="lamivudine" post="or telbivudine­associated myopathy had a complaint of numbness in"/>
   <result pre="by the study team. Out of 3,500 patients who received" exact="telbivudine" post="monotherapy in clinical trials, 10 (0.28%) were reported to"/>
   <result pre="combination therapy of pegylated interferon and telbivudine. Moreover, patients receiving" exact="telbivudine" post="treatment, suffer from weakness in upper and lower extremities"/>
   <result pre="were reported as the most frequent adverse events associated with" exact="telbivudine" post="use. Entecavir is a highly selective guanosine nucleoside analogue,"/>
   <result pre="(10%­-13%), and dizziness (9%), while 1-10% of patients treated with" exact="entecavir" post="suffer from insomnia. Entecavir­-associated myopathy and peripheral neuropathy cases"/>
   <result pre="cases were very rarely reported in the literature. Patients receiving" exact="entecavir" post="presenting with severe lactic acidosis, complain of weakness, reduced"/>
   <result pre="and potentially serious consequences. The combination of pegylated interferon and" exact="ribavirin" post="was the mainstay of treatment for hepatitis C infection"/>
   <result pre="loss of motivation, and depressed mood [13]. The use of" exact="ribavirin" post="in combination with either interferon or direct-acting antivirals may"/>
   <result pre="side effects of treatment with the combination of interferon and" exact="ribavirin" post="[13]. However, clinically signiﬁcant neurological toxicity is reported in"/>
   <result pre="rates of insomnia and fatigue as compared with rates from" exact="boceprevir" post="and telaprevir and suggested that these new agents may"/>
   <result pre="insomnia and fatigue as compared with rates from boceprevir and" exact="telaprevir" post="and suggested that these new agents may be better"/>
   <result pre="depression (1%) have been reported in relation to treatment with" exact="sofosbuvir" post="and may suggest mild neurotoxicity [21]. In patients receiving"/>
   <result pre="At the end of a course of treatment with a" exact="sofosbuvir" post="(SOF)-based regimen, patients with cirrhosis exhibited an increase in"/>
   <result pre="profile, though the strength of the association varies. Didanosine and" exact="stavudine" post="have been more strongly associated with peripheral neuropathy, whereas"/>
   <result pre="stavudine have been more strongly associated with peripheral neuropathy, whereas" exact="zidovudine" post="has more commonly been associated with myopathy and myelotoxicity."/>
   <result pre="more commonly been associated with myopathy and myelotoxicity. The pro-drug" exact="tenofovir" post="alafenamide, which leads to greater concentrations of the active"/>
   <result pre="cells, may be better tolerated than the initial formulation of" exact="tenofovir" post="disiproxil fumarate as well as most other NRTIs, though"/>
   <result pre="effect seems to be reversible, with gradual symptom improvement following" exact="zidovudine" post="discontinuation [28]. In contemporary clinical settings, the incidence of"/>
   <result pre="the incidence of peripheral neuropathy or myopathy during treatment with" exact="zidovudine" post="could be managed by drug discontinuation, given the availability"/>
   <result pre="compared to other NRTIs. Peripheral neuropathy is less common with" exact="tenofovir" post="compared to other NRTIs (especially stavudine), although it does"/>
   <result pre="A report of nine cases of neuropsychiatric complications arising following" exact="tenofovir" post="initiation in individuals on efavirenz containing regimen suggests the"/>
   <result pre="of neuropsychiatric complications arising following tenofovir initiation in individuals on" exact="efavirenz" post="containing regimen suggests the need for further monitoring and"/>
   <result pre="be reduced by the use of the more selective pro-drug" exact="tenofovir" post="alafenamide, though further research is warranted to determine whether"/>
   <result pre="inhibitors, and it is available in a fixed-dose combination with" exact="emtricitabine" post="and tenofovir, but tablets containing only efavirenz (to be"/>
   <result pre="fixed-dose combination with emtricitabine and tenofovir, but tablets containing only" exact="efavirenz" post="(to be used in combinations with other antiretroviral drugs)"/>
   <result pre="developed a few weeks after treatment initiation [35]. Abuse of" exact="efavirenz" post="has also been reported, primarily in South Africa where"/>
   <result pre="been reported, primarily in South Africa where crushed tablets of" exact="efavirenz" post="were smoked in a combination of drugs (including marijuana"/>
   <result pre="Recent evidence from in vitro and animal studies indicate that" exact="efavirenz" post="is a potent psychotropic drug with significant affinity GABA-A"/>
   <result pre="studies of efavirenz, are far more likely to occur with" exact="efavirenz" post="compared with other antiretroviral drugs and limit regimen tolerability"/>
   <result pre="case reports [38] of psychotic symptomatology and mania attributed to" exact="nevirapine" post="have been published, but such events have been exceedingly"/>
   <result pre="agent of this class to be approved in 1995 with" exact="ritonavir" post="following in 1996. Protease inhibitors may be used as"/>
   <result pre="As a class, they are notorious for pharmacokinetic interactions as" exact="ritonavir" post="is a potent inhibitor of CYP3A4, potentiating the effect"/>
   <result pre="of cerebral small vessel disease via this mechanism. Abuse of" exact="ritonavir" post="has also been reported, especially in combination with other"/>
   <result pre="drug of this class to be approved in 2007, with" exact="elvitegravir" post="and dolutegravir being approved in 2012 and 2013, respectively."/>
   <result pre="this class to be approved in 2007, with elvitegravir and" exact="dolutegravir" post="being approved in 2012 and 2013, respectively. They inhibit"/>
   <result pre="efavirenz. Integrase inhibitor-containing regimens are, however, far less likely than" exact="efavirenz" post="containing HAART regimens to be associated with neuropsychiatric side"/>
   <result pre="may contribute to decreased treatment adherence [48]. The association between" exact="dolutegravir" post="and psychiatric adverse events is stronger than for the"/>
   <result pre="and Fusion Inhibitors Among the most recently approved antiretrovirals are" exact="maraviroc" post="and enfuvirtide, two agents belonging to this class. They"/>
   <result pre="not been associated with treatment-limiting neuropsychiatric adverse effects. Substitution of" exact="efavirenz" post="with one of these drugs may reduce the risk"/>
   <result pre="clearly outweigh risk. Relevant only for oseltamivir. Antiehrpetic drugs (acyclovir," exact="ganciclovir" post="and analogs) Hallucinations, confusion, acute psychosis with acute onset"/>
   <result pre="antivirals – not clear whether side effects are attributable to" exact="ribavirin" post="alone. Direct-acting antiviral agents for hepatitis C Depression, insomnia,"/>
   <result pre="more prone to causing NPAE compared to sofosbuvir-based regimens. Concurrent" exact="ribavirin" post="use may exacerbated NPAEs. Nucleoside / Nucleotide analogues Peripheral"/>
   <result pre="most pronounced upon initiation of treatment 5-HT2A antagonism, serotonin and" exact="dopamine" post="reuptake inhibition, MAO inhibition, GABA-A receptor modulation NPAEs are"/>
   <result pre="association with NPAEs Unknown May be used in place of" exact="efavirenz" post="if it not tolerated due to NPAEs. Conclusions Neuropsychiatric"/>
   <result pre="in an adult patient with influenza a (H3N2) treated with" exact="oseltamivir" post="(Tamiflu): a case reportBMC Infect DisChenRFangZHuangY22419201930832611 2Risk of neuropsychiatric"/>
   <result pre="ScandHamaRBennettCL148160135201727364959 4Analysis of neuropsychiatric adverse events in patients treated with" exact="oseltamivir" post="in spontaneous adverse event reportsBiol Pharm BullUedaNUmetsuRAbeJet al.1638164438201526424023 5The"/>
   <result pre="oseltamivir in spontaneous adverse event reportsBiol Pharm BullUedaNUmetsuRAbeJet al.1638164438201526424023 5The" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
   <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatmentJ Antimicrob ChemotherHelldenALyckeJVanderTSvenssonJ-OOdar-CederlofIStahleL94594957200616540518 6Neuropsychiatric manifestations in a"/>
   <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatmentJ Antimicrob ChemotherHelldenALyckeJVanderTSvenssonJ-OOdar-CederlofIStahleL94594957200616540518 6Neuropsychiatric manifestations in a patient undergoing"/>
   <result pre="by lamivudineClin NeuropharmacolSongXHuZZhangH19319428200516062101 13Psychiatric side effects of pegylated interferon-alpha and" exact="ribavirin" post="therapy in Iranian patients with chronic hepatitis C: a"/>
   <result pre="14A case report of psychiatric symptoms following direct-acting antiviral and" exact="ribavirin" post="combination therapy for chronic hepatitis C in a patient"/>
   <result pre="studyBMJ Open GastroenterolVolpatoSMontagneseSZanettoAet al.042017 18Patient characteristics, safety, and tolerability with" exact="telaprevir" post="treatment for HCV in the clinic: a retrospective, multicenter"/>
   <result pre="retrospective, multicenter studyJ Clin Transl HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of" exact="boceprevir" post="plus peginterferon alfa-2b and ribavirin in patients with chronic"/>
   <result pre="studyJ Clin Transl HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of boceprevir plus" exact="peginterferon alfa-2b" post="and ribavirin in patients with chronic hepatitis C genotype"/>
   <result pre="HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of boceprevir plus peginterferon alfa-2b and" exact="ribavirin" post="in patients with chronic hepatitis C genotype 1: a"/>
   <result pre="31Neuropsychiatric adverse events after switching from an antiretroviral regimen containing" exact="efavirenz" post="without tenofovir to an efavirenz regimen containing tenofovir: a"/>
   <result pre="events after switching from an antiretroviral regimen containing efavirenz without" exact="tenofovir" post="to an efavirenz regimen containing tenofovir: a report of"/>
   <result pre="from an antiretroviral regimen containing efavirenz without tenofovir to an" exact="efavirenz" post="regimen containing tenofovir: a report of nine casesAntivir TherAllavenaCLe"/>
   <result pre="report of nine casesAntivir TherAllavenaCLe MoalGMichauCChiffoleauARaffiF263265112006https://www.researchgate.net/profile/Anne_Chiffoleau/publication/7141177_Neuropsychiatric_adverse_events_after_switching_from_an_antiretroviral_regimen_containing_efavirenz_without_tenofovir_to_an_efavirenz_regimen_containing_tenofovir_A_report_of_nine_cases/links/0c96053bf9003dddbe000000.pdf16640107 32Efficacy and safety of" exact="tenofovir" post="alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations"/>
   <result pre="casesAntivir TherAllavenaCLe MoalGMichauCChiffoleauARaffiF263265112006https://www.researchgate.net/profile/Anne_Chiffoleau/publication/7141177_Neuropsychiatric_adverse_events_after_switching_from_an_antiretroviral_regimen_containing_efavirenz_without_tenofovir_to_an_efavirenz_regimen_containing_tenofovir_A_report_of_nine_cases/links/0c96053bf9003dddbe000000.pdf16640107 32Efficacy and safety of tenofovir alafenamide versus" exact="tenofovir" post="disoproxil fumarate given as fixed-dose combinations containing emtricitabine as"/>
   <result pre="alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing" exact="emtricitabine" post="as backbones for treatment of HIV-1 infection in virologically"/>
   <result pre="review of the psychiatric side-effects of efavirenzAIDS BehavKenediCAGoforthHW1803181815201121484283 34Impact of" exact="efavirenz" post="on neuropsychological performance and symptoms in HIV-infected individualsAnn Intern"/>
   <result pre="medication in South AfricaAIDS BehavGrelottiDJClossonEFSmitJAet al.51151818201423955659 37The HIV antiretroviral drug" exact="efavirenz" post="has LSD-like propertiesNeuropsychopharmacologyGatchMBKozlenkovAHuangR-Qet al.2373238438201323702798 38Drug points: Neuropsychiatric complications of"/>
   <result pre="efavirenz has LSD-like propertiesNeuropsychopharmacologyGatchMBKozlenkovAHuangR-Qet al.2373238438201323702798 38Drug points: Neuropsychiatric complications of" exact="nevirapine" post="treatmentBMJWiseMEJMistryKReidS879324200211950737 39Stavudine- and nevirapine-related drug toxicity while on generic"/>
   <result pre="protease inhibitor-containing therapyClin Infect DisDuvalXJournotVLeportCet al.24825539200415307035 44Neuropsychiatric adverse events with" exact="dolutegravir" post="and other integrase strand transfer inhibitorsAIDS RevHoffmannCLlibreJM41021201930899113 45Neurological response"/>
   <result pre="infectionAIDSCohenCElionRRuanePet al.712252011 48Higher rates of neuropsychiatric adverse events leading to" exact="dolutegravir" post="discontinuation in women and older patientsHIV MedHoffmannCWelzTSabranskiMet al.566318201727860104 49Comparison"/>
   <result pre="switchingInfect ChemotherKimMJKimS-WChangH-Het al.23123847201526788406 50Safety, efficacy and indications of prescription of" exact="maraviroc" post="in clinical practice: Factors associated with clinical outcomesAntiviral ResLlibreJMRiveroARojasJFet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7473106/results/search/drugs/results.xml">
   <result pre="is involved in T-cell co-stimulatory activation via its association with" exact="adenosine" post="deaminase (ADA), caveolin-1, the caspase recruitment domain-containing membrane-associated guanylate"/>
   <result pre="of Th1, Th2, and Th17 lymphocytes [59]. Clinical treatment with" exact="sitagliptin" post="reduced the number of circulating CD4+ T cells, Th17"/>
   <result pre="type 2 diabetes [60]. Inhibition of DPP4 by siRNA or" exact="sitagliptin" post="diminished the effects of the MERS-CoV S protein on"/>
   <result pre="agents, have been proposed [70]. The broad-spectrum antiviral remdesivir and" exact="chloroquine" post="have been effective for viral control in vitro. Remdesivir"/>
   <result pre="been effective for viral control in vitro. Remdesivir is an" exact="adenosine" post="analogue which targets the RNA-dependent RNA polymerase and blocks"/>
   <result pre="RNA viruses including SARS/MERS-CoV. Other nucleoside analogues, such as favipiravir," exact="ribavirin" post="and galidesivir have also been suggested as potential treatments"/>
   <result pre="[70,71]. Studies supporting some role for broad-spectrum antiviral remdesivir and" exact="chloroquine" post="in COVID-19 were published [72–81]. Prolonged exposure to antiviral"/>
   <result pre="2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-932423584 76QaseemA, YostJ, Etxeandia-IkobaltzetaI, et al.Should Clinicians Use" exact="chloroquine" post="or Hydroxychloroquine Alone or in Combination With Azithromycin for"/>
   <result pre="ValFFA, SampaioVS, et al.Effect of high vs low doses of" exact="chloroquine" post="Diphosphate as Adjunctive therapy for patients hospitalized With severe"/>
   <result pre="trial. JAMA Network Open. 2020;3:e208857. doi: 10.1001/jamanetworkopen.2020.8857 78PrincipiN, EspositoS.Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19. Lancet Infect Dis. 2020;S1473-3099(20)30296-6. 79JakharD,"/>
   <result pre="prophylaxis of COVID-19. Lancet Infect Dis. 2020;S1473-3099(20)30296-6. 79JakharD, KaurI.Potential of" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 causes fears of shortages"/>
   <result pre="COVID-19. Lancet Infect Dis. 2020;S1473-3099(20)30296-6. 79JakharD, KaurI.Potential of chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 causes fears of shortages among people"/>
   <result pre="Nat Med. 2020;26:632. doi: 10.1038/s41591-020-0853-0 80YazdanyJ, KimAHJ.Use of Hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: What Every Clinician should Know."/>
   <result pre="Med. 2020;172(11):754–755. doi: 10.7326/M20-133432232419 81WangM, CaoR, ZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="94StrikAS, BerendsSE, MouldDR, et al.Dashboard driven vs. conventional dosing of" exact="infliximab" post="in inflammatory bowel disease patients: the PRECISION trial. Journal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7473320/results/search/drugs/results.xml">
   <result pre="been approved for use in infectious disease settings, such as" exact="palivizumab" post="for respiratory syncytial virus and ibalizumab-uiyk for the treatment"/>
   <result pre="indications that may benefit from mAb combination therapy (such as" exact="trastuzumab" post="with pertuzumab for HER2+ breast cancer), is the relative"/>
   <result pre="may benefit from mAb combination therapy (such as trastuzumab with" exact="pertuzumab" post="for HER2+ breast cancer), is the relative ease of"/>
   <result pre="doi:10.1002/jmv.25897 doi: 10.1016/j.jinf.2020.03.037 75GiambenedettoSD, CicculloA, BorghettiA, et al.Off-label Use of" exact="tocilizumab" post="in patients with SARS-CoV-2 infection. J Med Virol. 2020."/>
   <result pre="2020. doi:10.1002/jmv.25897. 76CavalliG, LucaGD, CampochiaroC, et al.Interleukin-1 blockade with high-dose" exact="anakinra" post="in patients with COVID-19, acute respiratory distress syndrome, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7475736/results/search/drugs/results.xml">
   <result pre="administration of lopinavir/ritonavir, an anti-human immunodeficiency virus (HIV) drug, and" exact="ceftriaxone" post="were commenced. Figure 2 illustrates the course of use"/>
   <result pre="We initiated mechanical ventilation in the pressure-controlled mode. Sedation with" exact="propofol" post="and fentanyl and administration of dopamine and noradrenaline were"/>
   <result pre="mechanical ventilation in the pressure-controlled mode. Sedation with propofol and" exact="fentanyl" post="and administration of dopamine and noradrenaline were commenced after"/>
   <result pre="pressure-controlled mode. Sedation with propofol and fentanyl and administration of" exact="dopamine" post="and noradrenaline were commenced after intubation. The antibiotic was"/>
   <result pre="day 24 with improvement in his symptoms. The administration of" exact="chloroquine" post="was also resumed on day 24. On day 32,"/>
   <result pre="not be recommended for COVID-19 treatment [11]. Next, we administered" exact="chloroquine" post="twice, on days 6-7 and on days 24–40. Since"/>
   <result pre="effect of favipiravir would outweigh that of chloroquine, we used" exact="chloroquine" post="as a substitute until favipiravir became available. It is"/>
   <result pre="a substitute until favipiravir became available. It is unclear whether" exact="chloroquine" post="was effective or not because of the short period"/>
   <result pre="already on a recovery course in the second period. Furthermore," exact="chloroquine" post="was suspected to be a cause of liver dysfunction"/>
   <result pre="virus disease therapeuticsNew England Journal of Medicine2019381242293230310.1056/nejmoa191099331774950 7WangM.CaoR.ZhangL.et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7498411/results/search/drugs/results.xml">
   <result pre="viral infectivity. [35] Au NPs 5, 50, 100 nm Thiol" exact="cysteamine" post="HCV In vivo, in vitro Nanovaccines DNA segment specific"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
